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Abstract
Naturally occurring CD4+CD25+ regulatory T cells are thought to play an essential 
role in the maintenance of immunological self-tolerance by actively suppressing auto­
reactive T lymphocytes. Exploitation of these cells could provide novel and effective 
therapies for the treatment of various clinical diseases, including autoimmune diseases 
and cancer. However the biology surrounding these cells is complex and there are many 
unresolved issues, including a lack of specific markers for these cells and an incomplete 
understanding of the mechanism of action of these cells.
The initial experiments described in this thesis attempted to identify cell surface 
markers that were specific to the human CD4+CD25+ regulatory T cell population. 
Functional assays were conducted in parallel in an attempt to identify cell surface 
molecules and cytokines that might be responsible for the cell-mediated suppression. 
The lack of identification of a specific molecule responsible for the suppressor 
phenotype highlights the complexity of this cell population.
As these studies progressed, a new marker of CD4+CD25+ regulatory T cells was 
reported called FOXP3. Subsequent experiments described in these studies focussed on 
investigating the effects of overexpressing human FOXP3 in human T cells. A novel 
cotransfection system was devised whereby the gene encoding FOXP3 was 
cotransfected with DNA encoding a specific receptor involved in T-cell activation 
(chimeric receptor). The data generated showed that overexpression of FOXP3 in 
resting human CD4+ and CD8+ T cells resulted in a significant inhibition o f 
subsequent T cell activation. Splice variant forms of the FOXP3 protein were also 
investigated and were shown to possess potent repressor activity.
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1.1 The immune system
The function of the mammalian immune system is to protect the host from invading 
pathogens. The cellular and molecular mechanisms that regulate this system although 
highly complex, generate a dynamic and extremely efficient network of protective 
responses. The ability of the immune system to recognise and destroy invading 
pathogens requires a high degree of receptor diversity and consequently the immune 
system has evolved additional mechanisms to distinguish between self and non-self 
antigens. This feature of the immune system, termed immune tolerance, is crucial to 
prevent the development of destructive immunopathologies against self antigen.
1.2 Thymic selection
Negative selection of self-reactive T cells in the thymus is an important process 
contributing to immune tolerance. Lymphoid progenitor cells arrive from the bone 
marrow and seed the thymus. The thymus contains two distinct anatomical areas, an 
outer region called the cortex and an inner region called the medulla. Within the 
cortex there are a small population of cluster of differentiation (CD) 4 and CD8- 
double negative thymocytes. These cells undergo a proliferative expansion and 
differentiation step which is driven by the pre-T cell receptor, resulting in the 
generation of CD4+CD8+ double positive (DP) thymocytes, each expressing a 
clonotypic ap  T cell receptor (TCR). The DP thymocytes interact with major 
histocompatability complex (MHC)-self peptide complexes displayed by cortical 
epithelial cells. At this stage the majority of the DP thymocytes (approximately 90%) 
die ‘by neglect’ due to a failure of the TCRap to engage with a peptide-MHC ligand.
2
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Positive selection of thymocytes occurs when the TCR of the thymocyte engages a 
peptide-MHC ligand with low affinity and receives a low-level TCR signal that 
induces survival and differentiation into single positive CD4+CD8- and CD4-CD8+ 
thymocytes. These cells are then exported from the thymus and populate the 
peripheral lymphoid organs. Approximately 5% of thymocytes are believed to 
undergo positive selection (Palmer, 2003; Sprent and Kishimoto, 2002)
Negative selection occurs when the TCR of a thymocyte engages with a peptide-MHC 
ligand with high affinity. This strong signal through the TCR induces apoptosis of the 
thymocyte. The location of negative selection within the thymus is an area of 
controversy. Some studies suggest that both positive and negative selection occur in 
the cortex. However negative selection is thought to require costimulatory signals as 
well as signalling through the TCR. The cortical epithelial cells lack the expression of 
costimulatory molecules such as CD80 and CD86, suggesting these cells are 
inefficient at inducing apoptosis. Conversely, the medulla region of the thymus is 
packed with antigen presenting cells (APCs), consisting of both dendritic cells and 
medullary epithelial cells that do express these molecules. The medulla is also readily 
accessible to soluble antigens entering the thymus from the bloodstream. Medullary 
epithelial cells have also been shown to be sites of promiscuous gene expression and 
to transcribe genes that are normally expressed in peripheral tissues (Palmer, 2003). 
Autoimmune regulator (AIRE) has recently been identified as a transcription factor 
expressed by medullary epithelial cells that promotes the expression of tissue-specific 
antigens, suggesting that AIRE is critical for thymic negative selection (Anderson et 
al., 2002). Indeed loss-of-function mutations in this gene can lead to autoimmune
3
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disease, highlighting the importance of negative selection in the generation of immune 
tolerance (Pitkanen and Peterson, 2003; Ramsdell and Ziegler, 2003).
Whilst negative selection plays an important role in generating central immune 
tolerance, autoimmune diseases do occur and there is evidence for the presence of 
autoreactive T cells in normal healthy individuals (Danke et al., 2004). This suggests 
that the process of elimination of self-reactive T cells within the thymus: is not 
infallible and may be because certain antigens are not expressed within the thymus, or 
that they are not expressed at high enough levels to induce tolerance.
1.3 TCR cross-reactivity
Whilst it once appeared that each TCR was specific for only one peptide (the ‘one 
clonotype-one specificity’ paradigm (Mason, 1998)), this is now believed not to be 
true. Recent studies suggest that the TCR is highly cross-reactive and it is postulated 
that a single TCR may recognise in the region of 106 different peptide ligands 
(Mason, 1998). This apparent high degree of cross-reactivity can be beneficial to the 
host organism by providing increased protective immunity. Studies in the mouse have 
shown that prior infection with lymphocytic choriomeningitis virus (LCMV) provided 
partial protection against Pichinde virus (PV). Although these viruses show only 
limited sequence similarities, CD 8+ T cells isolated from mice infected with either 
virus, were shown to cross-react with a nucleoprotein-derived peptide from the other 
virus (Brehm et a l, 2002).
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Whilst TGR cross-reactivity ensures that a sufficient number of T cells recognise 
novel pathogens and mount an effective immune response, the trade off is an 
increased potential for T cells to see self-antigens. Indeed studies with human myelin 
basic protein (MBP)-specific T cell clones, isolated from the blood of multiple 
sclerosis (MS) patients, have demonstrated that these cells can be activated by various 
microbial peptides (Wucherpfennig and Strominger, 1995). These data suggest that T 
cells reactive with both self and foreign peptides are present in the T cell repertoire. In 
addition, autoimmune diseases can be induced in animal models following 
immunisation with self-antigen in adjuvant (Sakaguchi, 2000). However, despite this 
high degree of cross-reactivity, the incidence of autoimmunity is low. This suggests 
that there must be other mechanisms operating to maintain peripheral tolerance to 
self.
1.4 Peripheral mechanisms of tolerance
A number of different mechanisms, dependent upon the interaction of the TCR with 
MHC-peptide complexes, have been proposed to account for the maintenance of 
peripheral self-tolerance. During an immune response to an invading pathogen, a frilly 
mature APC displaying antigen and expressing various costimulatory molecules, 
interacts with a naive T cell resulting in the generation of fully activated T cells that 
exhibit potent effector functions. However, in the absence of inflammation or 
infection, presentation of antigen by immature APCs will result in T cell 
unresponsiveness or anergy. Thus the presentation of self-antigens in the periphery in 
the absence of danger signals is believed to be one of the mechanisms of peripheral 
tolerance (Appleman and Boussiotis, 2003; Matzinger, 2002). Other suggested
5
Chapter 1
mechanisms for peripheral self-tolerance include T cell deletion via activation 
induced T cell death (Miller and Basten, 1996) and immunological ignorance, which 
is thought to occur when self-antigens are expressed at low levels (Zinkemagel et ah, 
1997).
Whilst these mechanisms certainly play a role in controlling T cell responses in the 
periphery, they do not account for the observation that in numerous experimental 
animal models o f autoimmune disease, onset of disease can be prevented following 
the reconstitution of the animals with certain T cell populations (Shevach, 2000). 
These data lead to the conclusion that there must be a specialised subset of T cells 
which have the ability to contribute to T cell tolerance in the periphery.
1.5 The Regulatory T cell
The concept of a specialised subset of T cells with an inherent ability to suppress 
immune responses was first proposed in 1970 (Gershon and Kondo, 1970). However 
the cellular and molecular mechanisms responsible for the mode of action of these 
cells, termed suppressor T cells, were never fully characterised and gradually interest 
in this field declined. Today the area of regulatory T cells as they have become 
known, has seen a massive explosion of interest following a seminal study carried out 
by Sakaguchi et ah in 1995. This work demonstrated that autoimmune disease could 
be induced in BALB/c athymic nu/nu mice following the adoptive transfer of 
CD4+CD25- T cells. Co-transfer of CD4+CD25+ T cells prevented the development 
of autoimmune disease (Sakaguchi et al., 1995). These studies were subsequently 
supported by data generated in vzYro showing that mouse CD4+CD25+ regulatory T
6
Chapter 1
cells could inhibit proliferation of CD4+CD25- T cells following stimulation with 
anti-CD3 monoclonal antibody (mAb) (Thornton and Shevach, 1998). Interestingly, 
the same group also showed that the co-culture of CD4+CD25- T cells isolated from 
the DO 11.10 mouse strain in the presence of the relevant ovalbumin peptide, with 
CD4+CD25+ T cells isolated from the BALB/c mouse, failed to show suppression. 
However, suppression was restored following stimulation with anti-CD3, highlighting 
the requirement for activation of the CD4+CD25+ T cells through the TCR. Together 
these early studies in the mouse provide evidence that a specific population of CD25 
expressing CD4+ T cells with regulatory function, appear to exist within the 
lymphocyte pool.
1.5.1 Origin of the CD4+CD25+ regulatory T cell
A fundamental question to be addressed is whether these CD4+CD25+ regulatory T 
cells represent a unique cell lineage, or whether all CD4+ T cells have the inherent 
ability to become regulatory T cells. There is evidence to suggest that these cells are 
indeed a dedicated cell lineage, arising naturally as a normal product of thymic 
selection. Neonatal thymectomy before day 3 after birth, results in the development of 
various autoimmune diseases in mice due to an absence of CD4+CD25+ cells (Suri- 
Payer et al., 1998). Moreover, transfer of thymocyte suspensions depleted of 
CD4+CD25+ cells into syngeneic athymic nu/nu mice also results in the development 
of autoimmune disease (Itoh et a l, 1999). Historically a developing thymocyte was 
always thought to have one of three fates, either death by neglect, positive selection or 
negative selection, as already described. However, it now appears that there is a
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potential fourth alternative fate which is dependent upon the thymocyte’s interaction 
with MHC-self-peptide.
The current hypothesis suggests that CD4+CD25+ arise when there are relatively 
high-affinity interactions with self-peptide-MHC complexes, which are just below the 
threshold for negative selection. Experiments demonstrating this have been performed 
using mice expressing a transgenic TCR that recognises an influenza haemagglutinin 
(HA) peptide crossed to a lineage expressing the HA peptide (Jordan et a l , 2001). In 
these double transgenic mice, the HA-specific T cells were not deleted as one might 
have expected, instead approximately 50% of them were CD25+ and functioned as 
CD4+CD25+ regulatory cells. However, the use of transgenic mice expressing a TCR 
with lower affinity for the HA peptide, resulted in positive selection of CD4+ T cells 
but failed to generate any CD4+CD25+ regulatory cells. Conversely, when the high 
affinity HA-specific TCR-transgenic mouse was crossed with a transgenic line that 
expressed higher amounts of HA peptide, clonal deletion occurred. This narrow 
window of selection for the CD4+CD25+ regulatory cell ensures they represent only a 
small proportion of positively selected thymocytes, yet they are more sensitive to self- 
peptide-MHC than the potentially pathogenic autoreactive T cells.
Glucocorticoid (GC) signalling also supports the concept that TCR affinity is 
important for thymic selection of CD4+CD25+ T cells. GCs are immunosuppressants 
and by blocking their signalling, the threshold for T cell activation decreases, which 
mimics an increase in TCR signal strength. A novel study showed that by using GC 
receptor knockout mice and by blocking endogenous GC with drugs, the thymic T cell
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repertoire was biased towards the production of CD4+CD25+ regulatory cells 
(Stephens and Ignatowicz, 2003).
At which stage in thymic development CD4+CD25+ cells are selected is not clear. 
The expression of CD25 suggests that this molecule may play a role in selection of 
these cells in the thymus. CD25 expression occurs relatively late in thymocyte 
development at the CD4+ single positive stage (Papiemik et a l, 1998). This suggests 
that if CD25 does play a role in the thymic selection of CD4+CD25+ regulatory T 
cells, the stimuli for the fourth alternative fate for T cell selection may occur in the 
medulla region of the thymus, either at the same time or after negative selection. 
Evidence that the interleukin (IL)-2 - IL-2 receptor (R) pathway may play a role in the 
selection of CD4+CD25+ regulatory T cells comes from the observation that IL-2, IL- 
2Ra(CD25) and IL-2RP (CD 122) knockout mice all exhibit lethal 
lymphoproliferative disorders and autoimmunity (Sadlack et al:, 1993; Willerford et 
al., 1995; Suzuki et al., 1995). There have also been reports of a young male patient 
who has a genetic mutation in the CD25 gene and lacks the expression of cell surface 
CD25. This patient has a phenotype similar to mice deficient in IL-2 or the IL-2R, 
exhibiting severe lymphadenopathy and multiorgan inflammatory infiltrates 
(Roifman, 2000). This lack of T cell regulation led to speculation that this process was 
driven by the failure of IL-2 to sensitise autoreactive T cells to undergo activation- 
induced cell death (AICD). However, subsequent studies have now shown that the 
lack of regulation is due to defective regulatory T cells. Indeed, reconstitiution of 
CD4+CD25+ regulatory T cells into IL-2 knockout mice has been shown to prevent 




In related experiments, the adoptive transfer of wild-type CD4+CD25+ regulatory T 
cells into neonatal IL-2RP-/- mice prevented the development of lethal autoimmunity 
(Malek et al., 2002). Also the thymic-specific expression of IL-2RP in IL-2Rp-/- 
mice restored the production of functional CD4+CD25+ regulatory T cells (Malek et 
al., 2000). The source of IL-2 required to drive this selection process may in part be T 
cell-independent; indeed DCs have been shown to produce IL-2 (Granucci et al.,
2001). It is likely that other pathways also play a role in the selection of CD4+CD25+ 
regulatory T cells. CD28-deficient and CD80/CD86 double-deficient mice also 
exhibit significantly diminished numbers of CD4+CD25+ regulatory cells, suggesting 
that CD28-mediated signals are also important in the development of CD4+CD25+ 
regulatory cells (Salomon et a l, 2000).
1.5.2 Human CD4+CD25+ regulatory T  cells
Following the publication by Sakaguchi in 1995 identifying CD25 as a marker for 
mouse regulatory CD4+ T cells, it took a further six years before confirmation of an 
equivalent cell type in the human was published. The reasons for this delay might 
reflect a sceptical human immunological fraternity who were reluctant to be drawn 
back into the field of suppressor T cell biology. The role o f T helper 1 (Thl) and Th2 
biology was also very prominent at this time and researchers were attempting to 
identify these cells in human disease (Romagnani, 1995). Nevertheless a number of 
groups did investigate whether CD4+CD25+ T cells with regulatory activity were 
present in the human immune system. Studies using both human CD4+CD25+ 
thymocytes and peripheral blood derived CD4+CD25+ T cells confirmed that these
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cells failed to proliferate and secrete IL-2 in response to TCR ligation, but were able 
to suppress the proliferative responses of both CD4+ and CD8+ T cells (Stephens et 
a l, 2001; Baecher-Allan et al., 2001; Levings et-al., 2001; Ng et al., 2001; 
Dieckmann et al., 2001; Taams et a l, 2001; Jonuleit et al., 2001).
In all of the studies the suppression was found to be dependent on cell-cell contact, 
confirming the observations seen with mouse CD4+CD25+ regulatory T cells in vitro 
(Thornton and Shevach, 1998). Further studies by Taams et al. showed that the 
CD4+CD25+ T cells expressed a highly diverse T cell repetoire and were able to 
recognise and respond to self antigens, dietary antigens and foreign antigens (Taams 
et al., 2002). The use of thymocytes in these studies confirmed that the thymus also 
appeared to play a role in the generation of human CD4+CD25+ regulatory T cells. A 
more detailed investigation into the correlation between CD25 expression and 
regulatory activity showed that in humans, only the very highest expressing CD25+ T 
cells exhibit regulatory activity, often referred to as CD25hl (Baecher-Allan et al., 
2001).
1,5.3 Mode of suppression: cell-cell contact
How the CD4+CD25+ regulatory T cell mediates suppression is still an unresolved 
phenomemon. As already mentioned, in vitro studies have shown that cell-cell contact 
is paramount for suppression to occur, suggesting that a particular cell surface 
molecule may be responsible for this functionality. One candidate for this role is 
cytotoxic T lymphocyte-assoicated molecule-4 (CTLA-4). Both human and mouse 
derived CD4+CD25+ regulatory T cells express elevated levels of CTLA-4
11
Chapter 1
suggesting a possible functional role for this molecule. Studies using a blocking 
antibody to mouse CTLA-4 have shown reversal of suppression mediated by 
CD4+CD25+ regulatory cells in vitro (Takahashi et al., 2000). Treatment with an 
anti-CTLA-4 mAb also abrogated the ability of CD4+CD25+ T cells to inhibit colitis 
(Read et al., 2000). Partial reversal of suppression has also been observed using a 
neutralising antibody to human CTLA-4 in cultures with human thymocyte-derived 
CD4+CD25+T cells (Annunziato et al., 2002).
However at present, the precise molecular mechanism underpinning CTLA-4 and the 
generation of regulatory T cell function remains unclear. Studies have shown that 
signalling through CTLA-4 may induce transforming growth factor beta (TGFP) 
(Chen et a l, 1998). Alternatively, in a complex in vivo environment, the CD4+CD25+ 
regulatory cell may also interact directly with the APC via CTLA-4 on the 
CD4+CD25+ regulatory T cell and CD80 and CD86 on the surface of the APC. This 
interaction may induce the upregulation of indoleamine 2,3-dioxygenase (EDO) within 
the APC, resulting in tryptophan catabolism. This may then lead to immune 
suppression resulting from a reduction in CD4+CD25- T-cell function and viability 
due to tryptophan depletion and the production of pro-apoptotic metabolites. 
(Fallarino et a l, 2003; Grohmann et a l, 2003). It is also feasible that CTLA-4 may 
even act directly on the CD4+CD25- effector cell via interaction with CD80 or CD86 
and initiate reverse signalling back into the effector cell, thus limiting T cell 
expansion (Paust et al., 2004). Interestingly CD4+CD25- T cells isolated from 
CD80/CD86 doubly-deficient mice were resistant to suppression by CD4+CD25+ 
regulatory T cells in vitro (Paust et al., 2004).
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However, the role of CTLA-4 in CD4+CD25+ mediated suppression is still somewhat 
controversial as there are many reports of in vitro studies where antibodies to CTLA-4 
have had no effect on suppression (Thornton and Shevach, 1998; Levings'e/ al., 2001; 
Baecher-Allan et al., 2001). Also CD4+CD25+ cells from CTLA-4-/- mice have been 
shown to possess suppressive activity (Piccirillo and Thornton, 2004).
Another cell surface molecule that has recently generated great interest as a potential 
candidate for mediating cell-contact dependent suppression is glucocorticoid-induced 
tumour-necrosis factor receptor family-related protein (GITR). GITR was initially 
identified as a cell surface marker of mouse CD4+CD25+ regulatory T cells, 
following transcriptional gene profiling of CD4+CD25+ T cells versus CD4+CD25- T 
cells (McHugh et al., 2002; Gavin et al., 2002). An alternative method using 
immunisation with mouse CD4+CD25+ T cells and subsequent hybridoma screening, 
also identified GITR as a specific marker of CD4+CD25+ regulatory T cells (Shimizu 
et a l, 2002). Adoptive transfer studies have shown that the transfer of GITR-depleted 
CD4+ T cells into athymic mice resulted in a more aggressive autoimmunity than that 
observed following the adoptive transfer of CD25-depleted CD4+ T cells 
(Uraushihara et a l, 2003). However, studies showing a direct role for this molecule in 
mediating regulatory function are lacking. Indeed in vitro studies using an agonising 
antibody to GITR resulted in the abrogation of suppressive activity by the 
CD4+CD25+ T cells (Shimizu et al., 2002). Conversely, addition of a Fab’ fragment 
of the antibody had no effect on the ability of the CD4+CD25+ T cell to regulate, 
therefore implying that GITR does not play a direct role in the suppressive 
mechanism. The GITR-deficient mouse also does not reveal any significant 
alterations in its thymic or peripheral T cell subsets and does not have any overt signs
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of autoimmunity (Ronchetti et a l , 2002). In agreement with this, human T cells do 
not express GITR ligands (Gurney et al., 1999) and whether human CD4+CD25+ T 
cells express elevated levels of GITR is also unclear.
A new molecule that has recently emerged as a potential contender for mediating cell 
contact-dependent suppression is lymphocyte activation gene 3 (LAG-3) or CD223 as 
it is also known. This molecule is an MHC class II binding homologue of CD4. 
Expression of LAG-3 is upregulated on the surface of mouse GD4+CD25+ regulatory 
T cells following activation. Ectopic expression of LAG-3 via retroviral transduction 
was able to confer regulatory activity to mouse CD4+CD25- T cells (Huang et al., 
2004). However the molecular mechanism of action of LAG-3 in unknown and its 
importance in human regulatory T cell function has yet to be determined.
Whilst it is an attractive hypothesis that there is a unique CD4+CD25+-associated 
molecule that is responsible for mediating suppression, it is possible that this is not 
the case. Instead the cell contact-dependent mediated suppression observed in vitro 
may be the result of different, already identified molecules, acting semi-redundantly 
together to generate a suppressive phenotype.
1.5.4 Mode o f suppression: soluble mediators
In vitro analysis has given an insight into how CD4+CD25+ T cells might mediate 
suppression through cell-cell contact. There is evidence in vitro that suppression by 
CD4+CD25+ T cells can occur in the absence for example, of APCs. Indeed, studies 
with human CD4+CD25+ regulatory T cells have shown that they can suppress
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CD4+CD25- T cells following stimulation with plate-bound anti-CD3 alone (Levings 
et al., 2001). Also, preactivated CD4+CD25+ were able to suppress the proliferative 
response of TCR-transgenic CD8+ T cells stimulated with soluble peptide-MHC class 
I tetramers (Piccirillo and Shevach, 2001). The use of transwells to investigate a role 
for soluble mediators has suggested a redundant role for cytokines in mediating 
suppression in vitro (Ng et al., 2001; Taams et a l, 2001; Jonuleit et a l, 2001; 
Dieckmann et al.,. 2001). However, these systems can never fully replicate the 
situation in vivo. The mode of action of the CD4+CD25+ regulatory T cell is thus 
probably much more complex than that observed in vitro. Moreover, the in vivo 
environment allows the regulatory cell to interact with many different cell types, a 
mechanism the regulatory cell may employ to amplify its suppressive effects.
The fact that the situation in vivo is likely to be much more complex and very 
different to that observed in vitro, may in part explain some of the discrepancies 
involving the role of cytokines in mediating suppression. Both IL-10 and TGFP have 
been shown to play a role in regulatory T cell mediated suppression in vivo. In a 
severe combined immunodeficiency (SCID) colitis model it has been shown that 
treatment with an anti-IL-10 receptor antibody, abrogated the suppressive function of 
CD45RBlow cells (Asseman et al., 1999). CD45RBlow cells are a population of 
regulatory T cells that are predominantly CD25 positive too. Similarly, CD45RBlow 
cells isolated from IL-10"7' mice, failed to protect against colitis when co-transferred 
with CD45RBhl cells (Asseman et al., 1999). IL-10"7 CD4+GD25+ T cells were also 
unable to inhibit Helicobacter hepaticus (H. hepaticus)-mducQd intestinal 
inflammation or anti-leishmania immunity (Kullberg et al., 2002; Belkaid et al.,
2002). Interestingly the role of IL-10 here appears to be linked to control of the innate
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immune system, so IL-10 may only play a role when the innate immune system is 
triggered. A recent publication has shown that CD4+CD25+ are responsible for 
inhibiting the sustained activation of the innate immune system following H. 
hepaticus infection of immune-deficient mice through the secretion of IL-10 (Maloy 
et al., 2003). This role for IL-10 in controlling the innate response may in part explain 
why CD4+CD25+ cells from IL-107' mice were fully competent suppressors in vitro 
(Thornton and Shevach, 1998).
Whether TGFp plays a role in the mechanism of suppression by CD4+CD25+ 
regulatory cells is another area of much debate. Again in the SCID-colitis model of 
inflammatory bowel disease (IBD), neutralising antibodies to TGFp were able to 
block regulatory T cell function (Powrie et al., 1996; Fuss et al., 2002). However, in a 
model of gastritis, TGFp was found to play no role in mediating regulatory T cell 
function (Piccirillo et al., 2002). In addition, CD4+CD25+ cells isolated from TGFp7' 
mice were functional suppressors in vitro (Piccirillo et al., 2002). A recently 
published study has shown that CD4+CD25+ regulatory T cells isolated from TGFp7' 
mice were also able to inhibit colitis (Fahlen et a l, 2005). However, the 
administration of an anti-TGFp antibody was still able to abrogate suppression by 
these cells. Interestingly the transfer of CD4+CD45RBhl cells expressing a dominant 
negative form of the TGFP receptor type II, were resistant to suppression by 
CD4+CD25+ regulatory T cells. These studies show that whilst the production of 
TGFp by CD4+CD25+ regulatory T cells is not essential for their function, it does 
play a role in their ability to suppress. Together these studies suggest that the 
CD4+CD25+ regulatory T cell may somehow induce TGFp secretion from different 
cell types that may be haematopoietic or stromal in origin.
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The concept that the CD4+CD25+ regulatory cell induces the expression of TGFP by 
other cell types, is supported by studies in vitro demonstrating the phenomenon of 
infectious tolerance. CD4+CD25+ cells have the ability to induce conventional T cells 
to become regulatory T cells through the release of the immunomodulatory cytokines 
IL-10 and TGFp (Dieckmann et fl/., 2002;Jonuleit et al., 2002). A recent study has 
further subdivided the CD4+CD25+ regulatory T cell into two different subsets 
defined by the expression of the integrins a4p7 or a4p l. They have shown that the 
a4p7 expressing regulatory cells induce IL-10 producing regulatory T cells and the 
a4 p i expressing regulatory cells induce TGFp producing regulatory T cells (Stassen 
et al., 2004). The authors speculate that that the expression of different integrins by 
CD4+GD25+ regulatory T cells ensures that they traffic to the correct tissues in vivo 
to control inflammation.
1.5.5 Extrathymic generation of CD4+regulatory cells
The concept of infectious tolerance is an attractive way to explain how relatively few 
CD4+CD25+ T cells can be effective at suppressing an immune response in vivo, and 
it also introduces the concept of inducible regulatory T cells, which are not 
conventionally selected in the thymus.
The two major classes of inducible regulatory T cells are the T regulatory type 1 (Trl) 
and the Th3 cell. The Trl cell is typically characterised by the production of IL-10 
and the Th3 cell by the production of TGFp. These cells can be generated using a 
variety of different methods, however one common factor in their generation is that 
they receive sub-optimal signals preventing optimal T cell activation. Trl cells were
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initially generated by the chronic stimulation of naive CD4+ T cells in the presence of 
IL-10 (Groux et al., 1997). These Trl cells are functionally suppressive in vivo and 
have been shown to inhibit both colitis and antigen specific IgE responses (Groux et 
al., 1997; Cottrez et al., 2000). Trl cells can also be generated in vivo by repeated 
exposure to antigen in a non-proinflammatory environment such as intranasal delivery 
of peptide. This has been demonstrated with Tg4 transgenic mice specific for a myelin 
basic protein (MBP) peptide. Multiple intranasal doses of peptide were efficient at 
protecting the mice from developing experimental autoimmune encephalomyelitis 
(EAE) following subcutaneous injection of spinal cord homogenate in complete 
Freund’s adjuvant (CFA) (Burkhart et al., 1999). This effect was dependent on IL-10, 
as administration of an anti-IL-10 antibody to peptide-treated mice, resulted in the 
mice developing EAE. Further characterisation of the IL-10 producing cells 
confirmed they were antigen-specific Trl cells (Sundstedt et al., 2003). Interestingly 
the ability of the Trl cells to suppress nai've Tg4 cells in vitro was not dependent on 
IL-10.
There are also reports of the generation of Trl cells in humans following peptide 
immunotherapy (Robinson et al., 2004). Interestingly there is evidence that inducible 
regulatory cells may develop during a normal immune response to severe chronic 
infectious diseases. One such study has shown that pathogen-specific Trl cells were 
generated in the lungs of mice infected with Bordetella pertussis (B. pertussis). These 
cells were able to inhibit subsequent Thl responses against B. pertussis both in vitro 
and in vivo (McGuirk et al., 2002). Subsequent studies have shown that the 
hpopolysaccharide (LPS) from B. pertussis can bind to toll-like receptor (TLR) 4 on 
the surface of dendritic cells (DCs) and induce them to produce IL-10, which
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facilitates Trl development (Higgins et a l , 2003). The generation of Trl cells in 
response to an invading pathogen was initially thought to be an evasion strategy by 
the pathogen to subvert protective Thl responses. However now it is speculated that 
the generation of Trl cells are beneficial to the host as they limit immune pathology 
and potential tissue destruction within the lungs. Evidence to support this has been 
demonstrated by studies in mice which lack functional TLR4, where B. pertussis 
infection was more severe (Higgins et al., 2003). There is also evidence to suggest 
that these cells occur as a natural population within the mouse gut where they regulate 
the responses to commensal flora (Cong et a l, 2002).
Th3 cells have been shown to be generated following oral administration of 
protein/peptide. In one study the oral administration of MBP, appeared to tolerise 
mice to MBP through the generation of Th3 cells, which suppressed the induction of 
EAE. This suppression was abrogated following the administration of an anti-TGF(3 
antibody (Chen et a l, 1994). Addition of TGFp to murine T cell cultures has also 
been shown to promote the induction of Th3 cells (Weiner, 2001).
The APC may also play a role in the generation of inducible regulatory T cells. In 
vitro studies with human monocyte-derived DCs have shown that repetitive 
stimulation of allogeneic nai’ve cord blood cells with immature DCs, resulted in the 
generation of Trl cells (Jonuleit et a l , 2000). Another study has investigated the 
response in humans to the injection of antigen loaded immature DCs. A single 
injection of immature DCs pulsed with influenza matrix peptide (MP) resulted in the 
specific inhibition of MP-specific CD 8+ T-cell effector function, i.e. cell killing and 
IFNy production. This inhibition of T-cell effector function was accompanied by the
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appearance of MP-specific IL-10 producing cells. Injection of mature DCs resulted in 
the restoration of CD8+ T-cell effector function (Dhodapkar et al:, 2001).
The lineage relationship of CD4+CD25+ regulatory T cells and Trl and Th3 cells is 
unclear. The CD4+CD25+ regulatory T cell is thought to derive from the thymus as a 
separate lineage. Conversely, the generation of Trl and Th3 cells is believed to occur 
in the periphery, derived from conventional CD4+CD25- naive T cells. The 
importance of each of the different regulatory T cell types in the regulation of immune 
responses is also unclear. What determines which cell acts when and where, is still to 
be resolved and is likely to be dependent on the microenvironment in vivo and the 
magnitude of the response. Whether the CD4+CD25+ regulatory T cell is the key 
orchestrater for the induction of these inducible regulatory cells also remains to be 
determined (Jonuleit et al., 2002; Dieckmann et al., 2002). The theory that 
CD4+CD25+ can transfer tolerising activity to induced regulatory cells is an attractive 
one and it is clear that in vivo the CD4+CD25+ regulatory T cell and the Trl and Th3 
cells intimately co-operate to regulate immune responses effectively.
1.5.6 Clinical significance of CD4+CD25+ regulatory T cells in autoimmune 
disease
The central role of CD4+CD25+ regulatory T cells in controlling immune pathology 
in various mouse models of autoimmune disease and inhibiting T cell activation in 
vitro, is an accepted phenomenon. The central question is whether these cells have 
any clinical significance in human diseases. If these cells are responsible for 
controlling immune responses to self-antigens one might expect either defective or a
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reduced frequency of CD4+CD25+ regulatory cells to be present in patients suffering 
from various autoimmune diseases.
Multiple sclerosis (MS) is an inflammatory demyelinating condition of the central 
nervous system where lymphocytes and macrophages dominate the inflammatory 
infiltrate. However, it is the T cell that is believed to be responsible for driving the 
autoaggressive response against the myelin components. Studies in vitro have shown 
that the magnitude of human CD4+ T cell proliferation in response to myelin 
oligodendrocyte glycoprotein (MOG) was increased following depletion of the 
CD4+CD25+ regulatory T cells. Conversely, the addition of CD4+CD25+ regulatory 
T cells to the cultures, inhibited MOG-specific proliferation (Wing et a l , 2003). 
These studies suggested that defective CD4+CD25+ T cells might play a fundamental 
role in the pathology of MS. Initial attempts to identify differences in CD4+CD25+ 
regulatory T cell frequencies between normal individuals and patients with MS, 
highlighted no significant variation (Putheti et al., 2004).
A second study showed that although there was no change in frequency of
VnCD4+CD25 T cells from patients and healthy controls, there was a marked decrease 
in the effector function of the CD4+CD25hl T cells (Viglietta et al., 2004). Following 
stimulation with sub-optimal levels of plate-bound anti-CD3 mAb, the level of T cell 
suppression was 80% with healthy control cells, but only 20% with MS patient- 
derived CD4+CD25hl cells. In contrast, optimal stimulation with soluble anti-CD3 and 
anti-CD28 revealed no differences in the ability of the patient derived cells to 
suppress when compared to the normal controls at a 1:1 ratio. These experiments
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demonstrate that the strength of signal delivered through both the TCR and 
costimulatory molecules, affects the levels of suppression achieved.
It is conceivable that this effect could be specific to MS, however other studies are 
now beginning to show defective regulatory T cells in other autoimmune diseases. 
Autoimmune polyglandular syndrome type II (AMPSII) is characterised by multiple 
endocrine diseases like type I diabetes and autoimmune thyroid disease. A recent 
study has shown that the suppressive capacity of the CD4+CD25+ regulatory T cells 
isolated from the blood of patients suffering from AMPS II was defective. However 
there were no obvious quantitative or phenotypic differences between the 
CD4+CD25+ regulatory T cells isolated from patients and controls (Kriegel e/ al., 
2004). Functional assays conducted using CD4+CD25hl regulatory T cells isolated 
from the blood of patients with psoriasis also confirmed a defect in their suppressor 
capacity (Sugiyama et al;, 2005). Importantly, each of the human ex vivo studies 
mentioned thus far, confirmed through the use of co-mixing experiments, that the 
defective suppressor capacity resided within the CD25+ population and not the 
responder CD25- population. Indeed, defective regulatory T cells in psoriasis have 
been confirmed by a second study showing reduced suppressive capacity (Viglietta et 
al., 2004).
An interesting study using CD4+CD25+ regulatory T cells isolated from the blood of 
patients with active rheumatoid arthritis (RA) has shown that the regulatory cells were 
able to suppress the responder CD4+ proliferative response, but failed to inhibit the 
secretion of the pro-inflammatory cytokines, TNFa and IFNy (Ehrenstein et al., 
2004). Interestingly, isolation of CD4+CD25+ regulatory T cells from the same group
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of patients after therapy with anti-TNFa mAh (Infliximab) showed that the regulatory 
T cells had regained the ability to inhibit TNFa and IFNy production. However, the 
addition of TNFa to the coculture system was unable to overcome this suppressive 
effect and conversely, in vitro neutralisation of TNFa was not sufficient to restore the 
defect in the CD4+CD25+ population. The CD4+CD25+ regulatory T cells isolated 
from the RA patients prior to treatment with anti-TNFa mAb, were also unable to 
induce infectious tolerance in CD4+CD25- T cells in vitro, but this was restored 
following treatment with anti-TNFa mAb. The molecular mechanism by which 
Infliximab modulates CD4+CD25+ regulatory T cell function remains to be 
elucidated.
Although the numbers of regulatory T cells in each of the autoimmune diseases 
described thus far have revealed no significant differences from healthy controls, 
there are reports of reduced numbers of CD4+CD25+ regulatory T cells in systemic 
lupus erythematosus (SLE) but there is no functional data (Crispin et al., 2003; Liu et 
al., 2004). To date there are no reports of dysfunctional CD4+CD25+ regulatory T 
cells from patients with inflammatory bowel disease (IBD), indeed one study has 
shown strong suppressive activity of regulatory cells isolated from the blood of 
patients with IBD (Viglietta et al., 2004). Clearly the role of regulatory T cells in 
controlling autoimmune pathologies is an area of great interest and further detailed 
studies involving monitoring the effects of various therapies on this regulatory T cell 
subset will help define their pathogenic role in human autoimmune disease.
23
Chapter 1
1.5.7 Clinical significance o f  CD4+CD25+ regulatory T  cells in cancer
The presence of functional CD4+CD25+ regulatory T cells is believed to contribute to 
the maintenance of peripheral tolerance by suppressing autoreactive T cells, thus 
preventing autoimmunity. Conversely, the failure of host anti-tumour immunity may 
be caused by the effective suppression of tumour-associated antigen-reactive 
lymphocytes, mediated by CD4+CD25+ regulatory T cells. A study using 
CD4+CD25+ regulatory T cells isolated from lung cancer patients showed that the 
regulatory cells were effective at inhibiting autologous peripheral blood mononuclear 
(PBMC) proliferation, following stimulation with either anti-CD3 alone or anti-CD3 
in combination with anti-CD28. The study also showed there were large numbers of 
regulatory T cells infiltrating into the tumours and they expressed high levels of 
surface CTLA-4 (Woo et al., 2002). Elevated numbers of CD4+CD25+ regulatory T 
cells have also been identified within the tumour-infiltrating lymphocyte population in 
patients with gastric and eosophageal cancers (Ichihara et al., 2003).
A recent study of ovarian cancer has found large numbers of CD4+CD25+ regulatory 
T cells in the malignant tumours and ascites. The isolation of these cells from the 
tumour ascites confirmed the ability of the cells to inhibit the proliferation of 
autologous responder T cells stimulated in vitro with myeloid dendritic cells pulsed 
with Her2 peptides. This effect was replicated in vivo with mice receiving primary 
human ovarian tumour cells to establish tumour formation. Twelve days later the mice 
were given either autologous tumour specific T cells alone, or in combination with 
tumour ascites derived CD4+CD25+ T cells. The mice that received the tumour 
specific T cells in combination with the CD4+CD25+ T cells, showed progressive
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tumour growth compared to the group that received the tumour specific T cells alone 
(Curiel et 0 /., 2004). These data indicate that tumour-derived CD4+CD25+ regulatory 
T cells may indeed hamper tumour-specific effector T cell immunity in individuals 
with cancer. Moreover, following analysis of 70 patients with ovarian cancer there 
was a significant negative relationship between number of CD4+CD25+ T cells 
present in the tumour tissue and survival.
1.5.8 Clinical significance o f CD4+CD25+regulatory T cells in allergic disease
Atopic allergic sensitisation is defined by the production of IgE against various 
innocuous environmental antigens such as grass pollen, house dust mite and animal 
dander. This can lead to the development of asthma, rhinitis and atopic dermatitis 
(Kay, 2001). The switch by B cells to produce IgE and the accumulation of 
eosinophils are under the control of TL-4 and IL-5, produced by Th2 cells. Studies 
vitro have confirmed that human CD4+CD25+ regulatory T cells are effective 
inhibitors of Th2 mediated responses (Tiemessen et a l, 2002; Bellinghausen et al.,
2003). One possible explanation for the development of atopy is the failure of the 
CD4+CD25+ regulatory T cell to effectively regulate this population of cells. A 
recent study has shown that the suppressive ability of CD4+CD25+ regulatory T cells 
from atopic subjects in co-cultures with allergen-stimulated autologus CD4+CD25- T 
cells, was significantly reduced as compared to CD4+CD25+ regulatory T cells 
isolated from non-atopics (Ling et al., 2004). Interestingly, the CD4+CD25+ 




Trl cells are also thought to play an important role in the prevention of atopic 
sensitisation. Indeed T cells engineered to secrete IL-10 were shown to greatly reduce 
the development of airway hyperactivity and airway inflammation (Oh et al., 2002). 
One study has shown an increased number of allergen-specific IL-10-producing 
CD4+ T cells in the blood of non-atopics as compared to atopies and these Trl cells 
were effective at inhibiting IL-4 production by allergen-stimulated T cells in vitro. 
This suppression was reversed following the addition of a blocking antibody to IL-10 
(Akdis et a l, 2004).
1.5.9 Clinical significance o f CD4+CD2 5+ regulatory T cells in infectious 
diseases
As already mentioned, the TCR is believed to be highly cross-reactive. Experiments 
conducted in vitro using tetanus toxoid and grass pollen as the stimulating antigens, 
have confirmed the ability of human CD4+CD25+ regulatory T cells to suppress the 
response of CD4+CD25- effector T cells to both antigens (Taams et a l, 2002; Ling et 
al., 2004). These studies highlight the ability of regulatory T cells to respond to 
foreign antigens. However, this observation does not necessarily mean that these cells 
participate in immune responses/indeed it was previously thought that regulatory T 
cells only inhibited responses to self-antigens thus preventing autoimmunity, whilst 
permitting T cell responses against pathogenic organisms to proceed unchecked. This 
view is now being challenged by data that suggests that far from being uninvolved, 




The induction of pathogen-specific responses is crucial in host protection and 
resolution of potentially fatal disease processes. However these same effector 
mechanisms that have evolved to protect the host from the invading pathogen, can 
also cause immune-mediated pathology such as severe inflammation and tissue 
damage, if  not tightly regulated. Evidence that CD4+CD25+ regulatory T cells play a 
role in infectious diseases has arisen mainly from mouse models of disease. One of 
the best characterised is infection with the parasitic pathogen, Leishmania major (L. 
major). Infection of C57BL/6 mice with L. major, results in a persistent low level of 
infection at the cutaneous infection site. Depletion of the CD4+CD25+ regulatory T 
cells resulted in clearance of the pathogen. However, as a consequence of the removal 
of the regulatory T cells, the mice did not establish lasting immunity and were 
susceptible to subsequent re-infection. In this model the presence of CD4+CD25+ 
regulatory T cells is beneficial to the host because although the parasite is allowed to 
survive, the persistence of the parasite confers immunity on the host to reinfection 
(Belkaid et al., 2002). CD4+CD25+ regulatory T cells have also shown beneficial 
effects in mouse strains that are susceptible to L. major infection by limiting the 
extent of tissue damage (Aseffa et al., 2002).
Conflicting data is emerging to suggest that CD4+CD25+ regulatory T cells may also 
play a role in the pathogenesis of human immunodeficiency virus (HIV) in humans. 
HIV infection is characterised by a loss of CD4+ T cells and progressive CD4+ T cell 
immune dysfunction, leading to impaired HIV-specific responses. One study has 
suggested that the presence of functional CD4+CD25+ regulatory T cells acts to the 
detriment’s of the host following infection with HIV. Depletion of CD4+CD25+ 
regulatory T cells from peripheral blood samples taken from patients with HIV,
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enhanced subsequent HIV T cell-specific responsiveness in vitro (Aandahl et al.,
2004). A second group have shown that infection of monocyte-derived DCs with HIV 
inhibited DC maturation, resulting in the production of IL-10 and induced regulatory 
T cells (Granelli-Pipemo et al., 2004).
Conflicting results were reported in a third study, which suggested that the decrease in 
response to HIV is due to defective CD4+CD25+ regulatory T cells. In the majority of 
healthy yet HIV-infected individuals, the CD4+CD25hl T cells were able to suppress 
cellular proliferation and cytokine production by both CD4+ and CD8+ T cells, 
following stimulation with HIV antigens/peptides in vitro. These patients also 
exhibited lower levels of plasma viraemia as compared to patients without regulatory 
T cell activity. The authors suggested that suppression of CD4+ T cell activation by 
the regulatory cells is beneficial to the host because it limits the level of viral 
replication, thus reducing the number of target cells available for the virus to infect 
(Kinter et al., 2004).
Clearly the role of CD4+CD25+ regulatory T cells in controlling infectious disease is 
complex and controversial, although these cells do appear to play an essential role by 
limiting the extent of immunopathology. However, there are also instances where the 
presence of CD4+CD25+ regulatory T cell may be detrimental to the host by 
suppressing anti-pathogen protective responses.
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1.5,10 Therapeutic application of regulatory T cells
Both the ‘naturally occurring’ CD4+CD25+ regulatory T cell and the extrathymically 
generated Trl or Th3 regulatory T cells are thought to play important roles in 
controlling the immune response. There is increasing evidence that these cells play 
important roles in human pathologies, suggesting that the therapeutic manipulation of 
these cells could be beneficial in treating various human diseases.
To be of clinical benefit however, CD4+CD25+ regulatory T cells must be capable of
Viiinhibiting established disease. A study in the SCID/CD45RB mouse transfer model 
of colitis has shown that following establishment of disease with CD45RBhl cells, the 
adoptive transfer of CD4+CD25+ regulatory T cells was able to reverse disease 
(Mottet et al., 2003). Whilst validating the concept that CD4+CD25+ regulatory T 
cells might be effective at treating autoimmune diseases, translating this into a 
successful therapy is somewhat more difficult. Boosting intrinsic CD4+CD25+ 
regulatory T cell activity or stimulating expansion of these cells in vivo may be one 
option for therapeutic intervention. Interestingly in vitro exposure of human 
CD4+CD25+ regulatory T cells to corticosteroids has been shown to increase their 
suppressive capacity following subsequent stimulation by allergen (Dao and 
Robinson, 2004). As already mentioned, treatment with anti-TNFa mAh, appeared to 
restore a defect in the suppressive capacity of the CD4+CD25+ regulatory T cell 
population isolated from patients with RA (Ehrenstein ^  a/., 2004).
Whilst treatment of autoimmune diseases may require expansion of the CD4+CD25+ 
regulatory T cell population, boosting anti-tumour immunity might be achieved
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through the selective depletion of CD4+CD25+ regulatory T cells. Indeed several 
studies have shown that depletion of CD25+ positive cells in vivo using a depleting 
anti-CD25 antibody, induced the rejection of immunogenic tumours (Onizuka et al., 
1999; Shimizu et al., 1999). Currently trials of a product called Ontak are underway 
in advanced cancer patients. Ontak is a recombinant cytotoxic protein composed of 
portions of the diptheria toxin and the binding domain of human IL-2. Ontak binds to 
CD25+ T cells and after internalisation, causes cell death (Kreitman, 2003). Other 
potential targets include blocking chemokine receptors to stop trafficking of the 
CD4+CD25+ regulatory T cells into the tumour sites. A potential candidate is the 
chemokine receptor CCR4 or its ligand CCL22. In vivo studies in the NOD/SCID 
mouse reconstituted with primary ovarian human tumours have shown that human 
CD4+CD25+ regulatory cell migration but not CD4+CD25- T cell migration, into 
tumour tissues is dependent upon CCL22 and can be blocked with an antibody to 
CCL22 (Curiel et al., 2004). Depletion of CD4+CD25+ regulatory T cells might also 
have beneficial effects in enhancing vaccination efficiency against persistent 
infections like HIV and hepatitis C.
Whilst the CD4+CD25+ regulatory T cell is an attractive target, some of the most 
promising therapeutic effects have arisen from studies looking at the generation of 
adaptive regulatory cells in the periphery. Initial studies focussed on treating allergic 
diseases with peptides to the sensitising allergen. Studies using either peptides of Fel 
d 1, a major cat allergen or phospholipase A2 (PLA2) peptides, from bee venom 
allergen, showed that following intradermal administration, patients were clinically 
hyporesponsive following challenge with the whole allergen (Oldfield et al., 2001; 
Muller et al., 1998). Following immunotherapy, PBMCs were isolated from the
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treated patients and cultured in vitro in the presence of the peptides. Analysis of the 
cultures showed reduced levels of CD4+ T cell proliferation and both Thl and Th2 
cytokine production. However there was a significant increase in IL-10 production, 
suggesting the generation of Trl cells. A further study using Fel d 1 peptides showed 
that the allergen-specific T cells did undergo functional modifications, resulting in the 
generation of a population of regulatory T cells that were able to suppress antigen- 
induced proliferation of effector T cells (Verhoef et a/., 2005).
The success of peptide immunotherapy in treating allergic diseases has led to studies 
looking at treating autoimmune diseases using the same approach. Clinical trials 
involving oral administration of myelin basic protein (MBP) in MS, collagen in RA, 
thyroglobulin in autoimmune thyroid disease and S-antigen in uveitis have been 
conducted (von Herrath and Harrison, 2003). Disappointingly, none of the trials 
resulted in any significant clinical benefit. There are many possible explanations for 
the lack of efficacy observed including the route of administration, the dose of 
antigen, the choice of antigen, and the timing of administration. Also patients with late 
stage disease may be less responsive to immunotherapy than patients at an early stage 
of disease, due to increased numbers of auto-reactive T cells. However, a new study 
looking at eptiope-specific immunotherapy in patients with early stage RA has shown 
some encouraging results. Following oral administration of dnaJPl, a bacterial heat 
shock protein, subsequent analysis of patient PBMCs revealed a significant increase 
in the number of IL-10 and EL-4 producing T cells, following in vitro peptide 
stimulation. There was also a significant decrease in the levels of proliferation and IL- 
2, EFNy and TNFa production (Prakken et al., 2004). Although this study was not
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investigating clinical efficacy, patients on the trial showed a marked improvement 
from baseline and the therapy was found to be safe.
Clearly modulation of regulatory T cell function in vivo provides an exciting new 
opportunity in the treatment of various human diseases. However there are many 
facets of CD4+CD25+ regulatory T cell biology that are poorly understood including 
the antigenic specificity of the CD4+CD25+ regulatory T cell, the mechanism of 
suppression, the in vivo targets of the cells and the relationship between the naturally 
occurring CD4+CD25+ regulatory T cell and the adaptive regulatory T cell 
populations. The issues represent challenges for regulatory T cell specific 
immunotherapies. However an exciting new molecule has been discovered which may 
be a target for immunotherapy. Compounds that either inhibit this molecule or 
activate it may have enormous therapeutic potential in controlling CD4+CD25+ 
regulatory T cell function. This molecule, called FOXP3, identified as defective in the 
scurfy mouse (Brunkow et al., 2001) has emerged as a leading contender for targeted 
therapies.
1.6 The Biology of FOXP3
1.6.1 The scurfy mouse
The original scurfy mutation occurred spontaneously in a partial inbred stock of mice 
at the Oak Ridge National Laboratory, USA in 1949. The discovery that the mutation 
was X-linked recessive provided early information on the sex-determining mechanism 
in mice (Russell, 1959). However it is the phenotype of the scurfy mouse that is of
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interest to the immunologist. The scurfy mutation manifests itself as a severe 
lymphoproliferative disease characterised by ranting, exfoliative dermatitis, 
thickening of the ears, squinted eyes, lymphadenopathy, splenomegaly and severe 
anaemia. These symptoms are so severe that death usually occurs between 15-24 days 
of age (Godfrey et a l, 1991). Studies using either anti-CD4 or anti-CD8  depleting 
antibodies to treat neonatal scurfy mice, have demonstrated that the effector cells 
responsible for development of the disease are CD4+ T cells (Blair et al., 1994). 
Indeed the adoptive transfer of CD4+ but not CD8 + T cells from scurfy mice into 
nude mice transmitted the disease (Blair et al., 1994).
Analysis of cytokine gene expression in the spleen, lymph nodes and skin of scurfy 
mice revealed dysregulated overexpression of various cytokine genes including IL-2 , 
IL-4, IL-5, IL-6 , IL-7, IL-10, EFNy and TNFa (Kanangat et a l , 1996). Further cellular 
characterisation of scurfy mice compared to normal littermates revealed differences in 
the numbers of macrophages and B cells. The onset of the disease was accompanied 
by a progressive increase in the numbers of Mac 1+ cells and a concomitant decrease 
in the numbers of B220+ cells found within the spleen and lymph nodes (Clark et a l , 
1999). There was also an increase in the number of CD4+ T cells and these appeared 
to be larger than CD4+ T cells from normal mice. The expression levels of the cell 
surface markers CD69, CD25, CD80 and CD8 6  were also elevated on the CD4+ T 
cells. Following stimulation through the TCR, the CD4+ T cells produced levels of 
GM-CSF more than 1000-fold greater than normal controls.
One interesting observation was the apparent hyper-responsiveness of the CD4+ T 
cells to TCR signalling. Lymph node cells freshly isolated from scurfy mice
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underwent significant levels of proliferation even in the absence of TCR stimulation. 
Purification of the CD4+ T cell population and stimulation with increasing 
concentrations of plate-bound anti-TCRp, showed that the CD4+ T cells were highly 
responsive to low levels of antibody as compared to normal controls. These cells also 
had a decreased requirement for costimulation through CD28. Interestingly these cells 
were highly refractory to inhibition by Cyclosporin A and showed reduced sensitivity 
to genistein and herbimycin A. This suggests some kind of impaired TCR signalling 
cascade which lowers the threshold for activation and then fails to downregulate the T 
cell activation response.
Although the in vitro T cell experiments described have shown a reduced threshold 
for T cell activation, an elegant study in the mouse showed the absolute requirement 
for stimulation through the TCR for the scurfy phenotype to manifest itself. Scurfy 
mice crossed with the DO 11.10 strain and bred on a recombinase activator gene 
(RAG) 1 knockout background so that 100% of the T cells are reactive to OVA 
peptide, did not develop disease (Zahorsky-Reeves and Wilkinson, 2001) suggesting 
that in the scurfy mouse, it is the recognition of endogenous self-antigens or 
environmental antigens, which drives pathology.
1.6.2 Identification o f the gene responsible for the scurfy phenotype
The gene responsible for the scurfy phenotype was identified using a classic 
positional gene cloning approach (Brunkow et al., 2001). Sequence analysis identified 
the gene as a novel member of the forkhead/winged-helix family of transcriptional 
regulators and was designated Foxp3. The forkhead/winged helix family of
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transcription factors comprises a large and diverse group of transcription factors that 
share a ‘winged helix’ DNA binding domain of approximately 110 amino acids. Over 
100 proteins with forkhead domains have been identified, comprising at least 17 
different subclasses (Jonsson and Peng, 2005). These proteins are believed to act as 
both transcriptional activators and repressors (Coffer and Burgering, 2004). The 
nomenclature is such that genes that encode human transcription factors are denoted 
by uppercase letters, i.e. FOX, whereas only the first letter is capitalised for genes that 
encode mouse transcription factors (Fox). Both human and mouse proteins are 
denoted by uppercase letters, i.e. FOX (Coffer and Burgering, 2004).
Unlike most members of the FKH family, FOXP3 is unique in having the functional 
FKH domain located near the C-terminus. Other interesting structural motifs in the 
FOXP3 protein include a proline-rich region at the amino terminus, a zinc finger and 
a leucine zipper (Gambineri eUo/., 2003). The significance and function of these 
domains is currently unknown. The FoxpS gene in the scurfy mouse has a 2 base-pair 
insertion just upstream of the FKH domain, resulting in a frameshift mutation and a 
premature stop codon. This results in a truncated gene product lacking the functional 
C-terminal FKH domain, which suggests an important role for this domain in 
controlling T cell activation.
1.6.3 Immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome 
(IPEX)
Although the human FOXP3 protein at 431 amino acids in size is 2 amino acids larger 
than the mouse FOXP3 protein, there is a high degree of sequence identity between
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the two proteins with an overall similarity index of 8 6 %. However within the FKH 
domain this rises to 94%, highlighting the importance of this domain to the 
functionality of the protein (Brunkowet al., 2001). As the scurfy mutation is so 
severe, one might expect mutations in this region to also manifest as severe disease in 
humans. Indeed this is the case with evidence that mutations within the FOXP3 gene 
in humans cause IPEX (Bennett et a l, 2001; Wildin et al., 2001).
EPEX is an X-linked fatal, recessive disorder that presents most commonly in early 
childhood. Enteropathy is the most common feature and patients often develop 
Crohn’s disease or ulcerative colitis. Endocrinopathies including diabetes and thyroid 
abnormalities are also common, as are skin disorders and increased susceptibility to 
infections (Gambineri et al., 2003). Patients also have high serum IgE levels and 
eosinophilia is sometimes present. There are also elevated levels of autoantibodies 
against different organs. Current therapy for IPEX patients involves the use of broad 
immunosuppressives like cyclosporin A and FK506, either alone or in combination 
with steroids. However these drugs are very toxic and long-term remission is never 
achieved. Bone-marrow transplantation is currently the only effective cure.
The mutations that cause IPEX within the human FOXP3 gene are spread throughout 
the gene. Currently 13 different mutations have been reported within the FOXP3 
gene. The majority of the mutations are missense mutations within the FKH domain 
(Bennett et al., 2001; Wildin et a l, 2001; Wildin et al., 2002; Kobayashi et al., 2001). 
There are also mutations affecting the leucine-zipper (Chatila et al., 2000), the 
proline-rich domain (Kobayashi et al., 2001) and there have been reports of deletions 
resulting in the removal of the stop codon, leading to proteins with C-terminal
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extensions (Bennett et al., 2001; Wildin et a l, 2001). Interestingly another report 
describes a patient who does not have a mutation within the coding region of the gene 
and exhibits a less severe form of the disease (Wildin et al,, 2001). The authors 
suggest that this patient may have a mutation in the non-coding region, which affects 
transcriptional regulation or RNA splicing. However, a recent report shows that in a 
cohort of 27 affected males from 24 families who were referred for sequencing of 
FOXP3 because of their clinical phenotype, only 60% had identifiable mutations 
within the coding region (Ochs et al., 2005). A further 10% exhibited low mRNA 
levels suggesting possible mutations in the non-coding region. The remainder could 
have mutations within the promoter region or alternatively, they may have mutations 
in other genes which directly or indirectly interact with the functionality of FOXP3.
1.6,4 Function of FOXPS
The severity of the phenotype of both the scurfy mouse and patients with IPEX 
highlights the essential role of this protein in maintenance of immune homeostasis. 
The first insight into how FOXP3 acts to regulate CD4+ T cell function came from a 
study in Jurkat T cells (Schubert et al., 2001). Overexpression of the protein in Jurkat 
T cells resulted in a dramatic reduction in the levels of IL-2 production. Confirmation 
that the FKH region of the protein is essential for function was demonstrated using an 
IL-2 reporter gene assay. A multimer of the essential regulatory nuclear factor 
activated T cells (NFAT) site from the mouse IL-2 promoter was cloned upstream of 
the luciferase reporter gene. Cotransfection of this construct with either FOXP3 or a 
mutant form of the gene lacking the FKH domain into Jurkat T cells and subsequent 
activation with phorbol-12-myristate, 13-acetate (PMA) and ionomycin, resulted in a
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significant reduction in the levels of luciferase production by the cells expressing full- 
length FOXP3. This was also confirmed using the proximal IL-2 promoter to drive 
luciferase expression. These studies suggest that FOXP3 is a transcriptional repressor 
and may bind directly to regions within the promoter/enhancer elements of certain 
genes. Indeed further studies by the same group identified potential FKH binding sites 
adjacent to critical NFAT elements in several cytokine promoters.
The phenotype of the scurfy mouse is one of dysregulated T cell function and elevated 
cytokine production, supporting a role for FOXP3 as a transcriptional repressor of 
certain cytokine genes. To study the function of FOXP3 in more detail, several 
different Foxpi-transgenic mouse lines were established (Khattri et al., 2001). Whilst 
expression of full-length FOXP3 protein prevented disease in each scurfy mutant 
mouse line, analysis of the T cell component of these mice revealed differences in T 
cell number dependent upon the number of copies of the transgene. Each of the lines 
showed reductions in the numbers of splenic and lymph node cells compared to 
healthy litter mate controls, with both CD4+ and CD8 + T cell numbers reduced. 
However this was most dramatic in the mouse lines expressing the highest copy 
number. Interestingly, transgenic animals that expressed the Foxp3 gene exclusively 
in the thymus, were susceptible to disease. This observation highlights not only the 
requirement for expression of FOXP3 in the periphery, but also the fact that the scurfy 
syndrome is unlikely to arise as a consequence of developmental defects in the 
thymus.
Functional analysis of the CD4+ T cells isolated from Foxp3 transgenic mice, 
revealed a significant reduction in the levels of proliferation and IL-2 production
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compared to control animals, following activation in vitro. Interestingly the 
proliferative response of thymic CD4+ T cells, was comparable to those isolated from 
control mice. However the levels of IL-2 production were reduced. Analysis of the 
CD8 + T cells revealed that although the cells still possessed cytolytic activity, they 
were less effective than CD8 + T cells isolated from control mice. Together these data 
indicate that FOXP3 acts as a central regulator of T cell activity.
1.6.5 FOXP3 and CD4+CD25+ regulatory T cells
The studies described thus far have highlighted the importance of FOXP3 in 
controlling T cell activation. An insight into a role for FOXP3 in regulatory T cell 
function has come from the observation that the scurfy phenotype can be rescued 
following the adoptive transfer of wild-type T cell enriched splenocytes (Smyk- 
Pearson et a l , 2003). Female carriers of the FOXP3 mutation are also apparently 
healthy. Even though they display random X chromosome inactivation, the presence 
of normal, in addition to mutated FOXP3 alleles, expressed in the peripheral CD4+ T 
cells o f  IPEX carriers, appears sufficient to prevent disease (Tommasini et a l, 2002). 
Together these observations are consistent with the theory that FOXP3 may play a 
role in regulatory T cell activity.
Evidence to support this theory has come from further studies with the Foxp3 
transgenic mouse (Khattri et al., 2003). These authors showed that FOXP3 expression 
correlated with CD4+CD25+ T cells and was not upregulated in CD4+CD25- T cells 
following activation, suggesting that FOXP3 expression is specific to T cells of the 
regulatory T cell lineage. In addition, CD4+CD25+ T cells from scurfy mice lacked
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regulatory activity whereas the CD4+CD25+ T cells from the Foxp3 transgenic mice 
had suppressive activity. They further showed that the CD4+CD25- and CD8 + T cell 
populations but not the B cell population from the transgenic mouse also had 
suppressive activity.
Complementary to the studies by Khattri et al. (2003), two separate groups confirmed 
the specific expression of Foxp3 in mouse CD4+CD25+ regulatory T cells. These 
studies showed that retroviral transduction of mouse CD4+CD25- T cells with the 
Foxp3 gene results in the generation of regulatory T cell activity (Hori et al., 2003; 
Fontenot et al., 2003). Perhaps most impressively, these Foxpi-transduced cells were 
able to protect against colitis following transfer into a lymphopenic host together with 
pathogenic CD4+CD25- T cells. Following the publication of these studies, a 
subsequent study has shown that Foxp3-transduced CD4+ T cells with specificity for 
islet antigen were able to stabilise and reverse disease in mice with recent-onset 
diabetes (Jaeckel et al., 2005).
Human CD4+CD25+ T cells have also been shown to express FOXP3 although 
interestingly in human cells, the protein appears to migrate as a doublet following 
immunoblot analysis (Walker et a l, 2003a). Overexpression of FOXP3 in human 
CD4+CD25- T cells following retroviral transduction was also sufficient to convert 
the cells into a regulatory phenotype (Yagi et al., 2004). The cells were 
hyporesponsive following stimulation with soluble anti-CD3 mAb and autologous 
APCs, and were able to suppress the proliferative response of non-transduced 
CD4+CD25- T cells. Together these data highlight a significant role for FOXP3 in 
CD4+CD25+regulatory T cell function.
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1.6.6 F0XP3 and other T cell subsets
Whilst it would be tempting to conclude that FOXP3 is a truly specific marker for 
CD4+CD25+ regulatory T cells derived from the thymus, data is emerging to suggest 
this is not always the case. Activation of human CD4+CD25- T cells in the presence 
of plate-bound anti-CD3 mAb and soluble anti-CD28 mAb, resulted in the 
upregulation of FOXP3 expression in the CD25+ fraction of cells and conferred 
suppressive function upon the cells, which was cell-contact dependent (Walker et al., 
2003a). Further studies by the same group have shown that antigen-specific 
CD4+CD25+ regulatory T cells can be derived from CD4+CD25- T cells isolated 
from peripheral blood (Walker et al., 2005). These data suggest that FOXP3 positive 
regulatory T cells may be generated in the periphery from CD4+CD25- T cells during 
an immune response, to help regulate the magnitude of the response. FOXP3 
expression can also be upregulated in both human and mouse GD4+CD25- T cells 
following culture in vitro with TGFp, resulting in the generation of suppressive 
activity (Fantini et al., 2004). Expression analysis in human lymphocytes has also 
revealed that FOXP3 is not unique to CD4+ T cells. Alloantigen specific CD8+CD28- 
suppressor T cells also express FOXP3 (Scotto et al., 2004). A recent paper has also 
shown that FOXP3 expression can be upregulated in CD8 + T cells following 
activation (Morgan et a l, 2005).
The relationship between naturally occurring CD4+CD25+ regulatory T cells and the 
extrathymically-derived Trl and Th3 regulatory T cells is still,not clear. However, the 
expression profile of FOXP3 had suggested that the adaptive regulatory T cells lacked 
FOXP3 expression and thus were a separate lineage of regulatory T cells. Indeed
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analysis of in vitro derived Trl regulatory T cells produced following stimulation with 
vitamin D3 and dexamethasone, showed that although the cells did riot express 
FOXP3, they were able to suppress the proliferation of CD4+CD25- responder T cells 
in the presence of anti-CD3 mAb and APCs. This suppression was cell-contact 
dependent and could not be reversed via the addition of blocking antibodies to IL-10, 
TGFp or CTLA-4 (Vieira et al., 2004). The in vivo generation of Trl cells following 
intranasal administration of a specific MBP peptide also generated cells that were 
FOXP3 negative (Vieira et al., 2004). However a recent study has challenged this 
theory and shown that a population of antigen-specific regulatory T cells expressing 
FOXP3 and producing both IFNy and IL-10, were generated following the adoptive 
transfer of antigen-pulsed mature CD8 a  dendritic cells (Stock et al., 2004).
Whilst there is clearly a functional association with FOXP3 expression and regulatory 
T cell activity there are still many questions to be answered regarding the mechanism 
of action of FOXP3 and also the role of FOXP3 in generating both naturally occurring 
and adaptive regulatory T cells. Whether FOXP3 has functions outside of regulatory 
T cells also needs to be determined. Clearly this is an exciting area of research and as 
the biology of FOXP3 is unravelled it will hopefully provide new options for the 
treatment of human autoimmune diseases and cancer. Indeed there is already evidence 
to suggest that one of the beneficial mechanisms of action of glucocorticoids used for 
the treatment of asthma is to induce FOXP3 expression and increase regulatory T cell 




The use of chimeric receptors to specifically target T cells to kill tumour cells through 
the antigen specific activation of T cells, is being considered as an immunotherapy 
approach to cancer (Sadelain et al., 2003). This approach involves engineering a T 
cell to express a chimeric receptor consisting of an antibody-binding region linked via 
a transmembrane region to an intracellular signalling domain or domains, involved in 
T cell activation. The antibody-binding region generates the specificity and can be 
engineered to recognise different tumour antigens. Once the T cell encounters the 
antigen expressed on the surface of the tumour cell, the T cell will become activated 
resulting in tumour killing (Sadelain et al., 2003).
Potent costimulatory signals can be delivered through the use of chimeric receptors 
with the intracellular signalling domain o f CD28 linked in series to the intracellular 
signalling domain of the < -̂chain from the TCR complex (Finney et al., 1998 and 
Figure 1.1). Stimulation of chimeric receptor transfected cells with solid phase 
antigen results in the production of IL-2, TNFa, IFNy and GM-CSF (Finney et al., 
2004). Chimeric receptors providing costimulatory signals through other molecules 
such as CD134, ICOS and CD137 have also been described (Finney et al., 2004). 
Whilst these molecules have been designed for use in targeted cancer immunotherapy, 







Figure 1.1 Schematic diagram of the CD28/TCR£ chimeric receptor.
The chimeric receptor consists of a single chain Fv specific for CD33, linked to an 
extracellular spacer comprising human IgGl hinge, CH2 and CH3. The spacer is linked to the 
transmembrane (T.M.) and intracellular regions of human CD28, which is linked to the 
intracellular region of human TCR^.
The extracellular region of the receptor illustrated in figure 1.1, is an antibody single 
chain Fv (scFv) that binds to CD33. It has been reported that the addition of chimeric 
receptor transfected human T cells to CD33-coated antigen plates, induces a strong 
activating signal into the transfected cells through the scFv (Finney et al., 2004). This 
mechanism of activation ensures that only the transfected cells receive stimulation. 





Regulatory T cell biology has become a vast subject encompassing both naturally 
occurring CD4+CD25+ regulatory T cells and various inducible regulatory T cell 
types. Functional characterisation of these different cell types in terms of both cell 
surface marker expression and mode o f action has produced differing results and 
conclusions. These discrepancies may partly be explained by species differences and 
also by the cellular environment within which the assays were conducted.
The primary aim of the studies described in this thesis was to carry out a thorough 
characterisation of human CD4+CD25+ regulatory T cells, derived from peripheral 
blood. A detailed analysis of the cell surface phenotype of freshly isolated and three 
day activated CD4+CD25+ regulatory T cells versus CD4+CD25- T cells, was carried 
out. Functional suppression assays were also established and the mechanism of 
suppression was investigated through the use of antibodies to various cell surface 
markers and cytokines, which have been implicated in regulatory T cell function.
The second aim of these studies was to investigate the function of FOXP3 following 
overexpression of the protein in both human CD4+ and CD8 + T cells. This was 
achieved through the establishment of a novel cotransfection system. This system 
utilised chimeric receptors to ensure that only transfected cells could receive 
activation signals. The final aim of the work presented in this thesis was to investigate 
the functionality of splice variant forms of the human FOXP3 gene generated during 









General laboratory chemicals were purchased from Sigma Aldrich Ltd, (Gillingham, 
U.K.) or BDH Ltd, (Poole, U.K.) unless stated otherwise. Ethanol and Methanol were 
from Hayman Ltd, (Witham, U.K.). Bacto-tryptone, bacto-agar and bacto-yeast 
extract were from Difco Ltd, (Detroit, U.S.A.).
All tissue culture media, supplements and biological buffers were supplied by 
Invitrogen Ltd, (Paisley, U.K.). Foetal calf serum (FCS) was from Helena Biosciences 
Ltd, (Sunderland, U.K.). Human AB serum was from Cambrex Biosciences Ltd, 
(Venders, Belgium.). All tissue culture plastic ware was purchased from Falcon, BD 
Biosciences, (Cowley, U.K.) with the exception of 96-well U-bottomed plates which 
were purchased from Costar, (New York, U.S.A.) and ELISA plates which were 
Nunc™ brand products supplied by Fisher Scientific, (Loughborough, U.K.). All 
cytokines were purchased from R&D Systems, (Abingdon, U.K.) with the exception 
of human IL-2 which came from Roche, (Lewes, U.K.). Tetanus Toxoid (TT) was 
purchased from CN Biosciences Ltd, (Nottingham, U.K.). CHO-K1 cells were from 
ECACC, (CAMR, Porton Down, U.K.).
'XThe radionucleotide methyl-[ H]- thymidine had a specific activity of 50pCi/mL and 
was purchased from Amersham Biosciences, (Chalfont St.Giles, U.K.).
Restriction endonucleases, dNTPs and DNA molecular weight markers were 
purchased from New England Biolabs Ltd, (Hitchin, U.K.). T4 DNA ligase (HC) and 
1 OX ligation buffer were purchased from Promega, (Southampton, U.K.). DNA
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sequences were cloned into pcDNA3.1+ or pTracer-CMV2 expression vectors, 
purchased from Invitrogen. QIAGEN Miniprep, Maxiprep, QIAquick PCR 
purification and gel extraction kits were all purchased from Qiagen Ltd, (Crawley, 
U.K.). Apparatus for horizontal gel electrophoresis was supplied by Invitrogen.
Big Dye Terminator Cycle Sequencing Ready Reaction DNA sequence kit was 
obtained from Applied Biosystems, (Warrington, U.K.). Sequencing reactions were 
carried out using a Biometra Trio-Thermablock (Anachem Ltd, Luton, U.K.). All 
other PCR reactions were carried out using a Primus 96 Plus PCR machine (MWG- 
Biotech, Milton Keynes, U.K.). Hot Start DNA polymerase was purchased from 
Novagen, (Nottingham, U.K.).
Tris-glycine SDS page gels and SeeBlue prestained molecular protein markers were 
supplied by Invitrogen. Immobilon-P PVDF membrane was from Millipore Ltd, 
(Watford, U.K.).
Small-scale centrifugation was performed using Eppendorf 5415D or Eppendorf 
5415R refrigerated benchtop microcentrifuges (Anachem Ltd, Luton, U.K.). Soryall 
RC3B and RC5B refrigerated centrifuges were used for large scale bacterial 




2.1.2 Buffers and solutions
PBS 137mM NaCl 
2.68mM KC1 
10.1mMNa2HPO4 
1.76mM KH2P 0 4 
pH7.4
TAE 40mM Tris-acetate pH 8.0 
2.5mM EDTA
TE lOmM Tris-HCl pH7 4 
ImMEDTA
Hi TNE 65mM Tris-HCl 
15mMEDTA 
4M NaCl








6 X protein sample buffer 60% glycerol 













Tris-glycine transfer buffer 25mM Tris base
192mM glycine 
2 0 %(v/v) methanol
MACS Buffer Sterile tissue culture grade PBS supplemented with 
0.5% bovine serum albumin (BSA) and 2mM EDTA. 
Sterile filtered and degassed.
Red cell lysis buffer Sterile tissue culture grade distilled water supplemented 
with 155mM NH4CI, lOmM KHCO3 and O.lmM 
EDTA. Sterile filtered.
LB Agar 1 % (w/v) Bacto-tryptone




SOC medium 2% (w/v) Bacto-tryptone
0.5% (w/v) Bacto-yeast extract





2X TY broth 2% (w/v) Bacto-tryptone 
1% (w/v) Bacto-yeast extract 
171mMNaCl 
1.5% (w/v) Bacto-agar 
pH7.0
2.1.3 Antibodies
The antibodies and fusion proteins used for functional assays are listed in table 2.1. 
All antibodies were used at lOpg/mL in functional assays, apart from the anti-CD3 
antibodies which were used at lpg/mL. The antibodies used for flow cytometric 
analyses are listed in table 2 .2 .
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Specificity Clone Isotype Function Source
Hu IL-10 23738.111 mu IgG2b neutralising R&D
Hu TGFp 1,(32,(33 1D11 muIgGl neutralising R&D
Hu IL-2 5334 mu IgGl neutralising R&D
Hu CD25 22722 muIgGl blocks ligand binding R&D
Hu CD 122 27302.1 m uIgGl blocks ligand binding R&D
HuCTLA-4 ANC 152.2/ 
8H5
mu IgGl blocks ligand binding Ancell
Hu CD28 CD28.2 mu IgGl costimulatory BD
Hu CD 134 L106 mu IgGl blocks ligand binding BD
HuGITR 110416 mu IgGl blocks ligand binding R&D
Hu Lag-3 17B4 mu IgGl blocks ligand binding Apotech
Hu TGFpRH polyclonal goatlgG blocks ligand binding R&D
HuIL-17 41809 mu IgG2b neutralising R&D
Hu TNFR2 2 2 2 2 1 mu IgG2a blocks ligand binding R&D
Hu CD95 SMI/23 mu IgG2b blocks apoptosis Alexis
Hu CD95 APO-1-1 mu IgGl Induces apoptosis 
upon cross-linking
Alexis
Hu CD3 OKT3 mulgG2a activation Celltech
Mu CD3 145-2C11 hamster
IgGl
activation BD
CD22-muFc mu IgGl control fusion protein Celltech
muCTLA-4muFc mu IgGl blocks ligand binding Celltech
control MOPC21 m uIgGl control Celltech
rat CD 134 MAROX2A mu IgG2a control Celltech.
control 20116.11 mu IgG2b control R&D
control polyclonal goat IgG control R&D
Table 2.1 Antibodies and fusion proteins used in functional assays. Human is abbreviated 
to hu and mouse is abbreviated to mu.
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Specificity Clone Isotype Fluorochrome Supplier Cone used
Hu CD4 RPA-T4 Mu IgGl FITC/PE BD 5nL/105 cells
Hu CD8 HIT8 a M uIgGl FITC/PE BD 5nL/105 cells
Hu CD25 M-A251 Mu IgGl PE BD 5nL/105 cells
Hu CD69 FN50 Mu IgGl PE BD 5nL/105 cells
Hu CD 134 ACT35 M uIgGl PE BD 5nL/105 cells
HuICOS DX29 Mu IgGl PE BD 5nL/105 cells
Hu CD45RA HI100 Mu IgG2b PE BD 5nL/105 cells
Hu CD45RO UCHL1 Mu IgG2a PE BD 5nL/105 cells
HuGITR 110416 M uIgGl PE R&D 10nL/105
cells
Hu CD95 LOB3/17 M uIgGl PE Serotec 5nL/105 cells
Hu TNFR2 22235 MuIgG2a PE R&D 1 0 nL/1 0 5
cells
Hu CTLA-4 BNI3 Mu IgG2a PE BD 5uL/105 cells
Hu CD 103 LF61 M uIgGl PE Serotec 5nL/105 cells
Hu CD27 M-T271 M uIgGl PE BD 5nL/105 cells
Hu CD62L DREG-56 M uIgGl PE BD 5nL/105 cells
Hu CD 122 Mik-p3 M uIgGl PE BD 10(ig/mL
HuCD132 TUGh4 Rat IgG2b PE BD 10jag/mL
Hu CD40L TRAP1 M uIgGl PE BD 5nL/105 cells
Hu CD 137 4B4-1 Mu IgGl PE BD 5|j.L/105 cells
HuBDCA-4 AD5-17F6 M uIgGl PE Miltenyi-
Biotec
5(xL/105 cells
HuPD-1 MIH4 M uIgGl FITC BD 10jag/mL
Hu Galectin-1 polyclonal goat unlabelled R&D lOjug/mL
Mu CD4 YTS
177.9
Rat IgG2a FITC Serotec 5nL/105 cells
Mu CD25 PC61 Rat IgGl PE BD lOpg/mL
CD33 scFv Hu protein FITC/Alexa 488 Celltech lpg/mL
Goat F(ab’)2 polyclonal rabbit FITC Jacksons 2pg/mL
control MOPC21 MuIgGl PE/FITC BD 5nL/105 cells
control G155-178 MuIgG2a PE BD 5nL/105 cells
control 27-35 MuIgG2b PE BD 5nL/105 cells
control R35-38 Rat IgG2b PE BD 5uL/105 cells
control Goat IgG unlabelled R&D lOjug/mL
Table 2.2 Antibodies and proteins used for flow cytometric analyses. Human is 




Oligonucleotides were designed using sequences in the Genbank nucleotide sequence 
database. Shown below are the cloning primers for human FOXP3, the flag-tagged 
FKH mutant and mouse Foxp3.
Human FOXP3 -  Genbank accession number AF277993: 
huFOXP3FWD2 (forward)




5’ -  GAGAGAGCGGCCGCTCAGGGGCCAGGTGTAGGGTTG -  3’
Notl
Human FOXP3 flag-tagged FKH mutant:
huFOXP3FWD2 was used as the cloning forward primer.
FKH_FOXP3_REV (reverse)
Stop
Hind. I ll Flag sequence _____ _
5’- GAGAGAAAGCTTCTACTTGTCATCGTCGTCCTTGTAGTCGTTGTGGAG 
GAACTCTGGGAATGTG -  3 ’
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Mouse Foxp3 -  Genbank Accession number NM_054039:
muFoxp3FWD (forward)
EcoKI Start
5’ -  GAGAGAGAATTCGCCACCATGCCCAACCCTAGGCCAGCCAAG -3 ’
muFoxp3REV (reverse)
Stop
5 ’ -  GAGAGAGCGGCCGCTCAAGGGCAGGGATTGGAGCACTTG -3 ’
Notl
2.2 Cell Culture Methods
2.2.1 Medium for mammalian cells
All human peripheral blood mononuclear cells (PBMCs) were maintained in RPMI 
1640 medium supplemented with 5% (v/v) human AB serum, 2mM L-glutamine, 
50U/mL penicillin and 50pg/mL streptomycin. Mouse splenocyte-derived cells were 
maintained in RPMI 1640 medium supplemented with 10% (v/v) FCS, 2mM L- 
glutamine, 50U/mL penicillin and 50pg/mL streptomycin. CHO-K1 cells were 
maintained in DMEM medium supplemented with 10% (v/v) FCS, 2mM ;L-glutamine, 
50U/mL penicillin, 50pg/mL streptomycin and IX non-essential amino acids. CHO- 
K1 cells are adherent cells and were removed by the addition of trypsin-EDTA.
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2.2.2 Isolation o f human PBMCs from blood
Human peripheral blood was obtained from normal healthy donors and was given 
with informed consent. Whole blood was taken by venous puncture and collected into 
heparinised containers (BD Biosciences). Blood was diluted 1:1 using RPMI 1640 
medium, prior to layering 30mL of diluted blood over 20mL of Ficoll-Paque™ PLUS 
(Amersham Biosciences). Layered blood was separated by density gradient 
centrifugation (470g for 25 minutes, no brake). The PBMC interface was pipetted off 
into fresh human AB serum-containing medium and centrifuged at 470g for a further 
10 minutes. The cell pellet was resuspended in fresh medium and centrifuged at 2;10g 
for 10 minutes to remove contaminating platelets. This was followed by a final wash 
and centrifugation step at 300g for 5 minutes.
2.2.3 Isolation o f human CD4+ and CD8+ T cells from peripheral blood
Human PBMCs were isolated from peripheral blood by density gradient 
centrifugation as described above. The CD4+ T cells and CD8 + T cells were purified 
via negative selection using MACS human CD4+ and CD8 + T cell negative selection 
isolation kits, LS+ separation columns and a Quadromacs magnetic separator, 
according to the manufacturer’s instructions (Miltenyi Biotec, Bergish Gladbach, 
Germany.). The negative selection kits allow the isolation of unlabelled CD4+ or 
CD8 + T cells by depletion of non-CD4+ or non-CD8 + T cells with a cocktail of 
biotin-conjugated antibodies to CD14, CD16, CD 19, CD36, CD56, CD123, TCRyb 
and glycophorin A. The addition of anti-biotin coated microbeads ensures the 
antibody bound cells are retained on the LS+ separation column, placed within a 
magnetic field, whilst the unbound cells are collected as flow-through. Where
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required, the LS+ column was removed from the magnetic field and the bound cells 
were eluted and used as CD4-depleted PBMCs.
2.2.4 Isolation o f human CD4+CD25+ and CD4+CD25- T cells from peripheral 
blood
Purified human CD4+ T cells were further separated into CD25+ and CD25- fractions 
using MACS human CD25 microbeads (Miltenyi Biotec). Purified CD4+ T cells were 
resuspended in 95 pL of MACS buffer per 107 cells. 5pL of CD25 microbeads per 107 
cells were added and the cells were incubated for 10 minutes at 4°C. The cells were 
washed in 10-20 times the original volume with MACS buffer and resuspended in 
500pL of MACS buffer per TO8 total cells. A LS+ column was placed into the 
QuadroMacs magnetic separator and prewashed with 3mL of MACS buffer. Cell 
suspension was loaded onto the column and the eluant was collected. Four further 
washes with 3mL of MACS buffer were conducted and the additional eluant was 
collected to ensure all the CD25- cells were isolated. The column was removed from 
the magnet and the bound cells were eluted in 5mL of MACS buffer (CD25+ 
fraction). Eluted cells were reapplied to a second LS+ column and the procedure was 
repeated to ensure optimal enrichment of the CD25+ population. The flow-through 
was discarded at this stage.
2.2.5 Isolation of human CD4+CD95+ and CD4+TNFR2+ T cells from peripheral 
blood
CD4+CD95+ and CD4+TNFR2+ T cells were isolated using a MACS two-step 
positive selection method with an anti-CD95-PE or anti-TNFR2-PE antibody and 
anti-PE-MACS beads (Miltenyi Biotec). Briefly the purified CD4+ T cells were
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resuspended in lOOpL of MACS buffer per 107 cells. lOpL of CD95-PE or TNFR2- 
PE antibody was added per 107 cells and the cells were incubated for 10 minutes at 
4°C. Cells were washed in 10-20 times the original volume with MACS buffer and 
resuspended in 90pL of MACS buffer per 107 cells. lO pL of anti-PE microbeads 
(Miltenyi Biotec) were added per 107 cells and the cells were incubated for a further 
10 minutes at 4°C. Cells were washed as above and resuspended in 500pL of MACS 
buffer per 108 total cells. Cells were purified into CD95+ and CD95- fractions (or 
TNFR2+ and TNFR2- fractions) following the method described for the purification 
of human CD4+CD25+and CD4+CD25-T cells.
2.2.6 Isolation of mouse CD4+CD25+ and CD4+CD25- splenocytes 
Spleens were obtained from 6 -8 -week-old BALB/c mice. Single cell suspensions were 
prepared by mechanical disaggregation through sterile nylon gauze (40pm). 
Contaminating erythrocytes were removed by a 5 minute lysis step in red cell lysis 
buffer. Cells were washed twice in RPMI 1640 medium containing 10% FCS and the 
CD4+ T cells were purified via negative selection using MACS mouse CD4+ T cell 
isolation kits, according to the manufacturer’s instructions (Miltenyi Biotec). Where 
required, the LS+ column was removed from the magnetic field and the bound cells 
were eluted and used as CD4-depleted splenocytes. CD4+CD25+ T cells were 
isolated using a MACS two-step positive selection method with an anti-CD25 PE 
antibody and anti-PE-MACS beads (Miltenyi Biotec) as described for the purification 
of human CD4+CD95+and CD4+CD95- T cells.
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2.2.7 Human CD4+CD25+ suppression assays in the presence ofPHA-L
CD4+ T cell-depleted PBMCs were y-irradiated for 50 minutes (25 sieverts, 137Cs 
source). The irradiated CD4-depleted PBMCs (5xl04/well) were cultured in 96-well 
U-bottomed plates with 2.5xl04/well purified CD4+CD25- or CD4+CD25+ T cells or 
both (2.5x104 each per well) .in the presence of lpg/mL PHA-L for 3 days at 37°C/
'l
5% CO2. On day 3, 0.5pCi/well H-thymidine (Amersham Biosciences) was added 
for 4-6 hours. Cells were then harvested onto glass-fibre filter mats (Perkin Elmer, 
Beaconsfield, U.K.) using a Skatron cell harvester and radionuclide uptake was 
measured by liquid scintillation counting. Supernatants were removed from duplicate 
cultures and assayed for IL-2, TNFa, IL-5 and IFNy. In some experiments, antibodies 
and exogenous cytokines (IL-2, TNFa and lymphotoxin (LT)) were added to the 
cultures at the start of the experiment. All antibodies were added at 10pg/mL unless 
otherwise indicated and those used are summarised in table 2.1. Exogenous cytokines 
were added at the concentrations indicated.
2.2.8 Human CD4+CD25+ suppression assays in the presence of tetanus toxoid 
(TT)
Irradiated CD4+ T cell-depleted PBMCs ( lx l0 5/well) were cultured in 96-well U- 
bottomed plates with 5xl04/well purified CD4+CD25- or CD4+CD25+ T cells or both 
(5xl04 each per well) in the presence of lpg/mL TT for 7 days at 37°C/ 5% CO2 . On 
day 7, 0.5pCi/well 3H-thymidine was added for 4-6 hours. Cells were then harvested 
onto glass-fibre filter mats using a Skatron cell harvester and radionuclide uptake was 
measured by liquid scintillation counting. Supernatants were removed from duplicate 
cultures and assayed for IL-2 and IFNy. In some experiments exogenous IL- 6  was 




The commercially available ELISA Duoset kits for human cytokines IL-2, IL-10, 
IFNy and TNFa (R&D Systems, Abingdon, U.K.) were used as indicated by the 
manufacturer. All standard curves were constructed and data analysed using Genesis 
II software (Labsystems, Altrincham, UK). Where indicated, additional measurements 
of the human cytokines IL-5, TNFa and IFNy were carried out using Luminex 
technology from R&D Systems, according to the manufacturer’s instructions.
2.2.10 Mouse CD4+CD25+ suppression assays
GD4+ T cell-depleted splenocytes were y-irradiated for 50 minutes (25 sieverts, 137Cs 
source). Irradiated CD4+ T cell-depleted splenocytes (5xl04/well) were cultured in 
96-well U-bottomed plates with lx l0 4/well purified CD4+CD25- or CD4+CD25+ T 
cells or both ( lx l0 4 each per well) in the presence of lpg/mL anti-CD3 antibody for 5 
days at 37°C/ 5% GO2. On day 5, 0.5pCi/well 3H-thymidine was added for 4-6 hours. 
Cells were then harvested onto glass-fibre filter mats using a Skatron cell harvester 
and radionuclide uptake was measured by liquid scintillation counting. Some 
experiments were performed in the presence of exogenous mouse IL-2 at the 
concentrations indicated.
2.2.11 Flow cytometric analysis
Round-bottomed 5mL polypropylene Falcon tubes were used for flow cytometric 
analysis (BD Biosciences). Cells (5xl04-lx l0 5/tube) were washed in 3mL/tube of ice- 
cold PBS supplemented with 5% (v/v) FCS and 0.1% (w/v) sodium azide (FACS 
buffer) and then incubated with the appropriately diluted antibody (or antibodies) for 
30 minutes on ice. The cells were then washed twice in 3mL/tube of FACS buffer and
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resuspended in 200pL/tube of FACS buffer. Analysis of the cells was carried out on a 
FACScalibur flow cytometer equipped with CellQuest software (BD Biosciences, San 
Jose, CA). All antibodies used are listed in table 2.2. CD33-FITC and CD33-Alexa 
488, both purified and conjugated in-house, were used at a final concentration of 
lpg/mL. Propidium iodide (PI) (BD Pharmingen) was used at a final concentration of 
0.5pg/mL.
2.2.12 Intracellular staining
Intracellular staining was carried out using Immunotech’s IntraPrep™ 
permeabilisation reagent, according to the manufacturer’s instructions (Beckman 
Coulter, High Wycombe, U.K.).
2.3 Protein Methods
2.3.1 Preparation o f cell lysates
Typically 5xl05- lx l0 6 cells were washed twice in PBS to remove all traces of serum. 
Pelleted cells were resuspended in 20pl of ice-cold lysis buffer (9mL of membrane 
preparation buffer, lmL of 10% Triton X-100 and a ‘complete’ protease inhibitor 
tablet (Roche Molecular Biochemicals, Lewes, U.K.). Cells were incubated on ice for 
5 minutes. Lysed cells were centrifuged at 16,100g for 10 minutes at 4°C in a bench- 
top centrifuge and supernatants were removed and stored at -20°C awaiting further 
analysis.
2.3.2 Determination of protein concentration
The total protein concentration of the cell lysates was determined using Micro BCA
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Protein Assay Reagents (Pierce Biotechnology, Rockford, U.S.A.) in accordance with 
the manufacturer’s protocol. Cell lysis buffer was used as the diluent for BSA 
standards and samples.
2.3.3 Immunological detection of protein (Western Blotting)
Samples were prepared for Western blot analysis by the additional of 6X protein 
sample buffer. Typically 3 pL of buffer was added to a 15pL sample. Samples were 
incubated at 100°C for 5 minutes and then briefly centrifuged in a bench-top centrifuge 
for 10 seconds. Samples were loaded onto 10% (w/v) Tris-Glycine pre-cast 
polyacrylamide gels (Invitrogen) alongside prestained molecular weight markers. Gels 
were electrophoresed in IX running buffer at 100V/35mA for approximately 90 
minutes, until the dye front had reached the bottom of the gel. Proteins were 
transferred to Immobilon-P PVDF membrane, which had been pre-wetted with 
methanol. Overnight transfer was carried out in transfer buffer at 80mA using a Hoefer 
TE series Transphor electrophoresis unit (Hoefer Scientific Instruments, San 
Francisco, U.S.A.). The blot was blocked in PBS containing 2% (w/v) milk powder for 
a minimum of 1 hour and then probed for 1-3 hours at room temperature with 
polyclonal rabbit antisera raised against recombinant human FOXP3, diluted 1:1,000 
in PBS containing 1% (w/v) milk powder and 0.1% (v/v) Tween-20. The blot was 
thoroughly washed in PBS containing 0.1% (v/v) Tween-20 before incubation for 1 
hour at room temperature with goat anti-rabbit Fc-HRP (Stratech Sci. Ltd, Luton, 
U.K.) diluted 1:10,000 in PBS containing 1% (w/v) milk powder and 0.1% (v/v) 
Tween-20. After a further thorough washing step, the blot was developed using Pierce 
Biotechnology’s Supersignal reagents (Illinois, U.S.A.) in accordance with the 
manufacturer’s instructions. The signal was detected Using x-ray film, which was
61
Chapter. 2
processed using an X-Omat automatic developer (Kodak Ltd., Hemel Hempstead, 
U.K.)
2.4 DNA Methods
2.4.1 PCR amplification of DNA fragments
Amplification of both human FOXP2 and mouse Foxp3 was performed using 
Novagen’s KOD Hot Start DNA Polymerase kit (Merck Biosciences, Nottingham, 
U.K.). To optimise PCR conditions, initial PCR reactions were carried out in a total 
volume of 20pL which contained approximately lOOng of cDNA, 0.3 pM each 
oligonucleotide, 0 2mM dNTP mix (dATP, dCTP, dGTP, dTTP), 2pL 10X PCR 
buffer, ImM MgSCU, 0.4pL KOD polymerase, 1-5% sterile 20% DMSO (1, 2, 3, 4 or 
5pL) and sterile dH20.
When PCR reactions were performed to generate DNA for cloning, reactions were 
scaled up to lOOpL, with each component in the same proportion as described above 
for the 20pL reactions. 5% DMSO was used in these reactions. Oligonucleotides were 
designed to have a melting temperature (Tm) of at least 72°C. Reactions were cycled 
under the following conditions:
94°C 3 minutes 
94°C 30 seconds 
60°C 30 seconds
68°C 2 minutes 
68°C 5 minutes 
4°C constant
Post-reaction, samples were analysed by agarose gel electrophoresis,
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2.4.2 Analysis o f DNA fragments by agarose gel electrophoresis
DNA samples were analysed by horizontal gel electrophoresis at 80V using 1% (w/v) 
agarose gels in lxTAE buffer. Appropriate size markers were included on each gel. 
Ethidium bromide was added to the gel to give a final concentration of 0.5pg/mL. 
DNA bands were visualised using ultraviolet (uv) transillumination at 254nm. Where 
agarose gel electrophoresis was used for the purification of DNA fragments, uv 
transillumination was at 366nm. This was to minimise the chance o f uv-induced 
mutations.
2.4.3 Phenol-chloroform extraction of DNA
After some PCR reactions and all restriction enzyme digests prior to purification by 
gel electrophoresis, DNA was extracted with phenol/chloroform/isoamyl alcohol 
(IAA). Briefly, to lOOpL of PCR reaction mix, 750pL phenol/chloroform/iosamyl 
alcohol, 80pL TE buffer and 20pL of H ITN E buffer were added and mixed well. 
Centrifugation (16,100g for 2 minutes) was used to separate the aqueous and organic 
layers. Aqueous layer was carefully removed and transferred to a fresh eppendorf tube. 
Any remaining phenol/chloroform/iosamyl alcohol was re-extracted with a further 
200jiL TE. Aqueous layer was combined with the first aqueous fraction and extracted 
with 750pL of chloroform and 15pL of IAA. DNA in the resultant aqueous layer was 
precipitated by the addition of 2.5 volumes of 100% ethanol , and incubated at -20°C 
for 1 hour. DNA was collected by centrifugation at 16,100g for 10 minutes, washed 
once with 70% ethanol and finally resuspended in an appropriate volume of TE buffer.
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2.4.4 Spin column purification o f PCR products
Following phenol-chloroform extraction, the PCR products were subjected to a further 
purification step using Qiagen’s QIAquick PCR purification kit, prior to restriction 
enzyme digestion. Purification of the mouse Foxp3 PCR product was carried out using 
this method alone, without the initial phenol-chloroform step. Briefly 5 volumes of 
buffer PB were added to 1 volume of PCR reaction and mixed. The sample was loaded 
onto a QIAquick spin column and centrifuged at 16,100g for 1 minute; the flow­
through was discarded. Column-bound DNA was washed with 750pL of buffer PE 
and centrifuged as before. The flow-through was discarded and the column was 
centrifuged for a further 1 minute. The DNA was eluted off the column by 
centrifugation following the addition of 50pL of buffer EB and an incubation step for 
1 minute at room temperature.
2.4.5 Restriction enzyme digests
For sub-cloning into an expression plasmid, the PCR product (purified as described 
above, sections 2.4.3 and 2.4.4), or approximately lOpg of plasmid DNA, was 
incubated with 20 units of each restriction enzyme in the appropriate buffer, overnight 
at 37°C. One unit is defined as the amount of enzyme required to completely digest 
1 pig of DNA in 1 hour. The digested fragments were then subjected to a phenol- 
chloroform extraction (2.4.3) prior to purification by gel extraction. For diagnostic 
analysis to detect clones containing the correct sized insert fragments, 0.5-lpg of DNA 
was incubated with 5 units of each restriction enzyme in the appropriate buffer for 2-4 
hours at 37°C. Digested plasmids were then analysed by gel electrophoresis.
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2.4.6 Purification of DNA fragments by gel extraction.
DNA fragments were purified from 1% agarose gels using Qiagen’s QIAquick Gel 
Extraction Kit, in accordance with the manufacturer’s instructions. Briefly the desired 
band was excised from the agarose gel under low uv wavelength light (366nm). The 
fragment was weighed and 3 volumes of buffer QG were added (the assumption was 
made that lOOmg of gel was equivalent to lOOpL volume). Following an incubation 
step at 50°C for 10 minutes to melt the agarose, 1 volume of isopropanol was added 
and the sample was loaded onto a QIAquick spin column. The column was centrifuged 
at 16,100g for 1 minute and the flow-through was discarded. The column was washed 
with 750pL of buffer PE. Finally the DNA was eluted in 50pL of buffer EB.
2.4.7 Ligation of DNA fragments
Ligation of gel purified DNA fragments was performed in a total volume of 20pL, 
comprising 2pL 10X ligation buffer, 0.4pL T4 DNA ligase (HC), approximately 50ng 
of vector DNA and a molar equivalent of insert fragment. Control reactions containing 
no insert were also carried out to allow assessment of the efficiency of the 
transformation. Ligation reactions were incubated overnight at 16°C, prior to 
transformation into E.coli cells.
2.4.8 Transformation of DNA into competent E.coli cells
Sub-cloning grade XL-1 blue E.coli cells were used for all transformations 
(Stratagene, California, U.S.A.). 60pL of cells were gently thawed on ice and lpL  of 
P-mercaptoethanol was added. Cells were incubated on ice for 5 minutes then lpL  of 
ligation mix was added. Cells were incubated on ice for a further 30 minutes. The cells 
were then heat-shocked at 42°C for 45 seconds and incubated for a further 2 minutes
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on ice. 950pL of SOC medium was added and the cells were incubated on a shaker 
platform at 37°C for 60 minutes. An appropriate volume of bacterial culture (typically 
a range of volumes from 10-200pL were used) was then streaked out onto LB-agar 
plates supplemented with lOOpg/mL carbenicillin. Plates were incubated at 37°C 
overnight.
2.4.9 Small-scale isolation of plasmid DNA.
Small-scale miniprep columns were used to prepare plasmid DNA for subsequent 
analysis by restriction enzyme digest or DNA sequencing. A single colony of 
transformed E.coli was used to inoculate lOmL of 2X TY culture broth containing 
TOOpg/mL carbenicillin. Culture was grown overnight at 37°C with shaking. Bacterial 
pellet was collected by centrifugation (l,500g for 15 minutes). Plasmid DNA was 
extracted using Qiagen’s miniprep columns, in accordance with the manufacturer’s 
instructions.
2.4.10 Large-scale isolation o f plasmid DNA.
Larger quantities of plasmid DNA were required for transfection experiments. A 
single colony of transformed E.coli was used to inoculate lOmL of 2X TY culture 
broth containing lOOpg/mL carbenicillin. Culture was grown for 8 hours at 37°C with 
shaking before being used to inoculate 200mLs of 2X TY culture broth containing 
lOOj-ig/mL carbenicillin. Following overnight culture at 37°C with shaking, the 
bacterial pellet was collected by centrifugation (4,600g for 15 minutes at 4°C). 
Plasmid DNA was then extracted in accordance with the manufacturer’s instructions.
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2.4.11 Optical density measurement o f  DNA
The concentration of DNA was determined via the measurement of the optical density 
at 260nm, using a quartz cuvette. An optical density reading of 1.0 was assumed to be 
equivalent to a concentration of 5 Opg/mL.
The concentration of DNA was hence calculated using the formula shown below: 
(OD260 x 50 x dilution factor)/ 1000 = mg/mL 
The purity of DNA was also calculated by dividing the OD260 by the OD280- Good 
levels of DNA purity give a value between 1.8-2.0.
2.4.12 DNA sequencing
DNA sequencing reactions were performed in 0.2mL thin-walled tubes (Anachem 
Ltd). Each reaction comprised 250ng of DNA, 5 pmoles sequencing primer, 1.5pL 
sequencing buffer and 1.5pL Big Dye Terminator Reaction Ready sequencing premix. 
Both the sequencing buffer and sequencing premix were included in the Big Dye 
Terminator Sequencing Ready Reaction DNA sequence kit, (Applied Biosystems). 
Distilled water was added to bring the volume to 7.5pL. The reaction was cycled 
under the following conditions:
96°C 30 seconds 
96°C 10 seconds ^
50"C 5 seconds L 25 cycles 
60°C 4 minutes 
4°C constant
DNA was then precipitated by the addition of 0.7 5 pL 3M sodium acetate (pH 4.6) and 
19.23pL 95% ethanol to each tube. Samples were then incubated at room temperature 
for 15 minutes and centrifuged at 1,5OOg for 45 minutes at 4°C. The resultant pellets
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were washed with 70% ethanol, air-dried and resuspended in IOjjL  formamide. The 
samples were then analysed on a 3100 automated DNA sequencer (Applied 
Biosystems).
2.5 Transfection Methods
2.5.1 Optimisation of transfection conditions
Transfections were carried out using the Amaxa Nucleofector™ technology (Amaxa 
Biosystems, Cologne, Germany.). Initial experiments were carried out using CHO 
cells. 2xl06 CHO cells were resuspended in 100pL of Nucleofector™ solution T. The 
cells were then mixed with 5pg of pTr.FQAP3 plasmid DNA and transferred to a 
cuvette. The cuvette was subjected to electroporation using programme U-24 in the 
Nucleofector™ electroporator. Cells were transferred to fresh medium and incubated 
for 24 hour at 37°C/5% CO2 . The cells were then analysed for GFP expression levels 
by flow cytometry. Optimisation of the human T cell transfection conditions was 
carried out using increasing numbers of cells and DNA, resuspended in 
Nucleofector™ human T-cell solution. Cells were subjected to electroporation 
programme U-l 3.
2.5.2 Transfection of human CD4+ or CD8+ T cells with FOXP3 for functional 
studies
4xl06 purified human CD4+ or CD8+ T-cells were resuspended in lOOpL of 
Nucleofector™ human T-cell solution. The cells were then mixed with 3pg of 
chimeric receptor DNA and 9pg of plasmid DNA containing either full-length 
FOXP3, an isoform of FOXP3, FKH mutant, or plasmid DNA with no insert, and
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transferred to a cuvette. The cuvette was subjected to electroporation using programme 
U-13 in the Nucleofector™ electroporator. Cells were immediately transferred to fresh 
culture medium and rested at 37°C for 4 hours. Following counting, cells were seeded 
at 5xl05 cells/well in either 96-well flat-bottomed CD33-coated plates (5pg/mL) or 
uncoated plates (stimulated versus unstimulated). The cells were then incubated for a 
further 24 hours. Supernatants were removed for cytokine analysis and cells were 
removed for analysis of cell viability, chimeric receptor expression levels and the 
levels of CD69 and CD25 expression, by flow cytometry. Cells were also harvested 
for analysis by Western blotting. For single transfections, 3pg of chimeric receptor and 
9pg of FOXP3 or control DNA (empty vector or FKH mutant) was used, per 4xl06 
cells.
2.5.3 Fluorescence microscopy
Cells were co-transfected as described above and incubated for 24 hours without 
CD33 stimulation. A dead cell removal step was carried out using a dead cell removal 
kit (Miltenyi Biotec) according to the manufacturer’s instructions prior to staining. 
Cytospins were prepared using lxlO5 cells/slide. The cells were fixed and 
permeabilised for 10 minutes in acetone and then air-dried for 30 minutes, before 
staining with lOOpL/slide of pre-mixed CD33-FITC (lpg/mL) and rabbit anti-sera 
raised against human FOXP3 (1:100). Slides were incubated at room temperature for 
30 minutes, before being washed in PBS supplemented with 5% FCS and 0.1% 
sodium azide and air-dried. Goat anti-rabbit IgG (Heavy+Light) Alexa Fluor 660 
antibody (Molecular Probes, Leiden, The Netherlands.) was added to each slide at a 
working concentration of lOpg/mL and the slides were incubated for a further 30 
minutes at room temperature. The slides were thoroughly washed in PBS and
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analysed on a Leica DMRXA fluorescence microscope. Images were manipulated 
using Openlab 2.2.0 deconvolution software (Improvision, Coventry, U.K.).
2.5.4 Proliferation assays with FOXP3-transfected cells.
CD4+ T cell-depleted PBMCs were y-irradiated for 50 minutes (25 sieverts, 137Cs 
source). The irradiated CD4+ T cell-depleted PBMCs (5xl04/well) were incubated in 
96-well U-bottomed plates with 2.5xl05 FOXP3 ox control vector-transfected cells 
and lpg/mL soluble anti-CD3. On day 3, 0.5pCi/well 3H-thymidine was added for 4-6 
hours. Cultures were harvested and radionuclide uptake measured by liquid 
scintillation counting.
2.5.5 Suppression assays with chimeric receptor-transfected CD4+ T  cells.
CD4+ T cells transfected with CD28/TCR<^ chimeric receptor alone (2x105/well) were 
co-cultured in a 1:2 ratio with CD4+ T cells co-transfected with either FOXP3 and 
CD28/TCR<^ chimeric receptor, or FKH mutant and CD28/TCR£ chimeric receptor 
(4xl05/well) in 96-well flat-bottomed CD33-coated plates for 24 hours at 37°C. 
Supernatants were removed and assayed for IL-2 production. This was repeated using 
CD4+ T cells co-transfected with either FOXP3 and TCR<̂  chimeric receptor, or FKH 
mutant and TCR£ chimeric receptor.
CD28/TCR£r transfected cells (1.5xl04/well) were also co-cultured in a 1:1 ratio with 
autologous preactivated CD4+CD25+ or CD4+CD25- T cells in 96-well flat-bottomed 
CD33-coated plates for 24 hours at 37°C. Supernatants were removed and assayed for 
IL-2 production. The preactivated cells were activated for 24 hours with lpg/mL 
PHA-L in the presence of autologous CD4+ T cell-depleted PBMCs. The cells were
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then repurified using a MACS CD4+ T cell negative isolation kit prior to addition to 
the suppression assay.
2.5.6 Suppression assays with chimeric receptor-transfected CD4+CD2 5+ 
regulatory T cells.
Human CD4+ T cells were purified from 200mL of peripheral blood. The purified 
CD4+ T cells were resuspended in Nucleofector™ human T-cell solution to give a 
cell concentration of 4xl06cells/100pL solution. Each lOOpL of cell suspension was 
then mixed with 3pg of CD28/TCR£ chimeric receptor DNA and transferred to a 
cuvette. The cuvette was subjected to electroporation using programme U-13 in the 
Nucleofector™ electroporator. Cells were immediately transferred to fresh culture 
medium and rested at 37°C for 4 hours. The cells were then purified into CD25+ and 
CD25- fractions following the protocol detailed in section 2.2.4. Chimeric receptor 
transfected CD4+CD25+ regulatory T cells (5x104/well) were co-cultured in 96-well 
flat-bottomed CD33-coated plates with 2.5xl04/well chimeric receptor transfected 
CD4+CD25- T cells (2:1 ratio). Cells were incubated for a further 24 hours at 
37°C/5% CO2. Supernatants were then removed and assayed for IL-2 production. 
Control wells included chimeric receptor transfected CD4+CD25+ regulatory T cells 
(5xl04/well) alone and chimeric receptor transfected CD4+CD25- T cells alone at 
2.5xl04/well, 5xl04/well and 7.5xl04/well. Both populations of transfected cells were 
also cultured for 24 hours at 37°C/5% CO2 in 96-well flat-bottomed uncoated plates 
(5xl04/well). Cells were then removed and viabilities and chimeric receptor 







The immune system is a highly complex entity requiring tightly controlled regulation 
to ensure tolerance to certain antigens and to prevent host tissue damage. Mechanisms 
that down-regulate an immune response are equally as important as mechanisms that 
activate a response. A seminal paper published in 1995, described a sub-population of 
CD4+ T cells whose function appeared to be the maintenance of self-tolerance in the 
periphery via down-regulation of the immune response (Sakaguchi et al:, 1995). 
These cells were characterised by the cell surface expression of CD25 and such was 
the impact of these studies, that the field of regulatory T cell biology was reborn. A 
plethora of papers have since been published on the phenotype of these naturally 
occurring CD4+CD25+ regulatory T cells, the activation requirements of these cells 
and the mechanisms by which these cells regulate. However, there are still many 
issues to be resolved before the biology of these cells is fully understood.
It is generally accepted that CD4+CD25+ regulatory T cells are derived from the 
thymus, although there may be mechanisms for generation of these cells in the 
periphery as well (Fehervari and Sakaguchi, 2004). They represent 5-10% of all 
peripheral CD4+ T cells and are characterised as being hyporesponsive in vitro to 
activation through the TCR (Jonuleit and Schmitt, 2003). In order to suppress 
CD4+CD25- responder cells, CD4+CD25+ regulatory cells require activation through 
the TCR and it appears that cell-cell contact is paramount for suppression in vitro. 
However, in vivo data suggests an additional role for soluble factors like IL-10 and 
TGFp (von Boehmer, 2005). The ability to suppress responses to a wide range of
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stimuli including self antigen, foreign antigen, dietary antigen and alio antigen, is an 
additional feature of these cells (Taams et al., 2002).
Reliable cell surface biomarkers that identify CD4+CD25+ regulatory T cells 
specifically, is an area of much research. CD25 has proved to be a reliable marker for 
the identification of resting CD4+CD25+ regulatory T cells, however it also a marker 
of activated T cells. Some of the other cell surface markers that have been identified 
by various groups as markers for CD4+CD25+ regulatory T cells include CD 103, 
0X40, 4-IBB, GITR, CTLA-4, TNFR2 and CD62L (Piccirillo and Thornton, 2004). 
Whether any of these markers also play a role in the functionality of these cells is 
unclear, as all appear to be dispensable for suppressor function.
The aim of this chapter was to address some of these issues by attempting to more 
fully characterise human CD4+CD25+ regulatory T cells, both in terms of cell surface 
marker expression and functionality. The expression of surface markers on both 
freshly isolated and three day activated CD4+CD25+ regulatory T cells was 
investigated and compared to CD4+CD25- T cells. Functional assays were also 
developed using both a polyclonal stimulus (PHA-L) and an antigen specific stimulus 
(tetanus toxoid). The mechanism of suppression was investigated by the use of 
antibodies to molecules implicated in regulatory T cell function, including antibodies 
to CTLA-4, IL-10, TGFp, CD25 and IL-2. The effect of certain cytokines on the 
ability of CD4+CD25+ regulatory T cells to regulate was also studied. Lastly, the 
isolation of regulatory CD4+ T cells on the basis of TNFR2 or CD95 expression and 




3.2.1 Purification o f  human CD4+CD25+ T cells from peripheral blood
Human CD4+CD25+ T cells were purified from PBMCs using a two-step MACS 
magnetic bead system. Initially the CD4+ T cells were isolated by negative selection 
followed by a positive selection for CD25. Analysis by flow cytometry o f the starting 
population o f PBMCs and the purified CD4+CD25+ and CD4+CD25- T cell 
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Figure 3.1 Isolation of human CD4+CD25+ regulatory T cells from peripheral blood.
CD4+ T cells were isolated from PBMCs using a MACS CD4+ negative selection isolation 
kit and separated into CD25+ and CD25- fractions using MACS CD25 microbeads. The 
starting PBMC population and the purified CD4+ T cells were analysed by flow cytometry 
for CD25 expression. Gates for CD25 expression were set using a mouse IgGl-PE antibody 
control. Percentage values for the number of CD25 positive cells are displayed. Data shown is 
representative of one of numerous donors.
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As is illustrated in the starting PBMC population in figure 3.1, there are 3 different 
cell populations staining for CD4 expression. The CD4 population represent the 
CD4+ T cells whilst the population staining medium-low for CD4 expression 
represent monocytes. The CD4 negative population primarily encompasses CD8+ T 
cells and B cells. The monocyte population is removed during the CD4+ T cell 
negative selection isolation step. Following purification with CD25 microbeads, a 
good enrichment of CD25 positive cells was obtained with high levels of CD25 being 
expressed on 86% of the CD4+ T cells. The dot-plots show that the purity of the 
CD4+CD25- population was higher than the CD4+CD25+ population, in this example 
99% versus 95% with respect to CD4 expression. Attempts to identify the 
contaminating population within the CD4+CD25+ population proved somewhat 
inconclusive and indeed, the levels of contaminating cells differed across donors. 
However the purity of the CD4+CD25+ population was consistently greater than 
90%.
3.2.2 Development of functional CD4+CD25+ suppressor assays
Having isolated a population of CD4+ T cells enriched for CD25 expression, the next 
step was to establish whether the cells were capable of inhibiting proliferation of 
CD4-CD25- responder T cells in a functional assay. Purified CD4+CD25+ T cells 
were co-cultured with purified CD4+CD25- cells in the presence of irradiated CD4+ 
depleted PBMCs and PHA-L. As is illustrated in figure 3.2a, the purified 
CD4+CD25+ cells significantly suppressed the proliferative response of the 
CD4+CD25- cells in response to PHA-L. Statistical analysis was by ANOVA and this 
analysis allows for comparison between multiple groups, however significance is
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usually only reached with experimental numbers greater than 3. As the majority of the 
experiments described in this chapter have experimental numbers of 3, it was decided 
that a Student T-test would be sufficient for statistical analysis of the remaining data 
described in this chapter. Hence, the levels of IL-2 (figure 3.2b), TNFa (figure 3.2c), 
IL-5 (figure 3.2d) and IFNy (figure 3.2e) were also significantly inhibited, as 
determined by a Student T-test. The CD4+CD25+ regulatory T cells also suppressed a 
cell population from undergoing low levels of proliferation and producing cytokines 
within the irradiated CD4-depleted cell population. This population although not 
formally identified, is thought to consist primarily of CD8+ T cells, as PHA-L is a 
potent T cell stimulator. For clarification, the abbreviation ‘++’ depicted on the 
graphs refers to double the number of CD4+CD25- T cells. This is to control for the 
total number of cells per well.
PHA-L is a mitogen and acts by cross-linking glycoproteins and glycolipids on the 
cell surface resulting in cellular activation. However it is not a physiological means Of 
activating cells. As an alternative, antigen-driven assays were, developed using tetanus 
toxoid. Purified CD4+CD25+ T cells were co-cultured with purified CD4+CD25- 
cells in the presence of irradiated CD4-depleted PBMCs and tetanus toxoid. The data 
illustrated in figure 3.3a shows that the CD4+CD25+ cells significantly inhibited the 
proliferative response of the CD4+CD25- cells in response to stimulation with tetanus 
toxoid. Production of IL-2 and IFNy was also inhibited by 59 ± 3% and 98 ± 2% 
respectively (figures 3.3b and 3.3c). These data confirm that peripheral blood-derived 
human CD4+CD25+ regulatory cells are capable of significantly inhibiting both the 
proliferative response of CD4+CD25-responder T cells and the release of both Thl 









irradiated CD4-depleted PBMCs + + + + +
PHA-L + + + + +
CD4+CD25+ - + - + -
CD4+CD25- . _ _ +  + ++
Figure 3.2a Inhibition of proliferation of CD4+CD25- responder cells by CD4+CD25+ 
regulatory cells following stimulation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 3-day culture 
period. Data shown are mean ± SEM of 6 donors. Value above *** indicates percentage 
inhibition ± SEM. Statistical analysis was by ANOVA with Bonferroni post-test. ***, 
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Figure 3.2b Inhibition of IL-2 production from CD4+CD25- responder cells by 
CD4+CD25+ regulatory cells following stimulation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. Supernatant was 
removed on day 3 and assayed for IL-2 levels by ELISA. Data shown are mean ± SEM of 3 
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Figure 3.2c Inhibition of TNFa production from CD4+CD25- responder cells by 
CD4+CD25+ regulatory cells following stimulation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. Supernatant was 
removed on day 3 and assayed for TNFa levels by LUMINEX. Data shown are mean ± SEM 
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Figure 3.2d Inhibition of EL-5 production from CD4+CD25- responder cells by 
CD4+CD25+regulatory cells following stimulation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. Supernatant was 
removed on day 3 and assayed for IL-5 levels by LUMINEX. Data shown are mean ± SEM of 
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Figure 3.2e Inhibition of IFNy production from CD4+CD25- responder cells by 
CD4+CD25+regulatory cells following stimulation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. Supernatant was 
removed on day 3 and assayed for IFNy levels by LUMINEX. Data shown are mean ± SEM 
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Figure 3.3a Inhibition of proliferation of CD4+CD25- responder cells by CD4+CD25+ 
regulatory cells following stimulation with tetanus toxoid.
Purified CD4+CD25- T cells were stimulated with tetanus toxoid and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 7-day culture 
period. Data shown are mean ± SEM of 3 donors. Value above * indicates percentage 
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Figure 3.3b Inhibition of IL-2 production from CD4+CD25- responder cells by 
CD4+CD25+regulatory cells following stimulation with tetanus toxoid.
Purified CD4+CD25- T cells were stimulated with tetanus toxoid and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. Supernatant was 
removed on day 7 and assayed for IL-2 levels by ELISA. Data shown are mean ± SEM of 3 
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Figure 3.3c Inhibition of IFNy production from CD4+CD25- responder cells by 
CD4+CD25+regulatory cells following stimulation with tetanus toxoid.
Purified CD4+CD25- T cells were stimulated with tetanus toxoid and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. Supernatant was 
removed on day 7 and assayed for IFNy levels by ELISA. Data shown are mean ± SEM of 4 
donors. Value above bar indicates percentage inhibition ± SEM.
81
Chapter 3
3.2.3 Potency o f  the CD4+CD25+ regulatory T  cell
To determine the potency of the CD4+CD25+ regulatory cells being isolated, a cell 
titration assay was established. The data illustrated in figure 3.4 shows that substantial 
inhibition of CD4+CD25- responder cells was achieved at a 1:1 cell ratio, where 
levels of 87% suppression were achieved. However even at a 3:1 ratio of responder to 
suppressor cells, the CD4+CD25+ were capable of approximately 50% inhibition. At 
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Figure 3.4 Titrating the suppressor response of CD4+CD25+T cells.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of titrating numbers of CD4+CD25- or CD4+CD25+ T cells. ❖ 
represents irradiated CD4-depleted PBMCS alone. <> represents the addition of CD4+CD25+ 
cells. O represents the addition of CD4+CD25- cells. The proliferative response was 
measured by 3H-thymidine incorporation during the last 4-6 h of a 3-day culture period. Data 
shown is representative of one of three experiments. Error bars represent SD of triplicate 
wells. Values next to data points indicate percentage inhibition ± SD.
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3.2.4 Investigation into whether IL-2 or certain proinflammatory cytokines can 
reverse CD4+CD25+-mediated suppression
The mechanism of suppression by human CD4+CD25+ regulatory cells in vitro is 
believed to be cell contact dependent. However there is conflicting data on the ability 
of different reagents to reverse suppression. In an attempt to determine whether the 
cells isolated in this study were responsive to IL-2, assays were established whereby 
increasing concentrations of human IL-2 was added to the co-cultures. Figure 3.5 
clearly illustrates that in this study, the ability of CD4+CD25+ regulatory cells to 
suppress CD4+CD25- responder cells, was not reversed following the addition of 
exogenous IL-2.
o  irradiated CD4+ depleted PBMCs 
<> + CD25+
L  o  +CD25-
o + 2xCD25
♦  + CD25+: C D 25-1:1 ratio 




Figure 3.5 Investigating the ability of exogenous IL-2 to reverse CD4+CD25+ T cell 
mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ at a 1:1 ratio of T cells. Exogenous human IL-2 was 
added at the start of the assay at the concentrations indicated. The proliferative response was 
measured by 3H-thymidine incorporation during the last 4-6 h of a 3-day culture period. Data 
shown are mean ± SEM of 3 donors.
To confirm that this result was not due to the nature of the activation stimulus, the 
experiment was repeated using tetanus toxoid as the stimulus (figure 3.6). A full dose 













this assay. However, in this system also, the addition of exogenous IL-2 did not result 
in full reversal of CD4+CD25+ T-cell mediated suppression. Previous studies using 












□HD lOOOU/mL IL-2 
lOOU/mL IL-2 
W777A lOU/mL IL-2
+ + + + + + + +
+  +  +  +  -f +  +  +
+  +  -  +  +  +  
-  -  +  ' + ■ ■ + +  +  +  + '
Figure 3.6 Investigating the ability of exogenous IL-2 to reverse CD4+CD25+ T cell 
mediated suppression following activation with tetanus toxoid.
Purified CD4+CD25- T cells were stimulated with tetanus toxoid and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. Exogenous human 
IL-2 was added at the start of the assay at the concentrations indicated. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 7-day culture 
period. Values above bars indicate percentage inhibition ± SEM. Data shown are mean ± 
SEM of 3 donors.
In a highly pro-inflammatory environment, one might expect suppression to be 
overcome in order to allow the host to mount an effective immune response to the 
invading pathogen. In this system, IL-2 alone did not appear to be having a profound 
effect, however other more proinflammatory cytokines could play such a role. Thus 
experiments were set up investigating the effect of exogenous IL-6, TNFa and 
Lymphotoxin (LT), on the ability of CD4+CD25+ T cells to suppress CD4+CD25- 
responder cells. The data from these experiments is illustrated in figures 3.7a-b and 
clearly shows that none of the aforementioned cytokines appeared to affect the ability
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of CD4+CD25+ cells to inhibit the proliferation of CD4+CD25- cells. The bioactivity 
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Figure 3.7a Investigating the ability of exogenous IL-6 to reverse CD4+CD25+ T cell 
mediated suppression following activation with tetanus toxoid.
Purified CD4+CD25- T cells were stimulated with tetanus toxoid and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. Exogenous human 
IL-6 was added at the start of the assay at the concentrations indicated. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 7-day culture 
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Figure 3.7b Investigating the ability of exogenous TNFa or LT to reverse CD4+CD25+ 
T cell mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. Exogenous human 
TNFa or LT was added at the start of the assay at the concentrations indicated. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 3 donors.
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3.2.5 Establishment o f  mouse CD4+CD25+ suppressor assays
The addition o f IL-2 had no significant effect on the ability o f  human CD4+CD25+ T 
cells to regulate CD4+CD25- T cells. It was decided to investigate whether the same 
effect was observed with mouse CD4+CD25+ regulatory cells. Much o f the reported 
data investigating the effect o f  IL-2 on reversing suppression had been conducted 
using mouse CD4+CD25+ regulatory T cells (Shevach, 2002). Mouse CD4+CD25+ T 
cells were purified from mouse spleens using a two-step MACS magnetic bead 
system. Initially the CD4+ T cells were isolated by negative selection followed by a 
positive selection for CD25. Analysis by flow cytometry o f the purified CD4+CD25+ 
and CD4+CD25- T-cell populations, is shown in figure 3.8. Following purification, a 
good enrichment o f CD25 positive cells was obtained with 78% o f the cells 
expressing high levels o f  CD25. The purity o f the CD4+CD25- and CD4+CD25+ 
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Figure 3.8 Isolation of mouse splenic CD4+CD25+ regulatory T cells.
CD4+ T cells were isolated from splenocytes using a MACS CD4+ negative selection 
isolation kit and separated into CD25+ and CD25- fractions using a MACS CD25 positive 
selection isolation kit. The purified CD4+ T cell populations were analysed by flow 
cytometry. Data is representative of one of 5 experiments.
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Purified CD4+CD25+ T cells were co-cultured with purified CD4+CD25- cells in the 
presence of irradiated CD4-depleted splenocytes and anti-CD3. As can be seen in 
figure 3.9, the purified CD4+CD25+ cells significantly suppressed the proliferative 
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Figure 3.9 Inhibition of proliferation of mouse CD4+CD25- responder cells by mouse 
CD4+CD25+regulatory cells following stimulation with anti-CD3.
Purified CD4+CD25- T cells were stimulated with anti-CD3 and irradiated CD4-depleted 
splenocytes in the presence of CD4+CD25+ T cells at a.l:l ratio of T cells. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 5-day culture 
period. Data shown are mean ± SEM of 5 mice. Value above bar indicates percentage 
inhibition ± SEM.*, p<0.05, paired t-test.
The addition of exogenous mouse IL-2 to the mouse suppression assay had a dramatic 
effect. As is illustrated in figure 3.10, the CD4+CD25+ mediated suppression of the 
CD4+CD25- T cells was completely reversed following the addition of lOng/mL 
(20U/mL) exogenous IL-2. This effect is in sharp contrast to the data obtained with 
human CD4+CD25+ T cells and suggests a fundamental difference in the 
CD4+CD25+ regulatory T cells between the two species. One possible explanation 
for this difference is the source o f cells used. The human CD4+CD25+ cells were
isolated from peripheral blood whereas the mouse CD4+CD25+ cells were isolated
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from spleen. However due to the availability of material, it was not possible to repeat 
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Figure 3.10 Reversal of CD4+CD25+ mediated suppression following the addition of 
exogenous mouse EL-2.
Purified CD4+CD25- T cells were stimulated with anti-CD3 and irradiated CD4-depleted 
splenocytes in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. lOng/mL mouse 
IL-2 was added at the start of the assay. The proliferative response was measured by 3H- 
thymidine incorporation during the last 4-6 h of a 5-day culture period. Data shown are mean 
± SEM of 3 mice. Value above bar indicates percentage inhibition ± SEM
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3.2.6 Investigation into whether IL-10 and TGF/3play a role in vitro
To further characterise the cells used in this study, neutralising antibodies to human 
IL-10 and human TGF-pi, -p2 , -P3 (TGFP) were added to the assay. The results 
illustrated in figures 3.11a and b clearly show that neutralising IL-10 or TGFp had no 













+  +  +  + ' ■ + ■ + "  +
+  + ■ + ' + . +  +  +
+  -  +  -  +  ■ +  
-  -  +  + ' + + ' +  +
nmm isotype control 
anti-IL-10
Figure 3.11a Investigating the ability of a neutralising anti-IL-10 antibody to reverse 
CD4+CD25+T cell mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. lOpg/mL of an anti- 
IL-10 or an isotype matched control antibody was added at the start of the assay. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 3 donors. Values above bars indicate 
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Figure 3.11b Investigating the ability of a neutralising anti-TGFpi,2,3 antibody to 
reverse CD4+CD25+ T cell mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. 10pg/mL of an anti- 
TGFp 1,2,3 or an isotype matched control antibody was added at the start of the assay. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 3 donors. Values above bars indicate 
percentage inhibition ± SEM.
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3.2.7 Analysis of cell surface marker expression -  resting cells versus activated 
cells
In an attempt to clarify which markers are most appropriate for human CD4+CD25+ 
T cells and also to identify markers that might play a role in regulatory T cell 
function, a full analysis of cell surface marker expression was carried out by flow 
cytometry of both the CD4+CD25+ regulatory T cell population and the CD4+CD25- 
responder T cells population. Both freshly isolated cells and cells activated for three 
days in the presence of PHA-L and irradiated CD4-depleted PBMCs were analysed.
Figure 3.12 illustrates some of the data obtained from the analysis of freshly isolated 
cells. Each dot-plot is representative of one of three donors analysed. The figures 
given above each dot-plot represent the mean percentage positive cells in the upper 
right quadrant ± SEM of 3 donors. In addition to CD25, both CD95 (Fas) and tumour 
necrosis factor receptor (TNFR) 2 were upregulated on the resting CD4+CD25+ T 
cell population compared to the CD4+CD25- T cell population. The percentage of 
CD4+CD25+ cells that expressed CD95 was 84.7 ± .1.6% compared to 38.9 ± 4.5% 
for the CD4+CD25- cells. Expression of TNFR2 on the surface of CD4+CD25+ T 
cells was 39.6 ± 9.8% compared to 9.3 ± 0.8% for the CD4+CD25- population. 
Levels of intracellular CTLA-4 were also higher for the CD4+CD25+ population with 
50.0 ± 15.9% of the CD25+ cells expressing intracellular CTLA-4 compared to 9.2 ± 
6.3% of the CD25- cells. However the levels of cell surface CTLA-4 were low for 
both populations, i.e. less than 1%.
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Expression of CD45RO was higher on the CD4+CD25+ cells (92.8 ± 1.4% versus 
62.9 ± 4.1%) and conversely the levels of CD45RA were lower (48.3 ± 7.7% versus 
74.2 ± 7.6%). There were also a few CD4+CD25+ T cells that expressed high levels 
of inducible costimulator (ICOS) (< 10%) and CD 103 (<5%). In contrast to reports in 
the literature, the data summarised in table 3.1 shows that the levels of GITR, CD 134 
(0X40), blood dendritic cell antigen (BDCA)-4, (neuropilin-1), galectin-1, 
programmed death (PD)-l and CD 137 (4-IBB) were not elevated on the freshly 
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Figure 3.12 Characterisation of cell surface molecules expressed on freshly 
isolated CD4+CD25- and CD4+CD25+ T cells.
Cells were stained with CD4-FITC (FL1) and a PE-labelled antibody to the 
surface marker of interest (FL2) and then analysed by flow cytometry. Dot plots 
are representative of 1 of 3 donors analysed. Values represent the mean 
percentage positive cells in the upper right quadrant ± SEM of 3 donors.
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Only a limited number o f differences in cell surface marker expression were noted 
between the two cell populations following activation in the presence o f  irradiated 
CD4-depleted PBMCs and PHA-L. Figure 3.13 highlights three o f  the surface 
molecules that did appear to show differential expression. The activated CD4+CD25+ 
regulatory cells expressed higher levels o f TNFR2 expression (86.1 ± 4.8% o f the 
cells were positive compared to 46.4 ± 7.1% o f the activated CD4+CD25- 
population). Conversely the number o f activated CD4+CD25+ cells that expressed 
CD40L was lower and there were fewer CD4+CD25+ cells expressing CD45RA. 
Analysis o f the remaining cell surface markers is summarised in table 3.1. Levels o f 
intracellular CTLA-4 remained high in the CD4+CD25+ regulatory population even 
after activation (91.4 ± 1.4% versus 62.8 ± 4.7% for the activated CD4+CD25- 
population).
CD4+CD25- CD4+CD25+
46.4 ±  7.1 86.1 ±  4.8
CD25-/CD25+
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Figure 3.13 Characterisation of cell surface molecules expressed on the surface of 
activated CD4+CD25- and CD4+CD25+ T cells.
Cells were activated for 3 days in the presence of CD4-depleted PBMCs and PHA-L.
Cells were then stained with CD4-FITC (FL1) and a PE-labelled antibody to the surface 
marker of interest and analysed by flow cytometry. Dot plots are representative of 1 of 3 
donors analysed. Values represent the mean percentage positive cells in the upper right 
quadrant ± SEM of 3 donors.
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Cell surface marker Freshly isolated CD4+ T cells 3 day activated CD4+ T cells
CD25- CD25+ CD25- CD25+
BDCA-4 0.3 ± 0.2 2.0 ± 1.1 5.3 ±1.2 7.0 ± 0.6
CD27 93.2 + 2.2 . 95.3 ±1.8 81.5 ±67 89.2 ±4.6
CD25 19.3 ±3.7 87.1 ±1.9 90.8 ± 2.9 92.6 ±1.9
CD40L 0.1 ± 0.1 0.2 ± 0.1 13.4 ±8.0 0.7 ±0.3
CD45RA 74.2 ±7.6 48.3 ± 7.7 87.0 ±4.4 67.6 ±5.1
CD45RO 62.9 ±4.1 92.8 ± 1.4 95.5 ±0.6 95.9 ±1.3
CD62L 88.1 ± 5.8 93.3 ±3.8 76.4 ±4.6 88.8 ±3.2
CD69 0.1 ±5.5 0.6 ± 0.1 47.0 ± 1.9 45.5 ±2,9
CD95 38.9 ±4.5 84.7 ±1.6 95.1 ±1.5 94.9 ± 0.6
CD103 1.2 ± 0.6 3.8 ± 1.6 2.1 ± 0.8 6.3 ±2.8
CD122 19.5 ± 2.5 32.3 ±5.9 50.1 ±16.5 68.8 ±10.3
CD132 9.8 ±5.6 6.7 ±2.2 27.9 ± 14.6 16.9 ±5,2
CD134 0.5 ±0.3 1.8 ± 1.1 75.8 ±10.7 64.3 ±1.5
CD137 0.2 ± 0.2 1.3 ±0.8 26.0 ± 9.4 25.7 ±1.7
CD 152 (CTLA-4, intracellular) 9.2 ±6.3 50.0 ±15.9 62.8 ±4.7 91.4 ±1.4 .
CD152 (CTLA-4, surface) 0.1 ±0 o.i ±0 14.3 ± 6.4 14.0± 1.6
Galectin-1 0.1 ±0 0.1± 0.1 0.4 ± 0.3 2.7 ± 1.5
GITR 0.3 ±0.1 1.5 ± 1.2 51.7 ±8.0 54.0 ± 2.0
ICGS 0.8 ± 0.1 8.5 ±2.0 51.3 ±15.7 33.7 ±4.3
PD-1 5.1 ±1.8 3.1 ±0.7 39.0 ±6.2 20.7 ±2.3
TNFR2 9.3 ±0.8 39.6 ±9.8 46.4 ±7.1 86.1 ±4.8
Table 3.1 Summary of data comparing the expression levels of various cell surface 
markers on freshly isolated peripheral blood derived and 3 day activated CD4+CD25- 
and CD4+CD25+T cells.
Cells were stained with CD4-FITC and a PE-labelled antibody to the surface marker of 
interest and analysed by flow cytometry. Data is expressed as the percentage positive CD4+ T 
cells for the cell surface marker of interest. Data shown are mean ± SEM of 3 donors.
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3.2.8 Investigation into the role o f IL-2 and its receptor
The regulatory T cells isolated in this study were purified on the basis of CD25 
expression. Indeed CD25 is generally accepted as the most reliable marker of a resting 
regulatory T-cell. However whether CD25 itself plays a role in regulatory T-cell 
function is unclear. Data published from in vitro studies in the mouse showed that IL- 
2 released early following activation of CD4+CD25- cells, was required by the 
CD4+CD25+ T cells before they were able to regulate (Thornton et al., 2004). These 
data suggest that the high levels of expression of CD25 might indeed be important for 
function. To address this question, experiments were conducted looking at the effect 
of a neutralising antibody to IL-2 and blocking antibodies to both CD25 (IL-2Ra) and 
CD122 (IL-2RP). The data shown in figures 3.14a-c demonstrate no significant effect 
of any of the antibodies on the ability of the CD4+CD25+ T cells to regulate.
m m  isotype control 
ESS) anti-IL-2
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CD4+CD25+ - + - + • - • + '  +
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Figure 3.14a Investigating the ability of a neutralising anti-IL-2 antibody to reverse 
CD4+CD25+ T cell mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and. irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. lOpg/mL of an anti- 
IL-2 or an isotype matched control antibody was added at the start of the assay. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 3 donors. Values above bars indicate 































Figure 3.14b Investigating the ability of a blocking anti-CD25 antibody to reverse 
CD4+CD25+ T cell mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. lOpg/mL of an anti- 
CD25 or an isotype matched control antibody was added at the start of the assay. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 3 donors. Values above bars indicate 
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Figure 3.14c Investigating the ability of a blocking anti-CD122 antibody to reverse 
CD4+CD25+ T cell mediated suppression following activation with PHA-L
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. lOpg/mL of an anti- 
CD 122 or an isotype matched control antibody was added at the start of the assay. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 3 donors. Values above bars indicate 
percentage inhibition ± SEM.
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3.2.9 Investigation into the role o f CTLA-4
CTLA-4 is a key negative regulator of T-cell activation. The molecule is also 
upregulated, at least at the intracellular level, on CD4+CD25+ cells. However it is 
unclear whether this molecule plays a role in regulatory T-cell function. In an attempt 
to address this, a blocking antibody to human CTLA-4 was added to the suppression 
assay (figure 3.15a). Conversely, an agonising anti-CD28 antibody was also assessed 
(figure 3.15b), Perhaps somewhat surprisingly, neither of the antibodies had any 
significant effect on the CD4+CD25+ mediated suppression. This suggests that 
CTLA-4 does not play a significant role in contributing to the inhibition of 
CD4+CD25- T-cell proliferation in this assay system. However one reagent that did 
have a significant effect on the suppression assay was mouse CTLA-4-Ig fusion 
protein. Addition of this reagent to the suppressor assay caused a significant 
augmentation of the suppressor response (figure 3.15c). CD80 and CD86 are both 
ligands for CD28 and are responsible for delivering the second signal in T cell 
activation (Alegre et al., 2001). However these molecules are also ligands for CTLA- 
4 and when engaged by CTLA-4, T-cell activation is inhibited. Therefore one possible 
explanation for the augmented inhibition of the response may be that the fusion 
protein preferentially binds CD80 and CD86, resulting in a reduced costimulatory 
signal being delivered through CD28 on the responder cell. This reduction in second 
signal leads to lower levels of activation of the CD4+CD25- cells resulting in reduced 
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Figure 3.15a Investigating the ability of a blocking anti-CTLA-4 antibody to reverse 
CD4+CD25+ T cell mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. lOpg/mL of an anti- 
CTLA-4 or an isotype matched control antibody was added at the start of the assay. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 5 donors. Values above bars indicate 
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Figure 3.15b Investigating the ability of an activating anti-CD28 antibody to reverse 
CD4+CD25+ T cell mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. 10pg/mL of an anti- 
CD28 or an isotype matched control antibody was added at the start of the assay. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 3 donors. Values above bars indicate 
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Figure 3.15c Investigating the effect of muCTLA-4-muFc on CD4+CD25+ T cell 
mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. lOpg/mL of 
muCTLA-4-muFc fusion protein or an isotype matched control antibody (MOPC21) or a 
control fusion protein (CD22-muFc) was added at the start of the assay. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 3-day culture 
period. Data shown are mean ± SEM of 3 donors. *, p<0.05, paired t-test as compared to 
either MOPC21 or CD22-muFc. Values above bars indicate percentage inhibition ± SEM.
3.2.10 Attempts to identify cell surface molecules involved in CD4+CD25+ T cell 
mediated suppression
The data presented thus far have failed to identify a key cytokine or cell surface 
molecule that is solely responsible for mediating human CD4+CD25+ T-cell 
suppression. These data have concentrated on some of the most likely candidates 
based on current published data. However, there are other potential candidates so 
further experiments were conducted using antibodies to some of the other potential 
targets that could be involved in CD4+CD25+ mediated suppression. Unfortunately 
none of the antibodies investigated had any effect on the ability of the CD4+CD25+
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cells to suppress the proliferative response of the CD4+CD25- cells following 
stimulation with PHA-L. The results obtained are summarised in table 3.2.
Antibody Isotype Mechanism of action Reversal of 
suppression
Anti-CD134 Mouse IgGl Blocks ligand binding No. effect
Anti-GITR Mouse IgGl Blocks ligand binding No effect
Anti-LAG-3 Mouse IgGl Blocks ligand binding No effect
Anti-TGFpRII GoatlgG Blocks TGFp binding No effect
Anti-IL-17 Mouse IgG2b Neutralises bioactive IL-17 No effect
Table 3.2 Summary of data investigating the ability of different antibodies to reverse 
CD4+CD25+ mediated suppression of CD4+CD25- cells following activation with 
PHA-L.
3.2.11 Purification of regulatory T cells on the basis o f either CD95 expression or 
TNFR2 expression
Characterisation of freshly isolated CD4+CD25+ cells by flow cytometry showed 
elevated levels of both CD95 and TNFR2 as compared to freshly isolated 
CD4+CD25- T cells (figure 3.12). One explanation for these elevated levels could be 
that one or both of these molecules play a role in regulatory T-cell function. It was 
decided initially to purify cells from the CD4+ T-cell population on the basis of either 
CD95 or TNFR2 expression and to investigate whether these cells had the ability to 
suppress. Human CD4+CD95+ T cells were purified from PBMCs using a two-step 
MACS magnetic bead system. The CD4+ T cells were isolated by negative selection 
followed by a positive selection for CD95 or TNFR2 using either an anti-CD95 PE- 
labelled antibody, or an anti-TNFR2 PE-labelled antibody and anti-PE microbeads.
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Following purification, the CD4+ T cell populations were stained for CD25 
expression levels. Analysis by flow cytometry o f the purified CD4+ populations is 













,0 ,7,2  1(J3 rn4
CD25




. . . . . . . . . .
r 1<T 10s10“ 10' 10̂ 0“  1-b
a a
42.5%




Figure 3.16 Isolation of human CD4+ T cells by positive selection for CD95 or TNFR2 
expression for assessment of regulatory function.
CD4+ T cells were isolated from PBMCs using a MACS CD4+ negative selection isolation 
kit and separated into CD95+, CD95- or TNFR2+ and TNFR2- fractions using the 
appropriately labelled PE antibody and anti-PE microbeads. The purified CD4+ T cells were 
analysed for CD25 expression by flow cytometry. Percentage values for the number of 
CD25+ cells are displayed. Data shown are of one of two donors analysed.
The dot plots in figure 3.16 show that the CD4+CD95+ T cells expressed higher 
levels o f CD25 than the CD4+TNFR2+ cells, 89 % versus 43%. Functional assays 
were set up to investigate the regulatory capacity o f these populations. Purified 
CD4+CD95+ T cells were co-cultured with purified CD4+CD95- cells in the presence 
o f irradiated CD4-depleted PBMCs and either PHA-L or tetanus toxoid. Identical 
assays were set up with CD4+TNFR2+ and CD4+TNFR2- T cells using cells isolated 
from the same donor. The results obtained with the CD95 selected cells are illustrated 
in figures 3.17a and b and the TNFR2 selected cells in figures 3.18a and b. 
Interestingly the results from the functional assays showed that the CD4+TNFR2+ T
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cells achieved significant levels of suppression compared to the CD4+CD95+ T cells, 
even though the CD4+TNFR2+ cells expressed lower levels of CD25. Unfortunately 
due to limits on the amount of blood that can be taken from any one donor, it was not 
possible to isolate cells on the basis of CD25 expression and compare the levels of 
suppression achieved in the same experiment with the CD95+ and TNFR2+ enriched 
cells. However the TNFR2 data appeared comparable to data obtained with CD25+ 
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Figure 3.17a Inhibition of proliferation of CD4+CD95- responder cells by CD4+CD95+ 
regulatory cells following stimulation with PHA-L.
Purified CD4+CD95- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD95+ T cells at a 1:1 ratio of T cells. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 3-day culture 
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Figure 3.17b Inhibition of proliferation of CD4+CD95- responder cells by CD4+CD95+ 
regulatory cells following stimulation with tetanus toxoid.
Purified CD4+CD95- T cells were stimulated with tetanus toxoid and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD95+ T cells at a 1:1 ratio of T cells. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 7-day culture 
period. Data shown are mean of 2 donors. Error bars represent minimum and maximum 
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Figure 3.18a Inhibition of proliferation of CD4+TNFR2- responder cells by 
CD4+TNFR2+ regulatory cells following stimulation with PHA-L.
Purified CD4+TNFR2- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+TNFR2+ T cells at a 1:1 ratio of T cells. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 3-day culture 
period. Data shown are mean ± SEM of 3 donors. Values above bars indicate percentage 
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Figure 3.18b Inhibition of proliferation of CD4+TNFR2- responder cells by 
CD4+TNFR2+ regulatory cells following stimulation with tetanus toxoid.
Purified CD4+TNFR2- T cells were stimulated with tetanus toxoid and irradiated CD4- 
depleted PBMCs in the presence of CD4+TNFR2 T cells at a 1:1 ratio of T cells. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
7-day culture period. Data shown are mean of 2 donors. Error bars represent minimum and 
maximum values. Values above bars indicate percentage inhibition.
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The functional assays described have revealed that CD4+ regulatory cells isolated on 
the basis of CD95 or TNFR2 expression are capable of suppressing responder CD4+ 
T cell proliferation. However the main question to be addressed was whether either of 
these molecules played a role in regulatory T cell function. To investigate this, 
antibodies to TNFR2 and CD95 were added to the suppressor T cell assays. The 
CD4+ regulatory cells used in these assays were purified on the basis of CD25.
The data illustrated in figures 3.19 and 3.20 clearly shows that neither the blocking 
antibodies to CD95 and TNFR2, nor the apoptosis-inducing anti-CD95 antibody had 
any effect on the ability of the CD4+CD25+ cells to inhibit the proliferation of the 
CD4+CD25- cells. These data suggest that in vitro at least, the mechanism by which 
CD25+CD4+ T cells suppress CD4+CD25- T cells is not dependent on TNFR2 or 
CD95. One might have expected the apoptosis-inducing anti-CD95 antibody to 
preferentially deplete the CD4+CD25+ cells and hence show signs of reversal of 
suppression. However this antibody requires cross-linking for apoptosis to be induced 
(Huang et al., 1999) and it is possible that optimal cross-linking did not occur in this 
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Figure 3.19 Investigating the ability of a blocking anti-TNFR2 antibody to reverse 
CD4+CD25+ T cell mediated suppression following activation with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. 10jug/mL of an anti- 
TNFR2 or an isotype matched control antibody was added at the start of the assay. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 3 donors. Values above bars indicate 
percentage inhibition ± SEM.
m m  isotype control 
Apo (anti-Fas)
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Figure 3.20 Investigating the ability of a blocking anti-CD95 antibody and an apoptosis- 
inducing anti-CD95 antibody to reverse CD4+CD25+ T cell mediated suppression 
following activation with PHA-L
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD25+ T cells at a 1:1 ratio of T cells. l Opg/mL of an anti- 
CD95 or an isotype matched control antibody was added at the start of the assay. The 
proliferative response was measured by 3H-thymidine incorporation during the last 4-6 h of a 
3-day culture period. Data shown are mean ± SEM of 3 donors. Values above bars indicate 
percentage inhibition ± SEM.
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3.2.12 Investigation into the effect of positive selection
The experimental data presented thus far has shown that human CD4+ T cells 
positively selected on the basis o f CD25, TNFR2 or CD95 cell surface expression, 
have the ability to suppress the proliferation of CD4+ T cells expressing low levels of 
the reciprocal marker. This is believed to be due to the isolation of a specific sub­
population of regulatory CD4+ T cells, characterised by the cell surface expression of 
these markers, which have the ability to inhibit activation of CD4+ responder T cells. 
An alternative explanation is that it is the method of isolation of these cells that 
somehow renders them suppressive. Whilst thought to be highly unlikely, it was an 
important issue to investigate. CD4+ T cells were purified by negative selection as 
previously described. The CD4+ T cells were then purified further into CD45RO+ 
and CD45RO- fractions using a GD45RO-PE labelled antibody and anti-PE 
microbeads. Functional assays were set up to investigate the regulatory capacity of 
these populations. Purified CD4+CD45RO+ T cells were co-cultured with purified 
CD4+CD45RO- cells in the presence of irradiated CD4-depleted PBMCs and PHA-L. 
The data illustrated in figure 3.21 shows that CD4+CD45RO+ T cells isolated using 
positive selection, do not have regulatory activity, thus confirming that positive 
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Figure 3.21 Investigating the ability of CD4+CD45RO+ T cells to inhibit 
CD4+CD45RO- T cell proliferation following activation with PHA-L.
Purified CD4+CD45RO- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs in the presence of CD4+CD45RO+ T cells at a 1:1 ratio of T cells. The proliferative 
response was measured by 3H-thymidine incorporation during the last 4-6 h of a 3-day culture 
period. Data shown is representative of one of two donors analysed. Error bars represent SD 
of triplicate wells.
3.2.13 Investigation into the effect o f antibodies to specific T cell surface markers 
on T cell proliferation.
One caveat with the studies described in this thesis, was the functionality of the 
antibodies used in the assays. Whilst the bioactivity of the cytokines has been 
confirmed in other cell based assays, a number of the antibodies used in these studies 
have not been evaluated in other cell-based assays and their reported function is solely 
based on the manufacturer’s description. Therefore caution should be taken when 




It was also possible that the antibodies were having an effect on the responder 
CD4+CD25- T cell population, which was masked in the coculture with the 
CD4+CD25+ regulatory T cells. In an attempt to address this, all the antibodies were 
screened to investigate their effect on the CD25- population alone, following 
stimulation with PHA-L in the presence of irradiated CD4-depleted PBMCs. The data 
shown in figure 3.22 summarises the results of one of two donors analysed. 
Interestingly none of the antibodies screened appeared to have a significant effect on 
responder CD4+ T cells proliferation. One might have expected the anti-IL-2 or anti- 
CD25 antibodies to affect proliferation however there are reports that strong 
stimulation through the TCR or with mitogens, only results in a partial inhibition of T 
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Figure 3.22 Investigating the effect of the antibodies and fusion proteins screened in the 
suppression assays on the CD4+CD25- T cell population alone, following stimulation 
with PHA-L.
Purified CD4+CD25- T cells were stimulated with PHA-L and irradiated CD4-depleted 
PBMCs. lOpg/mL of each antibody/fusion protein or isotype matched control antibody/fusion 
protein was added at the start of the assay. The proliferative response was measured by 3H- 
thymidine incorporation during the last 4-6 h of a 3-day culture period. Data shown is 




The main aims of this chapter were to characterise the cell surface phenotype of 
peripheral blood derived human CD4+CD25+ regulatory T cells and to investigate the 
mechanism of action of these cells in vitro.
As already mentioned, it is widely accepted that naturally occurring CD4+ regulatory 
T cells express elevated levels of CD25. Further analysis of the surface phenotype 
confirmed that the CD4+CD25+ T cells isolated in these studies expressed high levels 
of CD95, TNFR2, CD45RO and intracellular CTLA-4. Subsequent isolation of CD4+ 
regulatory cells on the basis of either CD95 or TNFR2 expression, confirmed the 
ability of these cells to suppress T cell proliferation following stimulation with either 
PHA-L or tetanus toxoid. These data validate both CD95 and TNFR2 as robust cell 
surface markers for resting CD4+ regulatory cells. However, subsequent experiments 
also showed that whilst upregulated on the surface of CD4+CD25+ regulatory cells, 
these molecules did not appear to play a functional role in vitro.
Studies with human thymocytes have confirmed elevated levels of TNFR2 expression 
on CD4+CD25+ T cells (Annunziato et al., 2002) and data from various groups have 
also shown upregulation of CD45RO and intracellular CTLA-4 (Taams et al., 2001; 
Annunziato et al., 2002; Dieckmann et al., 2001; Ng et al., 2001; Levings et al., 2001; 
Jonuleit et al., 2001). Studies showing upregulation of CD95 have led to the 
suggestion that CD4+CD25+ regulatory cells are a highly apoptosis prone and highly 
differentiated population (Taams et al., 2001) This is supported by other data showing 
that these cells have shortened telomeres and low levels of CD45RB expression
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(Taams et al., 2002). Overall, these data are consistent with the idea that in humans at 
least, the CD4+CD25+ regulatory T-cell subset might not represent a unique lineage 
of cells derived from the thymus but instead they are a suppressive population of T 
cells derived from effector GD4+ T cells that have become highly differentiated 
(Akbar et al., 2003).
Studies using human CD4+CD25+ thymocytes have confirmed however that they do 
exhibit regulatory activity (Annunziato et al., 2002; Stephens et al., 2001). Therefore 
it is conceivable that thymus-derived CD4+CD25+ T cells represent one type of 
regulatory cell and a second type of CD4+CD25+ T-cell may be derived in the 
periphery from fully differentiated effector T cells. Thus isolation of these cells from 
peripheral blood may contain a mixture of both regulatory cell types. Evidence for the 
generation of such CD4+CD25+ cells in the periphery is supported by data that has 
described the generation of FOXP3+ cells following activation of CD4+CD25- T cells 
with anti-CD3 and anti-CD28 mabs (Walker et al., 2003a). Recent data from mouse in 
vivo studies has shown that peripheral mouse CD4+CD25- T cells were able to 
convert into CD4+CD25+ regulatory cells following transfer into normal recipients 
(Liang et al., 2005).
In contrast to reports in the literature, the CD4+CD25+ regulatory cells isolated in 
these current studies did not appear to express elevated levels of CD 103 (Lehmann et 
al., 2002), 0X40, galectin-1, GITR (Shimizu et a l, 2002; McHugh et al., 2002), PD-1 
or neuropilin-1 (Bruder et al., 2004) when compared to CD4+CD25- cells. The 
number of CD4+CD25+ T cells expressing CD134 and GITR increased following 
activation, however this was also observed in the CD4+CD25- T cell population. The
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cell surface molecules described above are primarily associated with mouse 
CD4+CD25+ regulatory cells, thus it is possible that these discrepancies are a result 
of species-specific or tissue-specific differences. However it is clear that currently 
none of the markers identified as being unique to CD4+CD25+ regulatory cells are 
truly reliable, as many of the molecules, including CD25, are upregulated on the 
surface of CD4+CD25- T cells following activation. Indeed it is highly likely that 
there is no single unique surface marker for these cells and maybe a combination of 
various cell surface and intracellular proteins determine the regulatory cell phenotype.
Following the observation that CD 134 and GITR were not expressed at a higher level 
on CD4+CD25+ cells compared to CD4+CD25- T cells, it was not surprising to 
discover that neither of these molecules appeared to be responsible for suppressor 
function. This observation is supported by studies with anti-GITR antibodies that have 
shown reversal of suppression is only mediated with a whole antibody and not a Fab’ 
fragment. Therefore suggesting that engagement of GITR with its ligand is not 
responsible for CD4+CD25+ mediated suppression (Shimizu et al., 2002).
The titration experiment highlighted that maximal suppression in vitro was achieved 
when the ratio of responder cells to suppressor cells was 1:1 and as the numbers of 
suppressors declined, the level of inhibition also declined. This raises a question about 
how these cells can be effective at suppressing an immune response in vivo if  their 
frequency is so low. More recent data generated from mouse studies, has shown that 
far from being refractory to TCR induced proliferation, these cells do undergo 
proliferation in vivo (Walker et al., 2003b; Yamazaki et -al., 2003; Fisson et al., 2003). 
There is also evidence that these cells may amplify their suppressive action in vivo by
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acting on APCs to inhibit their maturation. Indeed coculture of activated 
CD4+CD25+ cells with APCs resulted in reduced expression of CD80 and CD86 
(Cederbom et ah, 2000). Additionally, studies conducted in vitro have shown that 
coculture of immature APCs with CD4+ T cells can lead to the generation of IL-10 
producing regulatory T cells (Jonuleit et a l, 2000).
Alternatively or concomitantly, the regulatory cells may interact with the APC via 
CTLA-4 and induce the upregulation of indoleamine 2,3-dioxygenase (IDO) resulting 
in tryptophan catabolism. This would lead to immune suppression resulting from a 
reduction in T-cell function and viability due to tryptophan depletion and the 
production of pro-apoptotic metabolites (Fallarino et al., 2003; Grohmann et al., 
2003). Another mechanism for amplification of the suppressor response is provided 
by evidence that CD4+CD25+ cells have the ability to induce conventional T cells to 
become regulatory T cells via a mechanism known as infectious tolerance. These 
induced regulatory cells have been shown to suppress via the release of the 
immunomodulatory cytokines IL-10 or TGFP (Stassen ah, 2004). Together these 
mechanisms may help to explain some of the discrepancies observed regarding 
CD4+CD25+ functionality in vitro versus in vivo.
The experimental data presented in this chapter has highlighted how little is still 
known about the cell-cell contact mechanism of suppression of human CD4+CD25+ 
regulatory T cells in vitro. The addition of various cytokines and antibodies to cell 
surface molecules implicated in CD4+CD25+ T-cell function had no significant effect 
on reversing suppression. This is in sharp contrast to the data obtained using mouse
116
Chapter 3
CD4+CD25+ regulatory T cells where suppression was fully reversible following the 
addition of exogenous IL-2.
Data from human in vitro systems regarding the ability of IL-2 to reverse suppression 
is mixed. Stephens et al. showed that human CD4+GD25+ thymocytes were 
responsive to IL-2 when it was added at lOOU/mL (Stephens et al., 2001). Conversely 
Annunziato et al. showed that human CD4+CD25+ thymocytes were not responsive 
to IL-2 (lOU/mL) but suppression was reversed with exogenous IL-15 (lOng/mL) 
(Annunziato et al., 2002). One could explain this discrepancy by arguing that 
Annunziato et al. may have seen reversal at higher concentrations of IL-2 but that 
does not account for the effect of IL-15.
Studies with human peripheral blood derived CD4+CD25+ cells are also unclear 
regarding the role of IL-2. Ng et al. showed full reversal of suppression with only 
lOU/mL of IL-2, however the overall suppression levels were only 50% (Ng et al., 
2001). Dieckmann et al. found partial reversal at only very high doses of IL-2 (100- 
lOOOU/mL). This response was improved if used synergistically with IL-15 
(Dieckmann et al:, 2002). In agreement with that data, both Taams et al. (2001) and 
Jonuleit et al. (2001) showed partial reversal of suppression with IL-2, however 
Jonuleit et al. were able to show full reversal with a combination of IL-2 and TL-4. 
This suggested that the responder cell population was a mix of both Thland Th2 cells 
and as such was responsive to different cytokines. Indeed data generated using Thl 
and Th2 cell clones has shown that suppression of the Th2 clones was reversed 
following the addition of IL-4 but not IL-2. Interestingly, suppression of the Thl
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clones could only be overcome by the addition of exogenous IL-15, not IL-2 (Cosmi 
et a l, 2004).
Data from the studies described earlier in this chapter have shown that the addition of 
exogenous IL-2 did not reverse PHA-L mediated suppression. The addition of 
exogenous IL-2 to the tetanus toxoid suppression assay resulted in a slight but not 
significant reversal of suppression. Reasons for this apparent unresponsiveness to IL- 
2 are unclear, however it would be interesting to evaluate cytokine combinations like 
IL-2, IL-15 and IL-4 in the same assay. The observation that suppression was 
reversed with exogenous IL-2 in the mouse assays is an interesting one. It is tempting 
to speculate that there might be intrinsic differences between human and mouse 
CD4+CD25+ T cells. This is also supported by the observed differences in Cell 
surface marker expression between the human cells analysed in this study and the 
published data on mouse cell surface markers.
Experiments were conducted to investigate whether IL-10 and TGFp were responsible 
for the CD4+CD25+ T cell mediated suppression. Blocking antibodies to both IL-10 
and TGFp and a blocking antibody to the TGFpRII receptor were added to the 
suppression assay, however no significant reversal of suppression was observed. This 
observation is in agreement with data generated from many groups and suggests that 
in vitro, soluble factors are not playing a role in CD4+CD25+ T cell mediated 
suppression (Jonuleit et a l, 2001; Taams et a l , 2001; Levings et a l, 2001; Thornton 
and Shevach, 1998). Evidence for the role of IL-10 and TGFp in CD4+CD25+ T cell 
mediated suppression originates from in vivo studies. Studies in the SCID colitis 
model have shown that by blocking IL-10 signalling with an anti-IL-10 receptor
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antibody, the suppressive function of CD45RBlow cells is abrogated (Asseman et al.,
1999). Similarly CD45RBlow cells isolated from IL-107' mice, failed to protect against 
colitis when cotransferred with CD45RBhl cells (Asseman et al., 1999). However, 
CD4+CD25+ cells from IL-107' mice were fully competent suppressors in vitro 
(Thornton and Shevach, 1998).
Studies again in the SCID colitis model have shown that regulatoiy T-cell function 
can be blocked with neutralising anti-TGFp antibodies (Powrie et al., 1996; Fuss et 
al., 2002). However again, CD4+CD25+ cells from TGFp7' mice were functional 
suppressors in vitro (Piccirillo et al., 2002). Why this discrepancy between in vitro 
and in vivo studies exists is unclear. One explanation could be due to differences in 
the complexities of the cellular environment and the different types of cells interacting 
with one another. Clearly the well of a tissue culture plate cannot substitute for a 
complex in vivo environment. Indeed, there is evidence that the release of IL-10 and 
TGFp by CD4+CD25+ cells in vivo is responsible for suppressing the innate immune 
response (Maloy et a l, 2003). However interesting data has emerged suggesting a 
link for IL-10 and TGFp in vitro through infectious tolerance. As mentioned earlier, 
studies by two groups have shown that CD4+CD25+ cells were able to induce a 
population of CD4+ T cells to produce either TGFP (Jonuleit et al., 2002) or IL-10 
(Dieckmann et al., 2002) following activation.
The CD4+CD25+ cells isolated in this study expressed high levels of intracellular 
CTLA-4, however a blocking anti-CTLA-4 antibody failed to reverse suppression. 
This observation suggests that in these studies, CTLA-4 was not responsible for the 
suppressive phenotype of the CD4+CD25+ T cells observed in vitro. Indeed the role
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of CTLA-4 in CD4+CD25+ T-cell mediated suppression is also somewhat 
contradictory. Studies have shown that suppression of IBD by CD45RBlow cells can 
be reversed following treatment with a blocking antibody to CTLA-4 (Read et al.,.
2000). The acceptance of skin grafts mediated by the generation of alloantigen 
specific CD4+CD25+ T cells can also be reversed following treatment with a 
blocking anti-CTLA-4 antibody (Kingsley et al., 2002). Interestingly partial reversal 
of suppression with an antibody to CTLA-4 has also been achieved using human 
thymocyte-derived CD4+CD25+ T cells and full reversal was achieved with 
antibodies to both CTLA-4 and TGFp (Annunziato et al., 2002). Assays conducted 
using CD4+CD25+CTLA-4+ enriched human regulatory cells have also shown a 
partial reliance on CTLA-4 for function. However this was not duplicated with 
CD4+CD25+CTLA-4- cells (Birebent et a l, 2004), thus highlighting again the 
complexity of the CD4+CD25+ T-cell population. In vitro studies have also shown 
that cross-linking of CTLA-4 resulted in the secretion of TGFp, thus providing 
another potential mechanism by which CTLA-4 may act (Chen et a l , 1998).
However in agreement with the observations presented earlier in this chapter, studies 
by various groups have shown that blocking CTLA-4 in vitro did not result in the 
reversal of suppression (Thornton and Shevach, 1998; Levings et a l, 2001; Baecher- 
Allan et a l, 2001). Also CD4+CD25+ cells from CTLA-47' mice have been shown to 
possess suppressive activity (Piccirillo and Thornton, 2004). Overall, the likely 
conclusions are that the role of CTLA-4 in vitro is not vital for function but in a more 
complex in vivo environment, it is likely to play a role either via the generation of 
TGFP or directly by acting on APCs. CTLA-4 may even act directly on the 
CD4+CD25- effector cell via interaction with CD80 or CD86 and initiate reverse
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signalling back into the effector cell, thus limiting T cell expansion (Paust et al., 
2004).
The addition of exogenous IL-6, TNFa and LT had no effect on the ability of the 
CD4+CD25+ cells to suppress, which was a surprising result. In a proinflammatory 
environment one might expect suppression to be reversed, resulting in effective CD4+ 
helper T cell responses. Indeed a study looking at the functionality of CD4+CD25+ 
cells from rheumatoid arthritis patients has shown the cells were ineffective at 
inhibiting cytokine production from CD4+CD25- cells, although they were able to 
inhibit proliferation. However cells isolated from patients on anti-TNFa therapy 
showed restoration of CD4+CD25+ function, suggesting that elevated levels of TNFa 
can directly or indirectly compromise regulatory T cell function (Ehrenstein et al., 
2004). Data from Pasare et al. showed that IL-6 in combination with another TLR- 
induced cytokine could also block CD4+CD25+ mediated suppression (Pasare and 
Medzhitov, 2003). Undoubtedly more experiments need to be done in vitro, ideally 
with combinations of cytokines to fully determine the effect of proinflammatory 
cytokines on regulatory T cell function. However perhaps it is a misconception that a 
proinflammatory environment would compromise regulatory T-cell function. 
Important evidence is now emerging that CD4+CD25+ regulatory T cells may be 
functional when pathogens invade in order to control the magnitude of the effector T 
cell response and to prevent excessive tissue damage (Rouse and Suvas, 2004).
The high constitutive expression of CD25 and the observation that CD25'7' mice 
develop a fatal lymphoproliferative disease (Willerford et al., 1995) led to 
experiments to investigate whether this molecule was involved functionally in
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suppression. Using a blocking antibody to CD25, no effects on suppression were 
observed. Blocking CD 122 or neutralising IL-2 had no effect either. Together these 
data suggested that IL-2 signalling was not playing a significant role in the generation 
of suppressor function in these studies. However data from mouse studies showed that 
transient production of IL-2 by CD4+CD25- responder cells was necessary to drive 
CD4+CD25+ suppressor cell function (Thornton et al., 2004). Is this highlighting 
another difference between mouse and human regulatory cells or is this an invitro  
characteristic of mouse cells that is not replicated in vivo? Studies with regulatory 
cells that had been isolated following homeostatic expansion in vivo, showed that 
although these cells had downregulated CD25 expression, they were still functional 
suppressors, suggesting that CD25 was not essential for regulatory T cell function 
(Gavin et al., 2002). Evidence from the studies described in this thesis has also shown 
that regulatory T cells enriched by selection for TNFR2 expression, had lower levels 
of CD25 expression than regulatory T cells enriched for CD95 expression, yet the 
TNFR2+ cells were more potent suppressors. Emerging evidence seems to support the 
concept that IL-2 -IL-2R signalling is essential in the generation of CD4+CD25+ 
regulatory T cells but not necessarily the functionality (Malek and Bayer, 2004).
This chapter has highlighted both the complexities and controversies surrounding 
regulatory T-cell biology. It is clear that there are discrepancies between both in vitro 
and in vivo systems and also between human and mouse CD4+CD25+ T cells. 
Resolution of some of these differences will require the identification of more robust 
cell surface markers that may result in the sub-typing of different CD4+CD25+ T-cell 
subsets with different functions. The identification of dysfunctional CD4+CD25+ T 
cells in human diseases should also aid our understanding of how these cells function.
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Perhaps most importantly, the generation of complex human assays that mimic more 
closely the in vivo environment in which many of the mouse studies have been 
conducted, would also be highly desirable. A new mouse model designed to study 
human immune cells in vivo has recently been described (Traggiai et al., 2004). The 
RAG2-/-yc-/- mouse is engrafted with human CD34+ stem cells from cord blood and 
eight to twelve weeks after engraftment, self-renewing human leukocytes can be 
detected including CD4+CD25+ regulatory T cells. Maybe in the future this model 
can be adapted to investigate the biology of human CD4+CD25+ cells in vivo. This 
would allow some of the complex interactions between both the innate and adaptive 
immune response to be followed and together this might help answer some of the 




Cloning of Human FOXP3 
and
Optimisation of Transfection Conditions.
Chapter 4
4.1 Introduction
In chapter 3 it was confirmed that freshly isolated human CD4+CD25+ T cells had the 
ability to suppress proliferation of CD4+CD25- responder T cells, following T cell 
activation. An attempt to identify more specific cell surface markers for this 
regulatory population of T cells proved unsuccessful. However in 2003, three papers 
were published identifying the existence of a new, more specific intracellular marker 
for CD4+CD25+ regulatory cells (Hori et al., 2003; Khattri et al., 2003; Fontenot et 
al., 2003). These papers also provided evidence that this molecule, called FQXP3, 
appeared to play a role in the generation of suppressive activity.
The identification of FOXP3 as a critical regulator of CD4+CD25+ regulatory T cells 
has generated a lot of interest and today, a significant proportion of the research on 
regulatory T cells centres on FOXP3. However at the commencement of these studies, 
the evidence that FOXP3 was highly expressed in CD4+CD25+ regulatory T cells 
was not in the public domain. Data implicating a role for FOXP3 in regulatory T cell 
function was also unpublished. Studies published in 2001 had identified a mutated 
form of the Foxp3 gene as being responsible for the phenotype of the scurfy mouse 
(Brunkow et al., 2001). This was supported by data from IPEX patients who also 
exhibited mutations in the FOXP3 gene (Smyk-Pearson et al., 2003). Together with 
data from studies in Jurkat T cells (Schubert et al., 2001) and from studies using cells 
isolated from Foxp3 transgenic mice (Khattri et al., 2001), the evidence suggested that 
FOXP3 played an important role in controlling T cell responsiveness to activation. 
The link with regulatory T cell function, although not published, had also been made 
and studies confirming this in the mouse were ongoing. However at this stage, there
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was no published data to support the function of this protein in human regulatory T 
cells.
The initial aim of this chapter was to confirm the expression of FOXP3 in human 
CD4+CD25+ regulatory T cells and then generate the necessary reagents to 
investigate the effect of overexpression of FOXP3 in human T cells. This required the 
cloning of both full-length human FOXP3 and a mutated from of the gene lacking a 
functional FKH domain. Validation of an appropriate transfection system was also 
carried out. The initial strategy employed a GFP-based expression system to allow for 
selection of transfected cells. Subsequently however the strategy changed and a co­
transfection system was validated. This system involved the transfection of two 
separate plasmids, one encoding FOXP3 and the second one encoding a chimeric 
receptor. All chimeric receptor constructs were kindly provided by Dr. Helene Finney.
The chimeric receptor used in the initial validation studies described in this chapter, 
consisted of the intracellular signalling region of the TGR zeta chain (TCRQ fused to 




spacer T.M. CD28 Zeta
S SS m i
Figure 4.1 Schematic diagram of the CD28/TCR£ chimeric receptor.
The chimeric receptor consists of a single chain Fv specific for CD3 3, linked to an 
extracellular spacer comprising human IgGl hinge, CH2 and CH3. The spacer is linked to the 
transmembrane (T.M.) and intracellular regions of human CD28, which is linked to the 
intracellular region of human TCR£.
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The extracellular region of the receptor is an antibody single chain Fv (scFv) that 
binds to CD33 . It has been reported that the addition of chimeric receptor transfected 
human T-cells to CD33-coated antigen plates, induces a strong activating signal into 
the transfected cells through the scFv (Finney et a l, 2004). This mechanism of 
activation ensures that only the transfected cells receive stimulation. Interestingly 
following transfection of T cells with the dual chimeric receptor, the strength of signal 
delivered through the chimeric receptor was found to be optimal with the CD28 
signalling region membrane proximal and the TCR<̂  signalling region membrane 





4.2.1 Expression of FOXP3 in human CD4+CD25+ regulatory T cells
Human CD4+CD25+ and CD4+CD25- T cells were purified from peripheral blood as 
described in chapter 3. Cell lysates were prepared and assayed for total protein 
content. Equal amounts of protein were then loaded onto 10% (w/v) tris-glycine SDS- 
PAGE gels and separated by gel electrophoresis. Following transfer onto PVDF 
membrane, the blots were probed with a rabbit polyclonal antisera raised against 
recombinant human FOXP3. The blots shown in figure 4.2 confirmed that the levels 
of FOXP3 expression were higher in the CD4+CD25+ T cell population as compared 
to the CD4+CD25- T cell population. The blots also revealed that FOXP3 appeared 
to migrate as a doublet with one band of approximately 5 OkDa corresponding to full- 
length FOXP3 and a slightly lower molecular weight band. This suggested the 
possibility that there might be more than one species of FOXP3. Further work 
investigating the identity of the doublet is described in chapter 6.
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Figure 4.2 Expression of FOXP3 in human CD4+CD25+ and CD4+CD25- T cells.
Cell lysates from human CD4+CD25- (lanes 1 and 3) and CD4+CD25+ (lane 2) T cells were 
prepared and analysed by Western blotting using rabbit polyclonal antisera to human FOXP3. 
Visualisation of the immunoreactive proteins was achieved using chemiluminescence after 
incubation of the blot with a goat anti-rabbit HRP-conjugated antibody. The arrow indicates 
the position of the FOXP3 doublet.
4.2.2 Cloning o f  human FOXP3
It was decided initially to clone full-length human FOXP3 into pTracer-CMV2 (figure 
4.3) via EcoRl and Notl restriction sites. This vector was chosen because it contains 
the GFP gene. Cells that express GFP should also co-express FOXP3, therefore 
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Figure 4.3 Schematic diagram of pTracer-CMV2.
The vector is approximately 6.2kb in size and contains the human cytomegalovirus (CMV) 
promoter which drives expression of cloned genes. Other essential elements include a 
multiple cloning site; bovine growth hormone (BGH) polyadenylation signal to allow 
efficient transcription termination and polyadenylation of cloned mRNA; human elongation 
factor la-subunit promoter (PEfi) to allow mammalian expression of the Cycle 3-GFP- 
Zeocin™ fusion; a synthetic bacterial promoter, EM-7 (Pem-7) to allow bacterial expression of 
the Cycle 3-GFP-Zeocin™ fusion; cycle3-GFP, an improved GFP gene fused to zeocin (GFP- 
zeocin) to detect transfected cells; a zeocin resistance gene for selection in both mammalian 
cells and E.coli and a SV40 polyadenylation signal. The vector also contains the |3-lactamase 
gene to confer resistance to ampicillin and a pUC origin for high copy number replication and 
propagation in E.coli.
The source o f cDNA used to clone the FOXP3 gene was human PBMC cDNA. This 
was provided by Dr. Patrick Slocombe and was generated from a mixture o f  both 
resting and activated PBMCs, from a number o f different donors. The published 
sequence (Genbank accession number AF277993) was used to design primers 
huFOXP3FWD2 (5’ primer) and huFOXP3REV (3’ primer) to allow amplification o f 
the FOXP3 gene. The 5 ’ oligonucleotide contained an iscoRI site to facilitate cloning 
and a partial Kozak translational initiation sequence for optimal gene expression, 
upstream o f the initiator methionine. The 3 ’ oligonucleotide contained a stop codon 
and a Notl restriction site. The base composition plot in figure 4.4 shows that the 
FOXP3 gene contains certain regions which are very G-C rich. These regions can 
cause problems during PCR reactions through the formation o f secondary structures 
that resist denaturation and prevent primer annealing. Thus it was decided to include 
varying concentrations o f DMSO in the PCR mix to disrupt the G-C base-pairing. The
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polymerase selected for use in the PCR reactions was KOD Hot Start polymerase. 
This polymerase contains a proof-reading enzyme to minimise PCR errors.
C+G
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Figure 4.4 G-C base plot for the human FOXP3 gene.
Analysis of the human FOXP3 gene highlighting regions where there are a high percentage of 
G-C base pairings. These G-C rich regions can lead to the formation of secondary structures 
during the PCR reaction
Six PCR reactions were set-up with increasing amounts of DMSO, ranging from no 
DMSO to 5% DMSO. Although all the conditions appeared to successfully generate a 
PCR product of approximately 1.3kb, it was decided to set-up a large scale cloning 
PCR reaction with 5% DMSO. The large-scale PCR reaction was successful and the 
PCR product was subjected to a phenol-chloroform extraction to remove 
contaminants from the PCR reaction. Both the PCR product and the cloning vector 
(pTracer-CMV2) were then digested with EcoRl and Notl and following a second 
phenol-chloroform extraction, the digests were separated on a 1% TAE agarose gel by 
gel electrophoresis and the bands excised under low wavelength uv light. The gel 




Ligated DNA, both vector alone and vector containing FOXP3 DNA (insert) were 
transformed separately into chemically competent E.coli. The transformation 
appeared to be successful with a large stimulation over the vector alone control. 
Twelve individual colonies were cultured and plasmid DNA was purified. To identify 
which clones contained the full-length FOXP3 gene, diagnostic digests were carried 
out using the restriction enzymes, EcoRl and Noil. The reactions were then separated 
by gel electrophoresis on a 1% TAE gel. Figure 4.5 shows that digestion of the clones 
yielded insert fragments of three different sizes. The expected fragment size was 
approximately 1.3kb, corresponding to the full-length FOXP3 gene, yet there 
appeared to be two smaller fragments. It was decided to sequence clones 2, 4, 6 and 











Figure 4.5 Identification of pTracer-CMV2 plasmids containing the full-length FOXP3 
gene.
Small-scale DNA preps were made of 12 clones. Diagnostic digests were carried out on each 
clone using the restriction enzymes EcoRl and Notl. Fragments were separated by gel 
electrophoresis on a 1% TAE gel. The red arrow indicates the fragment corresponding to full- 
length FOXP3.
The sequence alignment data confirmed that whilst clone 4 (and clone 6, not shown) 
contained full-length FOXP3, clone 2 (mutant 1) had a missing region o f 105 bases 
and clone 10 (mutant 2) whilst also missing this 105 base region, had an additional 
missing region o f 81 bases. At this stage o f the study the attention centred on the full- 
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Figure 4.6 Alignment of the published sequence for human FOXP3 with three different 
sized clones obtained from PCR reactions using human PBMC cDNA.
Amplification of the human FOXP3 gene yielded 3 different sized fragments. pTrFOXP3 
(clone 4) corresponds to the full-length 1296bp FOXP3 gene. Mutant 1 (clone 2) is lacking a 
region of 105 bases and mutant 2 (clone 10) is missing a region of 186 bases. The 5’ and 3’ 
cloning primers are shown. The blue residues indicate the enzyme restriction site and the 
green residues represent a partial Kozak translation initiation site. The red nucleotides protect 
the 5’-end of the primer.
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4.2.3 Expression o f  pTracer-CMV2-FOXP3 (pTr-F0XP3)
It was decided that all transfections would be carried out using electroporation. In 
2001 Amaxa Biosystems launched its nucleofector™ technology. This technology 
provides optimised solutions and electrical parameters to allow the transfection of 
both resting and activated primary cells by electroporation. Previous studies had 
already validated this methodology for expression of proteins in resting GD4+ T cells 
(Finney et al., 2004). A large-scale sterile DNA preparation of pTr-FOXP3 was 
prepared. To ensure the vector was functional, initial studies involved transfection of 
DNA into Chinese hamster ovary (CHO) cells. It was decided to transfect 5pg of 
DNA per 2x106 cells and then analyse the cells by flow cytometry, 24 hours post- 
transfection. The dot plots in figure 4.7 confirmed that GFP was being expressed 
following transfection of the pTr.FOXP3 plasmid. However, attempts to detect 
intracellular FOXP3 using the polyclonal anti-sera and flow cytometry were 
unsuccessful (data not shown).







Figure 4.7 Expression of GFP in transfected CHO cells.
CHO cells (2xl06 per transfection) were transiently transfected with 5pg of pTr.FOXP3 
plasmid and analysed for GFP expression by flow cytometry, 24 hours post-transfection. 
Untransfected cells are shown as a control. The percentage of cells positive for GFP is 
displayed. Cells likely to be non-viable were excluded on FSC/SSC plots.
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Optimisation of expression of GFP in resting human CD4+ T cells was the next goal. 
Human CD4+ T cells were purified from peripheral blood using a MACS CD4+ 
negative selection isolation kit as previously described in chapter 3. For the initial 
experiments, 5pg and 10pg of DNA were transfected per 2x106 CD4+ T cells. As a 
control, pTracer-CMV2 (pTracer) plasmid without insert was included. 
Disappointingly the expression levels were very poor with almost no detectable GFP 
when 5pg of DNA was transfected (data not shown) and only 24% of the cells 
positive for GFP following transfection with 10pg o f pTr-FOXP3 DNA (figure 4.8). 
Interestingly the percentage of cells positive for GFP expression following 
transfection with pTracer was 46%. The viabilities of both groups of transfected cells, 
as determined by forward and side scatter, were also very low with on average, only 
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Figure 4.8 Expression of GFP in transfected human CD4+ T cells (I).
CD4+ T cells purified from human peripheral blood using a MACS CD4+ negative isolation 
kit, were transiently transfected with either lOpg of empty pTracer or lOpg of pTr.FOXP3 
plasmid DNA. 2x106 CD4+ T cells were used per transfection. Cells were analysed for GFP 
expression by flow cytometry, 24 hours post-transfection. The percentage of cells positive for 
GFP is displayed. Cells likely to be non-viable were excluded on FSC/SSC plots.
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Due to low viability and poor expression levels, an increased cell number of 5x106 
cells per transfection was used to try and improve viability. An increased amount of 
DNA was also used for the transfection to try and boost the expression levels. The 
data illustrated in figure 4.9 shows the results following transfection of 5,10 and 20pg 
of both pTracer and pTrFOXP3. The increased cell number did have a beneficial 
effect on viability with greater than 65% viability being achieved (data not shown). 
However the expression levels were still disappointing with only 22% of the cells 
expressing GFP following transfection with 20pg of pTr-FOXP3.
It was observed that at all concentrations of transfected DNA, the empty vector 
control appeared to be expressed at a much higher level than pTr-FOXP3. At the 
highest concentration of DNA transfected this difference was 39% of cells positive for 
GFP versus 22%. This suggested the possibility that the CD4+ T cells were finding it 
difficult to co-express GFP and FOXP3. Attempts were made to sort both populations 
of GFP positive cells using a cell sorter and proliferation assays were set-up in the 
presence of PHA-L and IL-2. However, due to the low numbers of positive cells, very 
few cells were recovered and following activation, there were no differences in the 
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Figure 4.9 Expression of GFP in transfected human CD4+ T cells (II).
CD4+ T cells purified from human peripheral blood using a MACS CD4+ negative isolation 
kit, were transiently transfected with either 5, 10 or 20pg of empty pTracer or pTr.FOXP3 
plasmid DNA. 5x106 CD4+ T cells were used per transfection. Cells were analysed for GFP 
expression by flow cytometry, 24 hours post-transfection. The percentage of cells positive for 
GFP is displayed. Cells likely to be non-viable were excluded on FSC/SSC plots.
4.2.4 Expression ofpcDNA3.1.FOXP3 in  human CD4+ T  cells
Achieving high levels of expression of the pTr.FOXP3 plasmid in CD4+ T cells had 
proved difficult. Therefore it was decided at this stage to try a new FOXP3 plasmid 
that had been received as a gift from Dr. Roli Khattri. Full-length human FOXP3 
cDNA had been cloned as a HindJR fragment into the expression vector, pcDNA3.1+ 
(figure 4.10). One disadvantage of this construct was that it did not contain GFP,
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however it did contain a C-terminal flag tag that could be used for detection if  
required. Initial experiments involved transfecting increasing amounts of both 
pcDNA3.1 and pcDNA3.1.F0AP3 DNA into human CD4+ T cells. It was decided to 
use 4xl06 cells per transfection and 6, 9, 12 and 15pg of DNA. The transfected cells 
were incubated at 37°C overnight, harvested and cell pellets prepared. Cell lysates 
were then made and assayed for total protein content. Equal amounts of protein were 
then loaded onto 10% (w/v) tris-glycine SDS-PAGE gels and separated by gel 
electrophoresis. Following transfer onto PVDF membrane, the blots were probed with 
a rabbit polyclonal antisera raised against recombinant human FOXP3.
The immunoblot in figure 4.11 shows that there was a very low level of FOXP3 
protein being expressed at 24 hours following the transfection of 6pg of DNA. 
However transfection of 9pg of DNA resulted in the expression of high levels of 
FOXP3 protein, producing a distinct band of approximately 50kDa, corresponding to 
full-length FOXP3 protein. Similar results were observed with 12 and 15 pg of DNA.
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Figure 4.10 Schematic diagram of the expression plasmid, pcDNA3.1+/-.
The vector is approximately 5.4kb in size and contains the human cytomegalovirus (CMV) 
promoter that drives expression of cloned genes. Other essential elements include a multiple 
cloning site in both forward and reverse orientations to facilitate cloning; bovine growth 
hormone (BGH) polyadenylation signal to allow efficient transcription termination and 
polyadenylation of cloned mRNA; f l ' origin of replication; SV40 early promoter and origin 
of replication to drive high level expression of the neomycin resistance gene, which confers 
resistance to the antibiotic Geneticin and a SV40 polyadenylation signal. The vector also 
contains the |3-lactamase gene to confer resistance to ampicillin and a pUC origin for high 
copy number replication and propagation in E.coli.
A B A B  A B  A B
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Transfected plasmid DNA
Figure 4.11 Expression of FOXP3 protein in human CD4+ T cells transfected with 
increasing concentrations of plasmid DNA containing the FOXP3 gene.
Human CD4+ T cells were purified from peripheral blood using a MACS CD4+ T cell 
negative selection isolation kit. The CD4+ T cells were transfected with increasing amounts 
of either empty plasmid DNA (A) or plasmid DNA containing the FOXP3 gene (B). Cells 
were harvested (24 hours post-transfection) and cell lysates were prepared and analysed by 
Western blotting using rabbit polyclonal antisera to human FOXP3. Visualisation of the 
immunoreactive proteins was achieved using chemiluminescence after incubation of the blot 
with a goat anti-rabbit HRP-conjugated antibody.
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4.2.5 Development o f  a functional assay with CD4+ T  cells overexpressing 
F0XP3
Transfection of 9pg of plasmid containing FOXP3 DNA into human CD4+ T cells 
resulted in easily detectable levels of FOXP3 protein expression. This enabled the 
studies to progress to the development of functional assays. It was decided initially to 
investigate the response of transfected cells to activation, using an in vitro cell 
proliferation assay. Purified CD4+ T cells were transfected with either 9pg of 
pcDNA3.1 or 9pg of pcDNA3.1 .FOXP3. The transfected cells were rested for 4 hours 
and then co-cultured with autologous CD4-depleted irradiated PBMCs in the presence 
of lpg/ml soluble anti-CD3. Proliferation was determined 3 days later by 
incorporation of 3H-thymidine. The combined results obtained for 5 individual 
donors are shown in figure 4.12. Whilst not statistically significant, there was a trend 
towards reduced levels of proliferation by the cells transfected with FOXP3 when 









Figure 4.12 Proliferation of CD4+ T cells following transfection with either empty 
plasmid DNA (control) or plasmid DNA containing the FOXP3 gene (FOXP3).
Purified human CD4+ T cells were transfected with either empty plasmid DNA or plasmid 
DNA containing the FOXP3 gene. 4 hours post-transfection, cells were counted and 2.5x105 
transfected cells were co-cultured with autologous irradiated CD4-depleted PBMCs 
(5xl04/well) in the presence of lpg/ml anti-CD3. The proliferative response was measured by 
3H-thymidine incorporation during the last 4-6 h of a 3-day culture period. Data shown are 
mean ± SEM of 5 donors. Value above the bar indicates percentage inhibition ± SEM.
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4.2.6 Development o f  a co-transfection system.
Whilst encouraging, the result in figure 4.12 highlighted some of the limitations of the 
system. From previous observations with the pTracer construct, it was highly unlikely 
that the transfection efficiency was 100%. Consequently there were probably a 
significant proportion of cells within both populations that were not transfected. 
These cells would be responsive to stimulation by anti-CD3 and could be masking the 
inhibitory effect of FOXP3 overexpression. The low level of transfection efficiency 
achieved may also part explain why the FOXP3-transfected cells were not capable of 
inhibiting the proliferation of the cells likely to be untransfected. A system was 
therefore required that would ensure activation of only the transfected cells. A co­
transfection system was devised in which the FOXP3gone was co-transfected with a 
gene encoding a chimeric receptor. This system allowed activation to be controlled 
because signalling through the chimeric receptor via the scFv, results in the activation 
of only transfected T cells.
Initial experiments required optimisation of the co-transfection conditions, The blot in 
figure 4.11 had already shown that transfection of 9pg of DNA appeared to be 
sufficient for FOXP3 expression. However, because this system also required the co­
transfection of chimeric receptor DNA, it was decided to use both 9pg and 12pg of 
FOXP3 DNA in combination with 3 jug and 6pg of chimeric receptor DNA. Following 
transfection, the CD4+ T cells were rested for 4 hours and then plated onto CD33- 
coated 96-well flat-bottomed plates for 24 hours. The scFv portion of the chimeric 
receptor is specific for CD33, hence binding of CD33 to the scFv portion of the 
chimeric receptor delivers a strong activating signal into the transfected T cell. In
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duplicate, transfected cells were also plated onto uncoated 96-well flat-bottomed 
plates. Culture supernatants were removed from the CD33 coated plates and assayed 
for IL-2. The cells from the uncoated plates were removed and analysed for CD33 
scFv expression levels by flow cytometry.
The results obtained from the co-transfection experiment were again encouraging. 
Overexpression of human FOXP3 in human CD4+ T cells appeared to inhibit IL-2 
production following specific activation through the chimeric receptor (figure 4.13). 
This effect although observed with all four different combinations of DNA, appeared 
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Figure 4.13 Optimisation of co-transfection conditions.
Purified CD4+ T cells were co-transfected with either 3pg (A) or 6pg (B) of CD28/TCR^ 
chimeric receptor DNA in combination with either 9 or 12pg of FOXP3 or control plasmid 
DNA and then rested for 4 hours. Cells were then seeded onto CD33-coated plates (5x10s 
cells/well) and incubated for 24 h at 37°C. Supernatants were removed and assayed for IL-2. 
Data are presented as means of triplicate determinations ± SDs.
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The results from the analysis of chimeric receptor expression are shown in figure 
4.14. Levels of expression of chimeric receptor appeared to be comparable between 
the control plasmid transfected cells and the cells transfected with the FOXP3 
plasmid. This result was encouraging as it provided a basis for further studies to 
investigate the effect of overexpression of FOXP3 in human CD4+ T cells.
A B
□  control i i control
Amount of DNA Amount Of DNA
transfected (pg) transfected (pg)
Figure 4.14 Determination of chimeric receptor expression levels following 
cotransfection of FOXP3 DNA.
Purified CD4+ T cells were co-transfected with either 3pg (A) or 6pg (B) of CD28/TCR^ 
chimeric receptor DNA in combination with either 9 or 12pg of FOXP3 or control plasmid 
DNA and then rested for 4 hours. Cells were then seeded onto uncoated 96-well flat-bottomed 
plates (5x10s cells/well) and incubated for 24 h at 37°C. Cells were removed and analysed by 




4.2.7 Cloning the FKHmutant
The initial observations w ith FOXP3 transfected CD4+ T cells had used pTracer- 
CMV2 without an insert as a control. It was possible that , expression of any protein 
driven by the hCMV promoter would modify T cell behaviour. In order to confirm 
that the initial observations related to specific effects of FOXP3, a more appropriate 
control was needed. Based on published data (Schubert et a l, 2001) the,decision was 
taken to clone a mutated form of FOXP3 which encoded a protein that lacked a 
functional C-terminal FKH domain. The 5’ primer that was used to clone the full- 
length version of the gene was also suitable for cloning the mutant. However a new 
3’primer designated FKH_FOXP3_REV was designed. This 3’ oligonucleotide 
contained coding sequence from nucleotide position 981, a flag tag sequence, a 
terminal stop codon and a Hzwdlll restriction site. The gene product was amplified 
from the same human cDNA source that had been used to clone the full-length 
version, using the same PCR conditions.
The resultant PCR product and the cloning vector, pcDNA3.1- (figure 4.10) were 
digested with iscoRI and HindRl restriction enzymes. This yielded a PCR product of 
approximately 1008bp including the flag tag. Both the PCR fragment and the vector 
were gel-purified and ligations were set-up. Following a successful transformation 
into E.coli, 12 single colonies were cultured and plasmid DNA was purified. 
Diagnostic digests using EcoRl and Hindlll restriction enzymes were carried out on 
the 12 clones and all appeared to contain an insert of the correct size (figure 4.15). 
Sequence analysis of clones 1,2 and 3 confirmed the sequence was correct. Figure 
4.16 shows the sequence alignment of the FKH clone, FOXP3 from pcDNA3.1+ and
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the published full-length sequence. There is a base change at position 744 in the FKH 
mutant however this change does not alter the amino acid as both CTG and CTA 
encode leucine. This change maybe the result of a PCR error, although this is thought 
unlikely and instead it may represent a natural polymorphism. A large-scale DNA 










Figure 4.15 Identification of plasmids containing the FKH mutant gene.
Small-scale DNA preps were made of 12 clones. Diagnostic digests were carried out on each 
clone using the restriction enzymes EcoKl and Hindlll. Fragments were separated by gel 
electrophoresis on a 1% TAE gel. The expected fragment size is approx lkb.
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------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Section 14
(1015) 1015 .1020___________ J030___________ ,1040___________ (1050___________ J060 ___________ J070___________ J080____________1092
Published Sequence  (1015) c c t t t c a c c t a c g c c a c g c t c a t c c g c t g g g c c a t c c t g g a g g c t c c a g a g a a g c a g c g g a c a c t c a a t g a g a t c t a c  
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------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Section 15
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FKH.Flag ( 9 8 2 ) --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Section 16
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FKH.Flag ( 9 8 2 ) --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Published S eq u en ce  (1249) C G G A G C C A G A G G C CC A G CA G G TG TTC C A A C C CTA CA CC TG G C C C CTG A ------------------------------------------------------------------------
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FKH.Flag ( 9 8 2 ) ----------------------------------------------------------------------------------------------------------------------- G A C TA C A A G G A C G A C G A T G A C A A G T A G --
3 ’ -  G TGTAAGGGTCTCAAGGAGGTGTTG 1 (. VI < ,1 I C( I <, (  IX,C I \ (  I (, I IX ATCTTCGAAGAGAGAG -
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Figure 4.16 Sequence alignment of the published FOXP3 sequence with the cloned full- 
length FOXP3 gene and the FKH mutant.
A mutated form of the FOXP3 gene lacking a functional FKH domain was cloned from 
human PBMC cDNA into the expression vector pcDNA3.1. A C-terminal flag tag was 
included to correspond with the flag tag on the cloned full-length FOXP3 gene. The 5’ and 3’ 
cloning primers are shown. The blue residues indicate the enzyme restriction site and the 
green residues represent a partial Kozak translation initiation site. The red nucleotides protect 




When these studies began, there was no published data linking FOXP3 expression to 
regulatory T cell function. The phenotype of both the scurfy mouse and IPEX patients 
suggested a role for FOXP3 in controlling T cell activation. However evidence 
demonstrating the link with regulatory T cell function was not in the public domain. 
Studies by Shubert et.al.h2A  shown that overexpression of FOXP3 in the Jurkat T cell 
line resulted in inhibition of IL-2 production following stimulation with anti-CD3 
(Schubert et al., 2001). This led to the idea that one of the functions of FOXP3 was to 
act as transcriptional repressor. Studies using CD4+ T cells isolated from transgenic 
mice overexpressing FOXP3, showed reduced levels of proliferation and IL-2 
production following stimulation with anti-CD3 and anti-CD28 (Khattri et al., 2001). 
This supported the idea that FOXP3 played a role as a regulator of T cell activity.
Prior to the cloning of the FOXP3 gene, immunoblot studies performed using 
CD4+CD25+ and CD4+CD25- cell lysates, confirmed that FOXP3 protein was 
predominantly expressed within the CD25+ population. Interestingly the protein also 
appeared to be expressed as a doublet. Further investigation into the identity of the 
doublet is described in chapter 6. There were also faint levels of expression of the 
protein in the CD25- population. A low level of contaminating CD4+CD25+ T cells 
within the CD25- population may simply explain this. Alternatively there may be a 
population of CD25- T cells within the periphery, which express low levels of 
FOXP3. These cells may act as reservoir of committed regulatory T cells which can 
be rapidly recruited as required (Yagi et a l, 2004). This concept of peripheral
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generation of CD4+CD25+ regulatory T cells from CD4+CD25- T cells is further 
discussed in chapter 6.
In an attempt to try to understand more about the function of FOXP3, the gene was 
cloned in order to look at the effect of overexpression of FOXP3 in freshly isolated 
human peripheral blood derived T cells. Historically, transfection of primary cells 
involved using either retrovirus or adenovirus. However retroviral gene transduction 
is limited to actively dividing cells as the retrovirus needs to integrate into the host 
genome. This requires pre-activation of the cells prior to transfection (Miller et a l , 
1990). Adenovirus can infect resting non-dividing cells but a large volume of virus is 
required, making this method relatively labour intensive. A new device had recently 
been validated which delivered DNA directly into the nucleus of primary cells by 
electroporation. This technique termed nucleofection™, had proved to be more 
efficient for the transfection of non-activated human CD4+ T cells than the adenoviral 
method and was quick and relatively easy to use (Finney, 2002).
Transfection of resting cells rather than activated cells was advantageous as it meant 
that the timing of activation of the T cell and hence the activation of the FOXP3 
protein could be controlled. This decision was based on published data showing that 
the FOXP3 protein is only functionally active following stimulation through the TCR. 
These published studies have shown that crossing the scurfy mouse with the DO 11.10 
TCR transgenic strain of mouse on a RAG1 knockout background, produced progeny 
that were resistant to disease (Zahorsky-Reeves and Wilkinson, 2001). This is because 
the ap  T cells generated through this cross were strictly reactive only to chicken
151
' Chapter 4
ovalbumin peptide, 323-339, therefore in the absence of this peptide, there was no 
TCR signalling and no activation of the mutated form of FOXP3 protein.
The initial strategy had been to clone the full-length FOXP3 gene into a GFP- 
expressing vector and then sort the positive cells on the basis of GFP expression. 
Transfection efficiencies are never 100% so it was recognised that there would have 
to be an enrichment step, otherwise the untransfected cells could mask any functional 
effects of FOXP3 overexpression. Cloning of the FOXP3 gene into the expression 
vector pTracer was straightforward. However the percentage of cells expressing high 
levels of GFP following transfection of the expression vector into both CHO cells and 
human CD4+ T cells was very poor.
Attempts to improve the expression levels by increasing both the cell number and the 
amount of DNA transfected, proved ineffective. One possibility was that analysis of 
GFP expression at 24 hours was too early to detect optimal levels. However analysis 
of expression levels at 48 hours showed even lower levels of GFP expression (data 
not shown). The levels of GFP expression were lower following transfection of 
pTrFOXP3 compared to pTracer. One explanation for this observation is that the 
expression of two intracellular proteins compromised the levels of expression of GFP. 
The level of FOXP3 expression in these cells was not determined, however it was felt 
highly unlikely that the FOXP3 protein was directly inhibiting expression of GFP. As 
already mentioned, for FOXP3 to be functional it requires activation through the TCR 
and this stimulation was lacking in this system. It was also possible that the pTracer 
vector was not optimised for use with the nucleofector system.
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Efforts switched to a new vector called pcDNA3.1 .FOXP3. Unlike the pTracer vector, 
this vector does not contain GFP, hence it was felt expression levels of FOXP3 might 
be increased. Analysis of FOXP3 expression by immunoblotting showed that FOXP3 
protein was being expressed 24 hours post-transfection. However analysis of cell 
lysates at 48 hours (data not shown) revealed markedly lower levels of protein, 
indicating that the expression of the protein was very transient. Nevertheless, 
functional assays set-up in the presence of soluble anti-CD3 indicated a trend towards 
inhibition of proliferation, following overexpression of FOXP3.
Whilst encouraging, this result also highlighted the need for a system that selected for 
the transfected cells and a system with an early read-out. The new system that was 
developed involved cotransfecting pcDNA3.1 .FOXP3 with a chimeric receptor. This 
system had many advantages over the earlier attempts, primarily because it ensured 
that only transfected cells could become activated. The fact that two separate vectors 
were being transfected meant that the expression levels of each could also be 
optimised. This meant the levels of FOXP3 expression or frequency of cells 
expressing FOXP3, could be increased without also affecting the levels of chimeric 
receptor expression. This increased the likelihood that cells transfected with chimeric 
receptor, were also transfected with FOXP3, whilst reducing the numbers of cells 
transfected with chimeric receptor alone. The 24-hour timepoint for analysis was also 
crucial, as previous data had highlighted the transient nature of expression of FOXP3.
The early data validating this system showed that overexpression of FOXP3 appeared 
to inhibit the production of IL-2 from CD4+ T cells following activation through the 
chimeric receptor. Levels of expression of chimeric receptor were found to be
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equivalent between the control and the FOXP3 transfected cells. In contrast to the 
GFP data, the levels of expression of the chimeric receptor were high with over 45% 
of the viable cells being; positive for CD33 scFv expression. These early results 
provided a novel functional assay system, which could be further developed.
In order to fully exploit this system, it was decided to generate a more appropriate 
negative control vector. The phenotype o f the scurfy mouse is the result of a 2-base 
pair insertion within exon 8 of the FoxpS gene (Brunkow et al., 2001). This mutation 
results in a ffame-shift leading to the generation of a truncated gene product that lacks 
the carboxy-terminal FKH domain. Genetic studies involving IPEX patients have also 
shown mutations within the FKH domain (Bennett et al., 2001; Wildin et ah, 2001; 
Wildin et ah, 2002). The FKH domain is encoded by sequence covering exons 9, 10 
and 11 (Gambineri et al., 2003) and spans amino acid residues 337-420 (Brunkow et 
aL, 2001). Just upstream of the start of the FKH sequence is a potential nuclear 
localisation signal, starting at nucleotide position 994 (Brunkow et al., 2001). Based 
on this information and also data from studies using a human FKH mutant (Schubert 
et al., 2001), a mutated form of the gene that ended at nucleotide position 981 (amino 
acid 327) was cloned ready for use in expression studies.
These studies have concentrated on the development of a functional co-transfection 
system to study the effects of FOXP3 overexpression in human T cells. The 
following chapter uses this system to more fully investigate the effect of FOXP3 
overexpression in both human CD4+ and CD8+ T cells. The use of different chimeric 









Validation of the chimeric receptor co-transfection system in the previous chapter 
allowed further studies to be undertaken investigating the effect of overexpression of 
FOXP3 in human T cells. Evidence that FOXP3 plays an important role in controlling 
T cell activation arose initially from data generated from studies with CD4+ T cells, 
isolated from both the scurfy mouse and mice transgenic for the Foxp3 gene. The 
scurfy mouse mutant has a frameshift mutation within the Foxp3 gone resulting in a 
truncated protein lacking a functional FKH domain. Functional analysis of CD4+ T 
cells isolated from mice with this mutation showed that the CD4+ T cells were 
hyperresponsive to stimulation (Clark et al., 1999). Cytokine expression was also 
dysregulated within these mice with elevated levels of many different cytokines being 
measured (Kanangat et al., 1996). The effects of this mutation are so severe that the 
mice succumb to a fatal lymphoproliferative disease within a few weeks of birth 
(Godfrey et al., 1991).
Conversely, characterisation of CD4+ T cells from mice transgenic for the Foxp3 
gene showed that the CD4+ T cells exhibited diminished levels of proliferation and 
IL-2 production following stimulation, when compared to control animals (Khattri et 
al., 2001). Together these studies provide evidence to support a role for the FOXP3 
protein in controlling T cell activation. This mode of action for FOXP3 is further 
supported by data generated from studies looking at the effect of overexpression of 
the human FOXP3 gene in the Jurkat T cell line. In these studies, overexpression of 
FOXP3 resulted in an attenuation of activation-induced proliferation and cytokine 
production (Schubert et al., 2001).
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Whilst the studies described in this thesis were progressing, a new mode of action for 
FOXP3 was proposed. Three seminal papers published within a few weeks of one 
another showed the selective expression of FOXP3 in mouse CD4+CD25+ regulatory 
T cells. They also reported that the overexpression of FOXP3 protein in non- 
regulatory mouse T cells resulted in the acquisition of regulatory activity. This was 
demonstrated using both cells isolated from mice transgenic for the Foxp3 gene 
(Khattri et al., 2003) and cells retrovirally-transduced with the FoxpS gene (Hori et 
a l, 2003; Fontenot et a l, 2003). Perhaps even more remarkable, was the observation 
that the retrovirally-transduced cells were able to prevent colitis induced by 
CD4+CD25-CD45RBhl T cells (Hori et a l, 2003). The FOXP3-overexpressing CD4+ 
T cells also appeared to display a typical mouse CD4+CD25+ regulatory T cell 
phenotype with elevated expression levels of CD25 and GITR (Hori et al., 2003; 
Khattri et al., 2003).
At this stage there was no published data confirming this exciting new function for 
FOXP3 in human T cells, although a paper had been published confirming that 
FOXP3 expression was associated with human CD4+CD25+ regulatory cells (Walker 
et al., 2003a). Further experiments by this group had shown that FOXP3 could be 
upregulated in a proportion of human CD4+CD25- T cells following activation, and 
that these cells exhibited suppressive activity. These results suggested that FOXP3 
expression in human CD4+ T cells, could be directly linked to suppressive activity.
The initial aim of the work described in this chapter was to determine whether the 
reported role for FOXP3 as a key regulator of T cell activation, as shown by 
overexpression of the protein in both mouse and Jurkat T cells, was also true for
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human peripheral blood derived T cells. In order to determine this, co-transfection 
experiments were initially carried out using FOXP3 and the CD28/TCR^ chimeric 
receptor. The ability of FGXP3 to inhibit signalling through the chimeric receptor was 
measured. Subsequently the effect of FOXP3 overexpression on signalling through 
different costimulatory pathways was also investigated, using chimeric receptors 
containing the intracellular signaling regions of ICOS, CD134 and CD 137. Finally 
attention focussed on determining whether the overexpression of FOXP3 in human 





5.2.1 Expression o f  full-length F0XP3 and the FKH mutant.
In the previous chapter, a mutated form of the human FOXP3 gene was cloned which 
lacked a functional FKH domain. It was felt that this construct was a more appropriate 
negative control for functional studies than a control plasmid without an insert. It was 
important to confirm expression of the FKH mutant in human CD4+ T cells before 
functional studies were initiated. It was also important to show that the levels of 
expression of the FKH mutant protein were equivalent to that found with the full- 
length FOXP3 protein. Human GD4+ T cells were purified from peripheral blood as 
previously described. Transfections were carried out using 9pg of plasmid DNA 
containing either full-length FOXP3 or FKH mutant, per 4xl06 CD4+ T cells. Cells 
were incubated at 37°C for 24 hours. Cell lysates were then prepared and assayed for 
total protein content. Equal amounts of protein from each transfected cell population 
were then loaded onto 10% (w/v) tris-glycine SDS-PAGE gels and separated by gel 
electrophoresis. Following transfer onto PVDF membrane, the blots were probed with 
a rabbit polyclonal antisera raised against recombinant human FOXP3. The 
immunoblot in figure 5.1 confirmed that both the FKH mutant and the full-length 
FOXP3 protein were being expressed and they appeared to be expressed at similar 
levels. There are also some faint bands on the immunoblot which may represent 
endogenous FOXP3 within the CD4+T cell population.
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Figure 5.1 Immunoblot of CD4+ T cells transfected with plasmid DNA containing either 
full-length FOXP3 or FKH mutant.
Human CD4+ T cells were transfected with plasmid DNA containing either full-length 
FOXP3 or FKH mutant. 24 hours post-transfection, cell lysates were prepared and analysed 
by Western blotting using rabbit polyclonal antisera to human FOXP3. Visualisation of the 
immunoreactive proteins was achieved using chemiluminescence after incubation of the blot 
with a goat anti-rabbit HRP-conjugated antibody. The arrows indicate the position of both 
proteins. Data is representative of 1 of 3 independent experiments.
To further confirm the expression of both forms of the FOXP3 protein, studies were 
carried out using fluorescence microscopy. Cells were co-transfected with plasmid 
DNA containing the chimeric receptor and plasmid DNA containing either full-length 
FOXP3 or FKH mutant as described before, and incubated for 24 hours without CD33 
stimulation. Analysis of transfected cells by flow cytometry includes a gating step to 
exclude the dead cells. This is either set on the basis of propidium iodide (PI) uptake 
or FSC/SSC profile. Therefore it was decided to include a dead cell removal step in 
this procedure to increase the proportion of viable cells and thus aid detection. This 
was carried out using a dead cell removal kit purchased from Miltenyi Biotec. 
Cytospins were then prepared and after a fixation step, pre-mixed CD33-FITC and 
rabbit anti-sera raised against human FOXP3 were added. Following an incubation 
step, goat anti-rabbit IgG (H+L) Alexa Fluor 660 antibody was added to detect the 
anti-sera. Slides were then analysed on a Leica fluorescence microscope.
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Detection of unactivated human CD4+ T cells was not straightforward as the cells 
were very small and it was difficult to detect the cytoplasm. Figure 5.2 illustrates 
some of the results that were obtained. Red staining represents FOXP3 or FKH 
mutant protein and green staining represents the chimeric receptor protein. Previous 
immunoblot studies had already confirmed that the FKH mutant protein could be 
detected by the rabbit polyclonal antisera. Although cells that expressed FOXP3 
generally also appeared to express the chimeric receptor, the pattern of FOXP3 
expression was different between the FKH mutant (Figure 5.2A) and the full-length 
FOXP3 protein (Figure 5.2B). Double staining for the chimeric receptor and FKH 
mutant generated a yellow-orange colour, suggesting that the red and green colours 
overlie one another. In contrast, distinct red and green staining was observed with the 
full-length FOXP3 and chimeric receptor co-transfected cells. This suggests that the 
FKH mutant protein and the full-length FOXP3 protein were localised in different 
cellular sites within the cell. There was no fluorescence detected when transfected 
cells were stained with control rabbit serum or when untransfected cells were stained 
with CD33-FITC (data not shown).
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CD28/TCR£ FKH mutant Overlay
B CD28/TCRC FOXP3 Overlay
Figure 5.2 Detection of transfected CD4+ T cells by fluorescence microscopy.
Purified human CD4+ T cells were co-transfected with 3jug of CD28/TCR<^ chimeric receptor 
DNA and 9jug of plasmid DNA containing either full-length FOXP3 or FKH mutant. 24 hours 
post-transfection, dead cells were removed using a MACS dead cell removal kit. Cytospins 
were prepared and cells were stained with CD33-FITC to detect the chimeric receptor (green) 
and rabbit anti-sera to FOXP3. Detection of the anti-sera was achieved using a goat anti­




5.2.2 Investigation into the effect o f  F0XP3 overexpression on CD4+ T  cell 
activation.
It was initially important to establish that any effects observed following 
overexpression of full-length FOXP3 were not as a result of lower levels of cell 
viability, or chimeric receptor expression. Purified CD4+ T cells were co-transfected 
with 3pg of CD28/TCR^ chimeric receptor DNA and 9pg o f either full-length 
FOXP3 DNA or FKH mutant DNA. Viabilities were determined 24 hours post­
transfection by measurement of FSC/SSC profiles and by the levels of PI uptake. 
Detection of bound CD33-FITC by flow cytometry indicated the percentage of cells 
expressing the chimeric receptor.
Figures 5.3A, 5.3B and 5.3C illustrate the data obtained following analysis by flow 
cytometry of one representative individual donor. Figure 5.3A shows the viability of 
the co-transfected cells on the basis of FSC and SSC profiles, whilst figure 5.3B 
shows the viability of the cells on the basis of PI uptake. The levels of chimeric 
receptor expression are shown in figure 5.3C. The combined results for a number of 
donors are illustrated in the figures 5.3D and 5.3E. Figure 5.3D shows that the 
viabilities of the two transfected populations were equivalent with viability levels of 
around 60% being achieved. Comparison of the PI staining data with the analysis of 
viability via FSC/SSC profiles highlighted no significant differences in the percentage 
of viable cells. Thus validating both methods as comparable for measuring cell 
viabilities. There was also no significant difference in the percentage of chimeric 
receptor positive cells between the two populations of transfected cells with 
expression levels of around 60% being achieved (figure 5.3E).
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Figure 5.3 Measurement of CD4+ T cell viabilities and chimeric receptor expression 
levels following co-transfection with FOXP3 or FKH mutant DNA.
Human CD4+ T cells were co-transfected with CD28/TCRC chimeric receptor DNA and 
either DNA encoding FOXP3 or FKH mutant protein. 24 hours post-transfection, cell 
viabilities were determined using FSC/SSC profiles (A) and PI staining (B). Viable cells are 
shown in red. Values on dot-plots indicate percentage viable cells. Chimeric receptor 
expression was measured using CD33-FITC (C), gates were set using untransfected CD4+ T 
cells (data not shown). Values on dot-plots indicate percentage positive cells expressing 
chimeric receptor. Combined data for cell viability are mean ± SEM, n=4 (D). Combined data 
for CD33 expression are mean ± SEM, n=7 (E).
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Once it had been established that the transfection efficiency and the viabilities were 
equivalent between the two transfected populations, subsequent experiments 
concentrated on investigating whether overexpression of FOXP3 had any functional 
effect on signalling through the CD28/TCR^ chimeric receptor. Human CD4+ T cells 
were co-transfected with DNA encoding the CD28/TCR£ chimeric receptor and 
DNA encoding either FOXP3 or FKH mutant protein and seeded onto CD33-coated 
plates. The culture supernatants were harvested 24 hours post-transfection and 
assayed for human IL-2 and human TNFa. Cells were removed and stained for cell 
surface CD69 and CD25. Figure 5.4A shows that overexpression of FOXP3 in human 
CD4+ T cells significantly inhibited CD69 upregulation (p<0.05) following specific 
cell activation vza the CD28/TCR<^ chimeric receptor. The levels of CD25 expression 
on the surface of cells expressing full-length or truncated FKH mutant were not 
significantly different (Figure 5.4B). However there was also a significant inhibition 
of IL-2 (p<0.05) and TNFa production (p<0.05), as compared to the FKH mutant 
(Figures 5.4C and D). The culture supernatants were also assayed for human IL-10 
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Figure 5.4 Measurement of CD4+ T cell activation following co-transfection of 
CD28/TCR£ chimeric receptor DNA with either full-length FOXP3 or FKH mutant 
DNA.
Human CD4+ T cells were co-transfected with chimeric receptor DNA and either DNA 
encoding FOXP3 or FKH mutant protein and then rested for 4 hours post-transfection. Cells 
were then seeded onto CD3 3-coated plates and incubated for 24 h at 37°C. Cells were 
removed and stained for CD69 expression levels (A) and CD25 expression levels (B). 
Supernatants were removed and assayed for IL-2 (C) and TNFa (D). Results are mean ± 
SEM, n=8. Values above the bars indicate percentage inhibition ± SEM. *, p<0.05 as 
compared with FKH control (Paired T-test).
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5.2.3 Investigation into the effect o f F0XP3 overexpression on CD8+ T cell 
activation.
These data have confirmed that FOXP3 can act to inhibit aspects of CD4+ T cell 
activation. The next set of experiments concentrated on determining whether FOXP3 
could also inhibit CD8+ T cell activation. Human CD8+ T cells were purified from 
peripheral blood using a MAGS CD8+ T cell negative selection isolation kit. As for 
the CD4+ T cells studies, it was important to establish that any effects observed 
following overexpression of full-length FOXP3, were not as a result of lower levels of 
cell viability or chimeric receptor expression. Purified CD8+ T cells were co­
transfected with 3pg of CD28/TCR£' chimeric receptor DNA and 9pg of either DNA 
encoding full-length FOXP3 protein or FKH mutant. Viabilities were determined 24 
hours post-transfection by measurement of FSC/SSC profiles. Detection of bound 
CD33-FITC by flow cytometry indicated the percentage of cells expressing the 
chimeric receptor.
Figure 5.5A shows the viabilities of both populations of transfected cells were 
equivalent with viability levels of around 50% being achieved. The levels of chimeric 
receptor expression were also comparable between the two cell populations with 
expression levels of around 60% (figure 5.5B). Analysis of the expression levels of 
both full-length FOXP3 and the FKH mutant was carried out by immunoblotting as 
previously described. Figure 5.6 shows that the expression levels of both proteins 
appeared to be equivalent. There also appears to be some endogenous FOXP3 being 
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Figure 5.5 Measurement of CD8+ T cell viabilities and chimeric receptor expression 
levels following co-transfection with FOXP3 or FKH mutant DNA.
Human CD8+ T cells were co-transfected with chimeric receptor DNA and either DNA 
encoding FOXP3 or FKH mutant protein. 24 hours post-transfection, cell viabilities were 
determined by FSC/SSC profiles (A). Chimeric receptor expression was measured using 
CD33-FITC (B). Results are mean ± SEM, n=4.
FOXP3
Figure 5.6 Immunoblot of CD8+ T cells transfected with plasmid DNA containing either 
full-length FOXP3 or FKH mutant.
Human CD8+ T cells were transfected with plasmid DNA encoding either full-length FOXP3 
or FKH mutant protein. 24 hours post-transfection, cell lysates were prepared and analysed by 
Western blotting using rabbit polyclonal antisera to human FOXP3. Visualisation of the 
immunoreactive proteins was achieved using chemiluminescence after incubation of the blot 
with a goat anti-rabbit HRP-conjugated antibody. The arrows indicate the position of both 
proteins. Data is representative of 1 of 3 independent experiments.
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Once the viabilities and expression levels of both the chimeric receptor and the 
FOXP3 proteins had been confirmed as comparable, attention focussed on 
investigating whether FOXP3 had any functional effect on CD8+ T cell activation. 
Human CD8+ T cells were co-transfected with DNA encoding the CD28/TCR<^ 
chimeric receptor and DNA encoding either FOXP3 or FKH mutant protein and 
seeded onto CD33-coated plates. As for the CD4+ T cell studies, culture supernatants 
were harvested 24 hours post-transfection and assayed for human IL-2 and human 
TNFa levels. Cells were also removed and stained for cell surface CD69 and CD25 
expression.
In agreement with the data obtained with the human CD4+ T-cells, overexpression of 
human FOXP3 in human CD8+ T-cells resulted in a significant inhibition of CD69 
upregulation (p<0.001) and a significant inhibition of IL-2 (p<0.001) and TNFa 
(p<0.05) production, as compared to cells overexpressing the FKH mutant (Figures 
5.7A, 5.7C and 5.7D). There was trend towards reduced levels of CD25 expression 
between cells expressing full-length FOXP3 compared to cells expressing the FKH 
mutant (Figure 5.7B, p=0.081). However the levels of CD25 expression on the CD8+ 
T cells were considerably lower than the levels of CD25 expression on the surface of 
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Figure 5.7 Measurement of CD8+ T cell activation following co-transfection of 
CD28/TCR£ chimeric receptor DNA with either full-length FOXP3 or FKH mutant 
DNA.
CD8+ T cells were transfected with CD28/TCR^ chimeric receptor DNA and DNA encoding 
either FKH mutant or FOXP3 protein. Cells were rested for 4 hours and then seeded onto 
CD33-coated plates. Cells were removed 24 hours later and stained for CD69 expression 
levels (A) and CD25 expression levels (B). Supernatants were removed and assayed for IL-2 
(C) and TNFa (D). Results are mean ± SEM, n=4. Values above the bars indicate percentage 
inhibition ± SEM. *, p<0.05; **, p<0.001 as compared with FKH control (Paired T-test).
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5.2.4 Inhibition o f  IL-2 production is not restricted to the CD28/TCRC, signalling 
pathway.
These data have shown that overexpression o f FOXP3 in both human CD4+ and 
CD8+ T cells resulted in a significant inhibition o f CD28/TCR^ induced T cell 
activation. It was decided to investigate whether this was also true for other activation 
pathways. The first o f these co-transfection experiments was set-up using a 
CD134/TCR<^ chimeric receptor. This receptor, illustrated in figure 5.8, is identical to 
the CD28/TCR(^ chimeric receptor apart from the intracellular signalling region, 
which has been replaced with the intracellular signalling region o f CD 134. Published 
studies have confirmed the signalling components o f this receptor are functional and 
lead to enhanced levels o f IL-2 and TN Fa production compared with a chimeric 
receptor containing the TCR^ signalling region alone (Finney et al., 2004).
Anti-CD33 G1 CD28
scFv spacer T.M. CD 134 Zeta
Figure 5.8 Schematic diagram of the CD134/TCR£ chimeric receptor.
The chimeric receptor consists of a single chain Fv specific for CD33, linked to an 
extracellular spacer comprising human IgGl hinge, CH2 and CH3. The spacer is linked to the 
transmembrane (T.M.) region of human CD28 and the intracellular region of human CD 134, 
which is linked to the intracellular region of human TCR( .̂
Human CD4+ T cells were transfected with 3pg o f CD134/TCR(^ chimeric receptor 
DNA and 9jag o f FOXP3 or pcDNA3.1 (control vector) DNA. The FKH mutant was 
not used for these studies because it was unavailable. A proportion o f the cells were
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then incubated for 24 hours without any further stimulation and stained for cell 
surface expression of CD 134/TCR^ chimeric receptor. As is shown in figure 5.9A, 
there were comparable levels of expression of the CD134/TCR^ chimeric receptor on 
both cell populations. The cell viabilities of the two populations, as determined by 
FSC/SSC profiles, were also equivalent (figure 5.9B).
The remaining cells were seeded onto CD33-coated plates as before and culture 
supernatants were harvested 24 hours later and assayed for human IL-2 and human 
TNFa. The cells were also removed and stained for cell surface CD69 and CD25. As 
is shown in figure 5.10A, overexpression of FOXP3 in human CD4+ T cells resulted 
in a significant inhibition of CD69 expression (pO.OOl) following specific cell 
activation via the CD134/TCR£ chimeric receptor. There was also a significant 
inhibition of IL-2 production (p<0.05) as compared to the control vector (Figure 
5.IOC), although the levels of IL-2 production are considerably lower than those 
produced following signalling through the CD28/TCR£ chimeric receptor. The levels 
of CD25 expression and TNFa production were not significantly different between 
the cells expressing full-length FOXP3 and those transfected with vector alone. 
(Figures 5.1 OB and 5.1 OD). These data show that the ability of FOXP3 to inhibit IL-2 






















Figure 5.9 Measurement of CD4+ T cell viabilities and CD134/TCR£ chimeric receptor 
expression levels following co-transfection with FOXP3 or control plasmid DNA.
Cells were transfected with CD134/TCR^ chimeric receptor DNA and either control plasmid 
DNA (pcDNA3.1) or FOXP3 DNA and then rested for 4 hours prior to seeding onto 96-well 
plates. 24 hours post-transfection cells were analysed for CD134/TCR(^ expression levels by 
using CD33-FITC (A). Cells were analysed for viability on the basis of forward and side 
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pcDNA3.1 F0XP3 pcDNA3.1 F0XP3
Figure 5.10 Measurement of CD4 T cell activation following co-transfection of 
CD134/TCR£ chimeric receptor DNA with either full-length FOXP3 or control plasmid 
DNA.
Cells were transfected with CD134/TCR£ chimeric receptor DNA and either pcDNA3.1 or 
FOXP3 DNA. Cells were rested for 4 hours and then seeded onto CD33-coated plates. Cells 
were removed 24 hours later and stained for CD69 expression levels (A) and CD25 
expression levels (B). Supernatants were removed and assayed for IL-2 (C) and TNFa (D). 
Results are mean ± SEM, n=3. Values above the bars indicate percentage inhibition ± SEM. 
*, p<0.05; **, p<0.001 as compared with vector control (Paired T-test).
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These studies have shown that overexpression of functional FOXP3 in human CD4+ 
T cells resulted in a significant inhibition of T cell activation, following stimulation 
through either the CD28/TCR^ or the CD134/TCR^ signalling pathways. CD28 is a 
member of the immunoglobulin-like CD28-B7 receptor family and is reported to 
signal through PI3-K (Alegre et a l 2001). In contrast, CD 134 is a member of the 
TNFR family and signals via the recruitment of various TNFR-associated factor 
(TRAF) signalling molecules (Arch et al., 1998). ICOS like CD28 belongs to the B7 
superfamily whilst CD137 (4-1BB) is an additional member of the TNFR family.
It was decided to investigate whether FOXP3 could also inhibit CD4+ T cell 
activation induced by these two co-stimulatory molecules using the chimeric 
receptors, ICOS/TCRC and CD 137/TCRC (figures 5.11 A and 5.1 IB). Published 
studies have confirmed the signalling components of both of these receptor are 
functional and lead to enhanced levels of IL-2 and TNFa production compared with a 
chimeric receptor containing the TCR<  ̂signalling region alone (Finney et al. , 2004).
Human CD4+ T cells were transfected with ICOS/TCR<^ or CD137/TCR<^ chimeric 
receptor DNA and FOXP3 or pcDNA3.1 (control vector) DNA. The FKH mutant 
was not used for these studies as it was unavailable. A proportion of the cells were 
then incubated for 24 hours without any further stimulation and stained for cell 
surface expression of the chimeric receptor (figure 5.12A). Viabilities were 
determined by FSC/SSC profiles and were found to be equivalent between the FOXP3 
transfected cells and the cells transfected with control plasmid, with levels of around 
70% viability being achieved for both chimeric receptor constructs (data not shown).
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The remaining cells were seeded onto CD33 coated plates for 24 hours. Culture 




T.M. CD 137 Zeta
Anti-CD33
scFv spacer spacer
Figure 5.11 Schematic diagrams illustrating the ICOS/TCR^ and CD137/TCR£ chimeric 
receptors.
Both chimeric receptors consist of a single chain Fv specific for CD33, linked to an 
extracellular spacer comprising human IgGl hinge, CH2 and CH3. The spacer is linked to the 
transmembrane (T.M.) region of human CD28 and either the intracellular region of human 


















pcDNA3.1 FOXP3 pcDNA3.1 FOXP3
Figure 5.12 Measurement of chimeric receptor expression levels and CD4+ T cell 
activation following co-transfection of either ICOS/TCR^or CD137/TCR£ chimeric 
receptors with either full-length FOXP3 or control vector DNA.
Cells were transfected with ICOS/TCR^ or CD137/TCR^ chimeric receptor DNA and either 
pcDNA3.1 or FOXP3 DNA. Half the transfected cells were incubated for 24 h at 37°C 
without CD33 stimulation and then stained for chimeric receptor expression levels with 
CD33-FITC (A). The remaining cells were rested for 4 hours and then seeded onto CD33- 
coated plates as before. Supernatants were removed 24 hours later and assayed for IL-2 (B). 
Results are mean ± SEM, n=3. Values above bars represent percentage inhibition ± SEM.
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The data illustrated in figure 5.12 shows that both chimeric receptors were expressed 
at high levels in the purified human CD4+ T cells with expression levels of around 
70% being achieved, 24 hours post-transfection. Levels of IL-2 production were much 
lower than those achieved with the CD28/TCR<^ chimeric receptor. This was also 
observed following co-transfection of the CD134/TCR^ chimeric receptor. However 
this is not surprising as signalling through CD2 8 delivers a potent primary activation 
signal, whilst the other molecules are traditionally involved in later T cell activation 
events. Whilst not statistically significant, overexpression of FOXP3 did produce a 
trend towards inhibition of IL-2 production from both the ICOS/TCR^ and the 
CD137/TCR<^ chimeric receptors. Experiments with more donors would have 
probably resulted in statistical significance being achieved.
5.2.5 Investigation into whether overexpression of FOXP3 in human CD4+ T 
cells leads to the generation o f suppressive activity.
These data confirmed a potential role for FOXP3 as an inhibitor of T cell activation in 
both human CD4+ and CD8+ T cells. However recent data has shown that FOXP3 
also appears to play a pivotal role in the generation of suppressive activity (K onet al., 
2003; Khattri et al., 2003; Fontenot et al., 2003). Experiments were therefore carried 
out to determine whether this was also true of the cells being used in these studies. 
The literature suggests that for regulatory T cell function to manifest itself, there is a 
requirement both for FOXP3 expression and specific activation through the TCR 
(Zahorsky-Reeves and Wilkinson, 2002). In order to achieve this, the ‘suppressor’ 
cells had to be transfected with both FOXP3 and chimeric receptor. However the
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responder cells, i.e. the cells to be suppressed, only required transfection with the 
chimeric receptor. Co-culture experiments were carried out using CD4+ T cells 
transfected with both FOXP3 and CD28/TCR<^, mixed in a 2:1 ratio with CD4+ T 
cells transfected with only CD28/TCR^. Cells were seeded onto CD33-coated plates 
and 24 hours later, culture supernatants were removed and assayed for IL-2. The 







Figure 5.13 Schematic diagram of the experimental protocol followed for the FOXP3- 
CD28/TCR£ suppressor assay.
Purified human CD4+ T cells were co-transfected with CD28/TCR<  ̂chimeric receptor DNA 
and either plasmid DNA encoding full-length FOXP3 or the FKH mutant. The co-transfected 
cells were then mixed in a 2:1 ratio with cells transfected with the CD28/TCR£ chimeric 
receptor alone. The cells were seeded onto CD33-coated plates and incubated for 24 hours at 
37°C. Supernatants were removed and assayed for IL-2.
Results from the FOXP3-CD28/TCR^ suppressor assay are illustrated in figure 5.14. 
Evidently in this system, the FOXP3 co-transfected cells were unable to suppress the 
activation of the CD28/TCR^ transfected cells. This led to other assay formats being 
explored. The first involved pre-activation of the FOXP3 co-transfected cells via the 
chimeric receptor for 24 hours, prior to co-culturing for a further 24 hours with freshly
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transfected CD28/TCR^ CD4+ T cells on CD33-coated plates. The rationale for this 
strategy was that the activation o f the signalling pathways required to generate 
suppressive activity mediated by FOXP3, might require longer than 24 hours to 
become fully functional. However no suppression o f IL-2 production was observed 
(data not shown). This could be explained by the fact that these studies have 
previously shown that FOXP3 expression is very transient and decreases after 24 






Figure 5.14 Measuring CD4+ T cell activation following the co-culture of cells co­
transfected cells with FOXP3 or FKH mutant DNA and CD28/TCR£ chimeric receptor, 
with cells transfected with CD28/TCR£ chimeric receptor alone.
Purified human CD4+ T cells were co-transfected with CD28/TCR<^ chimeric receptor DNA 
and either plasmid DNA containing full-length FOXP3 or the FKH mutant (designated 
FOXP3 or FKH). The co-transfected cells were then mixed in a 2:1 ratio with cells transfected 
with the CD28/TCRL, chimeric receptor alone (C.R.). The cells were seeded onto CD33- 
coated plates and incubated for 24 hours at 37°C. Supernatants were removed and assayed for 
IL-2. Results are mean ± SEM, n=3.
There was a concern that the levels o f FOXP3 being expressed within the cell were 
not sufficient to inhibit both T cell activation within the co-transfected cells and to 
play a role in the additional cellular events required to initiate suppression o f
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neighbouring cells, if  indeed these pathways are distinct signalling events. A new 
chimeric receptor that only has the intracellular signalling region of TCR<  ̂was used in 
an attempt to address this issue (figure 5.15). It was believed that signalling through 
this receptor should be sufficient to reveal effects of FOXP3, but the overall level of 
activation within the cell would be low, therefore the majority of the FOXP3 protein 
would potentially be available to participate in other signalling events. However as is 
shown in figure 5.16, adoption of this strategy did not lead to the generation of 
FOXP3 specific suppressive activity. Interestingly, the co-culture conditions appeared 
to result in a non-FOXP3-dependent inhibition of chimeric receptor activation.
Anti-CD33 G1 Zeta
scFv spacer T.M. Zeta
Figure 5.15 Schematic diagram illustrating the TCR£ chimeric receptor.
The chimeric receptor consists of a single chain Fv specific for CD33, linked to an 
extracellular spacer comprising human IgGl hinge, CH2 and CH3. The spacer is linked to the 









Figure 5.16 Measuring CD4+ T cell activation following the co-culture of cells co­
transfected with FOXP3 or FKH mutant DNA and TCR£ chimeric receptor, with cells 
transfected with CD28/TCR£ chimeric receptor alone.
Purified human CD4+ T cells were co-transfected with TCR(^ chimeric receptor DNA and 
either plasmid DNA containing full-length FOXP3 or the FKH mutant (designated 
FOXP3/zeta or FKH/zeta). The co-transfected cells were then mixed in a 2:1 ratio with cells 
transfected with the CD28/TCR^ chimeric receptor alone (C.R.). The cells were seeded onto 
CD33-coated plates and incubated for 24 hours at 37°C. Supernatants were removed and 
assayed for IL-2. Data shown are mean of 2 donors. Error bars represent minimum and 
maximum values.
It was possible that the activation o f CD4+ T cells through the chimeric receptor 
signalling pathway generated a population o f cells that were resistant to suppression. 
In an attempt to determine whether this was true, experiments were conducted 
investigating whether naturally occurring CD4+CD25+ regulatory T cells were able to 
inhibit CD28/TCR^ transfected CD4+ T cells. As already mentioned, CD4+CD25+ 
regulatory cells require activation through the TCR to be functional suppressor T 
cells, this meant a pre-activation step was required prior to co-culture w ith the 
chimeric receptor transfected cells. Freshly isolated CD4+CD25+ regulatory T cells 
were co-cultured for 24 hours in the presence o f irradiated autologous CD4-depleted
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PBMCs and lpg/mL PHA-L. The CD4+ T cells were repurified using a MACS CD4+ 
negative isolation kit and then co-cultured in a 1:1 ratio with CD28/TCR£, transfected 
CD4+ T cells on CD33-coated plates for a further 24 hours. Culture supernatants were 
removed and assayed for IL-2. Pre-activated CD4+CD25- T cells were used as a 
control.
The data illustrated in figure 5.17 shows that pre-activated CD4+CD25+ regulatory T 
cells were capable of inhibiting T cell activation induced through chimeric receptor 
signalling. Levels of IL-2 measured in this assay system were considerably lower than 
those measured in the FOXP3-CD28/TCR<^ suppressor assay (figure 5.14). This is 
because ten-fold less cells were used in these experiments due to poor recoveries of 
activated CD4+CD25+ regulatory cells following the purification step. These data 
together with the data presented in figure 5.16 suggest that chimeric receptor 










Figure 5.17 Measurement of IL-2 production following co-culture of CD28/TCR£ 
transfected CD4+ T cells with preactivated CD4+CD25+ regulatory T cells.
Purified human CD4+CD25+ and CD4+CD25- T cells were stimulated for 24 hours in the 
presence of irradiated autologous CD4-depleted PBMCs and 1 jug/ml PHA-L. The cells were 
repurified using a MACS CD4+ negative selection isolation kit and mixed in a 1:1 ratio with 
CD4+ T cells transfected with CD28/TCR£, chimeric receptor DNA. The cells were seeded 
onto CD33-coated plates and incubated for 24 hours at 37°C. Supernatants were removed and 
assayed for IL-2. Data is representative of 3 independent experiments. Data is presented as 
mean cpm ± SD.
Another explanation for the lack o f observed suppressive activity by the FOXP3- 
transfected cells, is that the CD28/TCR(^ signalling pathway does not give the correct 
activation signals to reveal the suppressor function properties o f FOXP3. This was 
unlikely as the chimeric receptor signalling pathway should mimic conventional T cell 
activation. However, to confirm that the chimeric receptor signalling pathway was 
sufficient to reveal FOXP3 suppressive activity, transfection experiments were 
undertaken using freshly isolated CD4+CD25+ regulatory cells. CD4+ T cells were 
isolated from peripheral blood as previously described and transfected with 3jrg
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CD28/TCR<^ chimeric receptor DNA. Transfected cells were rested for 4 hours and 
then purified into CD25+ and CD25- fractions by using MACS CD25 microbeads. 
Transfected CD4+CD25+ cells were mixed in a 2:1 ratio with the transfected 
CD4+CD25- cells and seeded on CD33-coated plates. Cells were incubated for 24 
hours and supernatants were removed and assayed for IL-2. A proportion of cells 
from each population were left unstimulated and viabilities and chimeric receptor 
expression levels were determined, 24 hours post-transfection.
The viability data displayed in figure 5.18A shows that the transfected CD4+CD25+ 
regulatory cells were significantly less viable than the transfected CD4+CD25- cells. 
Viable cells were then gated and the levels of chimeric receptor expression were 
measured. Figure 5.18B shows that the levels of CD28/TCR^ chimeric receptor 
expression were also slightly lower within the CD4+CD25+ regulatory T cell 
population. Nevertheless, the data shown in figures 5.19A and 5.19B reveals that the 
chimeric receptor-transfected CD4+CD25+ regulatory cells were capable of 
suppressing the transfected CD4+CD25- cells, resulting in a significant inhibition of 
activation-induced IL-2 production. These data confirm that signalling through the 
CD28/TCR^ chimeric receptor is sufficient to activate suppressive activity, 
potentially through the activation of endogenous FOXP3. Confirmation that the 
observed inhibition is not simply due to increased cell number following the co­
culture of transfected CD25+ cells with CD25- cells, is shown in figure 5.19C where 
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Figure 5.18 Measurement of cell viabilities and CD28/TCR£ chimeric receptor 
expression levels following transfection of CD4+CD25+ regulatory T cells and 
CD4+CD25- T cells.
Purified CD4+ T cells were transfected with 3 jug of chimeric receptor DNA and rested for 4 
hours. Cells were further purified into CD25+ and CD25- T cell populations using MACS 
CD25 microbeads and incubated for 24 hours at 37°C. Cell viabilities were determined using 
FSC/SSC profiles (A) and chimeric receptor expression was measured using CD33-FITC (B). 
Dot plots are representative of 1 of 5 donors analysed. Values on dot-plots indicate percentage 
viable cells (red) (A) and percentage positive cells expressing chimeric receptor (B) Bar 
graphs show combined data for 5 donors ± SEM. Values above the bars indicate percentage 

























Figure 5.19 Measurement of CD4+ T cell activation following the co-culture of 
CD28/TCR£ transfected CD4+CD25+ regulatory T cells with CD28/TCR^ transfected 
CD4+CD25- T cells.
Purified CD4+ T cells were transfected with 3 jag of chimeric receptor DNA and rested for 4 
hours. Cells were further purified into CD25+ and CD25- T cell populations using MACS 
CD25 microbeads. The transfected CD25+ cells were then mixed in a 2:1 ratio with the 
transfected CD25- cells and seeded onto CD33-coated plates. 24 hours post-transfection, 
supernatants were removed and assayed for IL-2 (A and B). Increasing numbers of CD25- 
transfected cells were also seeded onto CD33-coated and supernatants were assayed for IL-2, 
24 hours post-transfection (C). Results are mean ± SEM, n=5 with the exception o f the 
data for 3xCD25- where data are n=3. Values above the bars indicate percentage inhibition 




Optimisation of the CD28/TCR^ chimeric receptor co-transfection system, described 
in the previous chapter, provided a basis for further investigation into the effect of 
overexpression of FOXP3 on subsequent human T cell activation. Evidence that 
FOXP3 plays a role in regulating T cell activation came initially from studies with 
CD4+ T cells isolated from the scurfy mouse. The CD4+ T cells were found to be 
hyperresponsive to TCR stimulation, resulting in the production of elevated levels of a 
number of cytokines including GM-CSF, IL-2, IL-4, IFNy and TNFa (Clark et a l , 
1999; Kanangat et al., 1996). Conversely, characterisation of CD4+ T cells isolated 
from mice transgenic for the Foxp3 gene, showed reduced proliferative responses to 
various stimuli and low levels of IL-2 production (Khattri et a l, 2001). Studies with 
the Jurkat T cell line had also shown that transient expression of FOXP3 resulted in an 
attenuation of activation-induced IL-2 production (Schubert et a l, 2001).
In an attempt to determine if FOXP3 played a role in human T cell activation, 
experiments were initially performed using freshly isolated peripheral blood-derived 
human CD4+ T cells. The CD4+ T cells were co-transfected with DNA encoding the 
CD28/TCR<^ chimeric receptor and FOXP3. Stimulation of the transfected cells for 24 
hours through the chimeric receptor, resulted in a significant inhibition of CD4+ T 
cell activation as measured by the release of both IL-2 and TNFa, and the levels of 
cell surface CD69 expression. These data confirmed a role for FOXP3 in regulating 
human CD4+ T cell activation and also confirmed that the FKH mutant was unable to 
suppress CD4+ T cell activation. This is believed to be because the FKH mutant is 
unable to translocate to the nucleus (Schubert et a l, 2001) and indeed the data
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generated from the microscopy studies described in these studies supports this. 
Certainly the pattern of staining obtained indicated that the FKH mutant and the full- 
length FOXP3 protein were localised within different regions of the cell.
Interestingly, overexpression of FOXP3 did not affect the levels of CD25 cell surface 
expression. However, the levels of CD69 were inhibited and so it would not have 
been surprising for the CD25 levels to also be inhibited. The most likely explanation 
for this difference is that measuring CD25 expression 24 hours post-activation, was 
too early a time-point to see any difference in expression levels. CD25 expression 
typically peaks around 3 days after activation unlike CD69, which is an early 
activation marker. Alternatively there is data suggesting that CD25 expression is 
linked to FOXP3 expression., Retro viral transduction of FOXP3 into both mouse and 
human CD4+CD25- resulted in elevated levels of CD25 expression compared to 
control transduced cells (Hori et al., 2003; Yagi et al., 2004). Again it is possible that 
24 hours post-activation may have been too early a time-point to observe this effect in 
these studies. However it is also important to note that retrovirally-transduced cells 
are pre-activated, therefore it is conceivable that FOXP3 does not induce CD25 
expression but rather maintains its expression.
Although adoptive transfer experiments have shown that the disease in scurfy mice is 
mediated by CD4+ T cells (Blair et ah, 1994), a role for FOXP3 in CD8+ T cell 
function has been proposed by data generated from studies with CD8+ T cells isolated 
from mice transgenic for the Foxp3 gene. These studies have shown that the 
transgenic CD8+ T cells have reduced cytolytic activity and are also defective in their 
ability to produce IL-2 (Khattri et al., 2001). There is also evidence from the
189
Chapter 5
literature, that sub-populations of both naturally occurring human and rat CD8+ T 
cells express FOXP3 (Walker et a l , 2003a; Xystrakis et al., 2004). Indeed 
immunoblot data presented in this thesis supports the observation that a population of 
naturally occurring CD8+ T cells express FOXP3. This led to further studies being 
undertaken using CD8+ T cells instead of CD4+ T cells. Co-transfection of purified 
human CD8+ T cells with CD28/TCR^ chimeric receptor and FOXP3 resulted in a 
significant inhibition of chimeric receptor-induced T cell activation. These data 
support the concept that FOXP3 is a key regulator of T cell activation. Interestingly 
overexpression of FOXP3 in mouse B cells did not appear to affect B cell function 
(Khattri et a l, 2001). Polyclonal activation of B cells isolated from Foxp3 transgenic 
mice, revealed normal antibody responses. The transgenic B cells were also 
competent at generating antibody responses following immunisation with KLH, 
providing non-transgenic CD4+ T cells were present. These data suggest that either 
the signalling pathways required to activate FOXP3 are lacking in B cells or the 
downstream targets o f FOXP3 are absent.
Optimal activation of lymphocytes requires an antigen specific signal (signal one) and 
a co-stimulatory signal (signal two). This two-signal model for lymphocyte activation 
was first proposed in 1970 (Bretscher and Cohn, 1970). Signal one; is delivered 
following engagement of the peptide-MHC complex with the TCR. Signal two is 
delivered to T cells by co-stimulatory molecules expressed on the surface of APCs. 
Co-stimulation through CD28 appears to be crucial for the activation of naive T cells. 
This activation results in high levels of IL-2 production, expansion of T cell numbers 
and resistance to apoptosis through the upregulation of BCL-Xl (Riley and June, 
2005; Alegre et a l, 2001). Activation of memory T cells and effector T cells is
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believed to be less dependent on CD28 signalling. Rather other molecules such as 
ICOS, CD134 (0X40) and CD 137 (41-BB) are thought to play an active role in 
sustaining the immune response and in the generation of T-cell memory (Croft, 2003; 
Sharpe and Freeman, 2002). It was therefore decided to investigate whether FOXP3 
was also capable of inhibiting CD4+ T cell activation initiated through these three 
alternative signalling pathways.
The data obtained using chimeric receptors specific for CD 134, ICOS and CD137, 
confirmed that FOXP3 was capable of inhibiting CD4+ T cell activation initiated by 
all three of these alternative immunoregulatory pathways. Validation of the 
functionality of each of these receptors had been confirmed by studies showing 
enhanced antigen-induced IL-2 and TNFa production, compared with the chimeric 
receptor with TCR^ signalling alone (Finney et a l, 2004). It was observed both in 
these published studies and the studies presented in this thesis, that the levels of IL-2 
produced following activation were much lower than those obtained following 
activation via the CD28 signalling pathway. However this is a reported phenomenon, 
with other cytokines being preferentially unregulated by these signalling pathways 
(Kroczek et al., 2004; Sharpe and Freeman, 2002). These studies have shown that 
providing CD4+ T cells receive a signal through the TCR signalling pathway, FOXP3 
can act as an inhibitor of T cell activation induced by a number of different co­
stimulatory pathways. One minor caveat with measuring inhibition of IL-2 production 
as a measure of suppression is that inhibition could be due to IL-2 consumption. To 
resolve this issue, IFNy could be measured or a blocking antibody to CD25 could be 
included in the assay.
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The observation that FOXP3 inhibits T cell activation suggests that during the course 
of an immune response, one function of FOXP3 might be to limit the extent of the 
response following activation-induced upregulation. Evidence that FOXP3 is 
upregulated following CD4+ T cell activation is provided by studies which showed 
that culturing of CD4+CD25- T cells with plate-bound anti-CD3 and soluble anti- 
CD28 resulted in the upregulation o f FOXP3 expression (Walker et a l , 2003a). 
Further evidence for a role for FOXP3 as a regulator in the periphery is supported by 
the phenotype of the Foxp3 transgenic mouse. When Foxp3 expression was under the 
control of the lek proximal promoter as opposed to its natural promoter, and thus only 
expressed during thymic development, the transgenic mice succumbed to the scurfy 
phenotype (Khattri et al., 2001). These studies suggest the absolute requirement for 
continued expression of FOXP3 in the periphery to prevent lymphoproliferative 
disease.
Whilst these studies have shown that FOXP3 can act to directly inhibit T cell 
activation, it is now becoming apparent that FOXP3 plays a more complex role in 
controlling T cell activation and is linked to the biological activity of CD4+CD25+ 
regulatory T cells. Evidence for this link arose from a detailed analysis of the T cell 
populations isolated from both the scurfy mouse and mice transgenic for the Foxp3 
gene. Scurfy mice were found to lack CD4+CD25+ regulatory cells whereas the 
transgenic mice possessed an increased percentage of CD4+CD25+ regulatory cells 
(Khattri et al., 2003). It was also interesting to observe that both the CD4+CD25- and 
CD4-CD8+ cells isolated from the transgenic mice had suppressive activity but not 




Retroviral transduction of Foxp3 into mouse CD4+CD25- T cells confirmed that 
overexpression of FOXP3 protein resulted in the generation of cells, which had 
regulatory activity both in vitro and in vivo (Hori et a l, 2003; Fontenot et al., 2003). 
This has been further supported by recent data showing that a single injection of islet 
antigen-specific T cells transduced with Foxp3, was able to reverse disease in mice 
with recent-onset diabetes (Jaeckel et al., 2005). All of the studies described thus far 
have investigated the effect of overexpression of FOXP3 in mouse T cells. It was 
therefore decided to investigate whether overexpression of FOXP3 in human CD4+ T 
cells also resulted in the generation of regulatory T cells.
Although overexpression of human FOXP3 resulted in a significant inhibition of both 
CD4+ and CD8+ T cell activation, these studies showed that the transient expression 
of FOXP3 was not sufficient to generate CD4+ T cells with suppressive properties. It 
is tempting to speculate that this is the result of an intrinsic difference between mouse 
and human CD4+ T cells. Certainly differences between mouse and human 
CD4+CD25+ regulatory T cells have been shown, including differences in cell 
surface marker expression and responsiveness to different cytokines, as highlighted 
earlier in these studies. One possibility is that overexpression of FOXP3 is necessary 
but not sufficient to convert a human CD4+ T cell into a regulatory T cell. However a 
recent publication has shown that retroviral transduction of human CD4+CD25- cells 
with FOXP3 did result in conversion of the cells into a regulatory phenotype (Yagi et 
al., 2004). This suggests that the system used in the studies described in this thesis, 
may not be optimised sufficiently for the detection of regulatory function.
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Additional experiments carried out within these studies confirmed that the activation 
of chimeric receptor transfected cells could be inhibited following co-incubation with 
pre-activated CD4+CD25+ regulatory T cells. Studies using CD4+ T cells transfected 
with TCRC, chimeric receptor and either FOXP3 or FKH mutant also appeared to 
partially inhibit the activation of CD4+ T cells transfected with CD28/TCR<^ chimeric 
receptor. One possible explanation for this inhibition is that following the delivery of 
an activation signal through the TCR£ chain in the absence of a costimulatory signal, 
an anergic phenotype was induced within these cells. These cells were then able to 
partially suppress the response of the CD28/TCR<^ transfected cells. Studies by 
Lombardi et al. have confirmed that some anergic human T cell clones are able to act 
as functional suppressor cells in vitro (Lombardi et al., 1994).
Signalling through the chimeric receptor was also sufficient to deliver the necessary 
signals required for activation of regulatory function within naturally occurring 
CD4+CD25+ regulatory cells. Although not proven, this is likely to be due to 
activation of FOXP3 because FOXP3 is required for regulatory function. Together 
these data suggested that the lack of regulatory activity might have been due to the 
levels of FOXP3 expression that were achieved, or the interplay of the activation 
pathways used and the levels of FOXP3 transfected. Studies comparing the functional 
activity of CD4+CD25+ regulatory T cells isolated from Foxp3 transgenic mice with 
CD4+CD25+ regulatory T cells isolated from wild-type mice support this theory. The 
transgenic cells were shown to express 10-15 times more mRNA for Foxp3 than the 
wild-type cells, although the functional activity of the transgenic cells on an activity 
per cell basis was slightly reduced (Khattri et al., 2003).
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This is further supported by the observation that all the experiments in which 
overexpression of FOXP3 has been shown to generate regulatory function, have used 
expression systems that allow the continuous expression of FOXP3 protein (Hori et 
al., 2003; Khattri et al., 2003; Fontenot et ah, 2003; Yagi et al., 2004). In some 
instances, this has also included an enrichment step to ensure only the highest 
producing cells were used (Yagi et al., 2004; Hori et al., 2003). In contrast, the system 
used in these studies only supports a short transient expression o f FOXP3, which 
although sufficient to inhibit T cell activation, was perhaps not sufficient to reach the 
threshold required to also generate regulatory function.
Another key difference between the retroviral system and the nucleofection technique 
adopted in these studies is the activation state o f the cells prior to transfection. These 
studies have used freshly isolated resting cells whereas for the retroviral studies, the 
cells required pre-activation. It is conceivable that certain pathways necessary to 
activate the regulatory function of FOXP3 were lacking in the resting cells or at the 
very least, required more than 24 hours stimulation to become fully functional. 
Attempts were made to co-transfect pre-activated CD4+ T cells with chimeric 
receptor and FOXP3, however the results obtained were variable and were not 
pursued. Recent data has been published showing that FOXP3-transfected Jurkats 
have suppressive activity (Choi et a l, 2005). However it should be also noted that 
Jurkats are in a permanent state of activation and therefore cannot be classed as 
resting T cells. Also the data was obtained using a stable selected Jurkat clone, so the 
levels of FOXP3 expression were constant.
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In conclusion, the most likely explanation for the lack of suppressive activity 
observed in these studies, is probably due to the levels of FOXP3 expression that were 
achieved. The system described involved a very transient expression of the protein 
that peaked at 24 hours. There was also no enrichment or selection step for the very 
highest producing cells. To fully determine whether FOXP3 overexpression in resting 
human T cells does result in the generation of suppressive activity, studies need to be 
undertaken with viral vectors that are capable of infecting non-dividing cells, such as 
lentiviral vectors. This would ensure stable expression of the FOXP3 protein.
An important question that remains unanswered is how the overexpression of FOXP3 
can switch a cell into becoming a CD4+CD25+ regulatory cell. There is evidence 
showing that activation through the TCR is required for FOXP3 to be functional, 
suggesting that either components of the TCR signalling cascade are responsible for 
regulating the activation of this protein, or FOXP3 acts on constituents of this 
pathway. However, this is not thought to involve direct phosphorylation of the 
FOXP3 protein because there is no consensus PKB/AKT site (Ramsdell, 2003). The 
activated FOXP3 protein may act as a transcriptional repressor, possibly by binding 
directly to FKH binding sites in the promoter regions of various pro-inflammatory 
genes and switching them off (Schubert et al., 2001). It is feasible that this inhibition 
of activation pathways via the direct suppression of certain genes, then allows the 
expression of other as yet unidentified genes that are responsible for the regulatory 
phenotype. This theory suggests a sequential pathway of events. Recent data has 
suggested that FOXP3 induces the expression of heme oxygenase-1 (HO-1) and 
blockade of HO-1 using SiRNA to HO-1, was able to abrogate the suppressive 
function of a FOXP3 stably-transfected Jurkat T cell clone (Choi et at., 2005).
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Alternatively, activation through the TCR triggers two independent signalling 
pathways for FOXP3, one of which is involved in T cell activation and the other in T 
cell regulation. Clearly there are still many questions to be answered regarding the 
mechanism of action of FOXP3. The following chapter uses the chimeric receptor co­
transfection system to investigate the functionality of two splice variant forms of the 








The first forkhead (FKH) transcription factor was discovered in the fruit fly 
Drosophila melanogaster over ten years ago (Weigel et al., 1989). These proteins are 
characterised by the presence of a ‘winged helix’ DNA binding domain, similar to the 
shape of a butterfly, which constitutes the FKH domain (Clark et a l, 1993). Over 100 
different proteins with FKH domains have been identified and these have been 
subdivided into 17 different classes on the basis of the amino acid sequence of the 
FKH domain (Lehmann et a l, 2003). One characteristic of these proteins is that they 
can all bind DNA, although the functional effect of this can either be the 
transactivation or inhibition of gene transcription (Coffer and Burgering, 2004).
FOXP3 is a member of the forkhead-winged helix family of transcription factors and 
is believed to act as a transcriptional repressor. Indeed experimental data generated in 
these studies have confirmed the ability of FOXP3 to inhibit T cell activation. These 
studies have also confirmed the absolute requirement for the functional C-terminal 
forkhead domain for inhibition to occur. Other important structural domains present 
within the FOXP3 protein include a proline-rich region, a zinc finger domain and a 
leucine-zipper motif (Gambineri et a l, 2003).
Proline-rich motifs are believed to be important in protein-protein interactions. They 
tend to be exposed on the Outer face of the protein thus allowing fast on and off-rates 
for binding (Kay et a l, 2000). Proline-rich regions are often found in situations where 
there is a requirement for rapid recruitment or interchange of several proteins, as 
occurs during the initiation of transcription and in signalling cascades. These regions
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are also believed to participate in ‘adaptor’ systems where they can act as an adaptor 
to bring together other proteins (Kay et al., 2000). Zinc finger domains have been 
reported to have many different functions including interactions with DNA, RNA and 
protein. To stabilise the structure of the zinc finger, these domains require the 
presence of one or more zinc ions (Laity et al., 2001). A leucine-zipper typically 
consists of a stretch of 35 amino acids containing 4-5 leucine residues separated from 
each other by 6 amino acids (Landschulz et al., 1988). This protein domain promotes 
dimer formation and these dimers can either be homodimers or heterodimers (Busch 
and Sassone-Corsi, 1990). The formation of dimers can be important for efficient 
DNA and protein binding (Abel and Maniatis, 1989).
During the cloning of the full-length version of the human FOXP3 gene, as described 
in chapter 4, two novel splice variant forms of the gene were identified. Mapping 
studies described in the following results section, showed that the isoform referred to 
as clone 2, was found to lack exon 2, a region mapping within the proline-rich part of 
the gene. The other isoform, referred to as clone 10, lacked both exons 2 and 7. Exon 
7 maps to a region forming part of a leucine-zipper structure. Since the discovery of 
these two splice variants, there have been two published reports showing expression 
of the isoform lacking exon 2 in human CD4+CD25+ regulatory T cells (Yagi et al., 
2004; Scotto et al., 2004). However there is currently no published functional data 
using this variant. There is also no published data identifying the second isoform that 
lacks both exons 2 and 7. Thus the functionality of the splice variant forms of the 
human FOXP3 protein are currently unknown.
The aim of this chapter was to determine whether the two isoforms of FOXP3 were
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functional inhibitors of CD4+ T cell activation. In order to determine this, 
cotransfection experiments were carried out using the previously described 
CD28/TCR^ chimeric receptor activation system. In addition, an investigation into 
whether splice variant forms of the Foxp3 gene existed in mouse CD4+CD25+ 




6.2.1 Mapping the missing regions within the F0XP3 splice variants
As discussed in chapter 4, amplification of full-length human FOXP3 from human 
PBMC cDNA resulted in the generation of three different sized PCR products. These 
PCR products were cloned into the expression vector pTracer-CMV2 and sequenced. 
Sequence analysis revealed the presence of two splice variant forms of the gene as 
well as a full-length version (clone 4). Clone 2 was found to be lacking a region of 
105 bases and clone 10 whilst also missing this 105 base region, lacked an additional 
region of 81 bases.
The human full-length FOXP3 gene is 1296bp in size and has been reported to consist 
of 11 different exons (Gambineri et al., 2003). The Ensembl Exonview mapping 
programme used to predict the exon structure of the FOXP3 protein, also suggested 
the existence of 11 coding exons. This exon predicition programme also enabled the 
missing nucleotide regions within the splice variants to be mapped to specific regions 
within the protein. The missing 105 bases (35 amino acids) identified in both clones 2 
and 10 corresponded to exon 2 and the missing region of 81 bases (27 amino acids) 
identified in clone 10, corresponded to exon 7 (figure 6.1).
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1 MPNPRPGKPSAPSLALGPSPGAS PSWRAAPKASDLLGARGPGGTFQGRDLRGGAHAS S S S 
6 1  LNPMPPSQLQLPTLPLVMVAPSGARLGPLPHLQALLQDRPHFMHQLSTVDAHARTPVLQV 
1 2 1  HPLESPAMISLTPPTTATGVFSLKARPGLPPGINVASLEWVSREPALLCTFPNPSAPRKD  
1 8 1  STLSAVPQSSYPLLANGVCKWPGCEKVFEEPEDFLKHCQADHLLDEKGRAQCLLQREMVQ 
2 4 1  SLEQQLVLEKEKLSAMQAHLAGKMALTKASSVASSDKGSCCIVAAGSQGPWPAWSGPRE 
3 0 1  APDSLFAVRRHLWGSHGNSTFPEFLHNMDYFKFHNMRPPFTYATLIRWAILEAPEKQRTL 
3 6 1  NEIYHWFTRMFAFFRNHPATWKNAIRHNLSLHKCFVRVESEKGAVWTVDELEFRKKRSQR 
4 2 1  PSRCSNPTPGP
Figure 6.1 Human FOXP3 Exon Structure
A predicted exon structure for the human FOXP3 protein sequence, calculated using the 
Ensembl Exonview mapping programme. The regions encoded by the 11 exons are depicted 
in alternating black and blue colours. Exons 2 and ,7 are highlighted in bold. The amino acids 
depicted in red represent residue overlap splice sites, i.e. the new exon starts within the 
coding region of an amino acid.
A proposed structure of the human FOXP3 protein is shown in figure 6.2. The 
schematic diagram shows that in addition to the functional FKH domain at the C- 
terminus of the protein, the protein is also thought to consist of a proline-rich region, a 
zinc-finger and a leucine zipper. The exons believed to be responsible for coding the 
different regions are also shown. Based on this proposed structure, it appeared that 
clone 2 was lacking a proportion of the proline-rich domain, a region important in 
protein-protein interactions (Kay et a/., 2000). Clone 10 however, in addition to 
missing a large proportion of the proline-rich domain, also appeared to lack a large 
proportion of the leucine-zipper. The presence of a leucine-zipper indicates the 
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Figure 6.2 Schematic diagram of the human FOXP3 protein.
Structure of the human FOXP3 protein schematically represented, highlighting the important 
structural domains and the corresponding exons encoding them.
6.2.2 Subcloning the FOXP3 splice variants
Before a detailed investigation into the functionality o f the splice variants could 
occur, the genes had to be subcloned from the expression vector pTracer-CM V2 into 
the expression vector pcDNA3.1+. The rationale for the subcloning was because 
transfection studies described in chapter 4 had shown poor expression o f the pTracer- 
CV2 plasmid in human CD4+ T cells, whereas the co-transfection system consisting 
o f the pcDNA3.1 plasmid containing FOXP3.flag and the CD28/TCR^ chimeric 
receptor, had been successful. At this stage it was also decided to reclone the full- 
length FOXP3 clone (clone 4) from pTracer-CMV2. The rationale for doing this was 
to confirm that the inhibition o f T cell activation observed thus far, was due to the
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functional effects of FOXP3 and was not influenced by the presence of the C-terminal 
flag tag.
Each of the three different variant forms of the FOXP3 gene were excised from 
pTracer-CMV2 using the restriction enzymes EcoRl and Notl. The cloning vector, 
pcDNA3.1+ was also digested with these enzymes. Following a phenol-chloroform 
extraction, the digested fragments were separated by gel electrophoresis on 1% TAE 
agarose gels and the correct sized fragments were excised under low wavelength uv 
light. The gel fragments were purified using a Qiagen gel extraction kit and ligations 
were set-up overnight at 16°C. Ligated DNA, both vector alone and vector containing 
FOXP3 DNA (insert) were transformed separately into chemically competent E.coli. 
As the transformation appeared to be successful, only six colonies were selected for 
culture from each FOXP3 clone. Plasmid DNA was purified and diagnostic digests 
were carried out using the restriction enzymes EcoRl and Notl. The reactions were 
then separated by gel electrophoresis on 1% TAE agarose gels. All the plasmids 
appeared to contain inserts corresponding to the expected sized version of the FOXP3 
gene.
Large-scale DNA preparations were made of each of the 3 different FOXP3 clones 
and a further EcoRJJNotl double digest was carried out to confirm the presence o f the 
correct sized inserts. Figure 6.3 confirms that each FOXP3 clone was successfully 
sub-cloned into the expression vector pcDNA3.1. Clone 4 generated an insert 
fragment of 1.296kb corresponding to the full-length gene, whereas clone 2 yielded a 
fragment of 1.191kb and clone 10 a fragment of l.llk b . Sequence analysis further 
confirmed that the sequences were as expected (data not shown).
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Figure 6.3 Diagnostic digests of plasmid DNA preparations containing either full-length 
FOXP3, clone 2 or clone 10.
Large scale DNA preparations of the full-length FOXP3 clone (lane 1) and both clones 2 
(lane 2) and 10 (lane 3) were prepared. Diagnostic digests were carried out using the 
restriction enzymes EcoRl and Notl. The digested fragments were separated on a 1% TAE 
agarose gel to confirm each plasmid preparation contained the expected sized variant form of 
the FOXP3 gene.
6.2.3 Expression o f  the FOXP3 splice variants
Prior to studying the functionality o f the splice variants, it was important to show that 
each variant was capable o f being successfully translated. Initially this was confirmed 
using CHO cells. Transfections were carried out using 3 jug o f plasmid DNA encoding 
a variant o f FOXP3, per lx l0 6 cells. Cells were incubated at 37°C for 24 hours. Cell 
lysates were then prepared and assayed for total protein content. Equal amounts o f 
total protein were then loaded onto 10% (w/v) tris-glycine SDS-PAGE gels and 
separated by gel electrophoresis. Following transfer onto PVDF membrane, the blots 
were probed with a rabbit polyclonal antisera raised against recombinant human 
FOXP3. The immunoblot in figure 6.4 shows that both splice variant forms o f the 
FOXP3 gene were successfully translated.
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Figure 6.4 Expression of different variant forms of the FOXP3 protein in CHO cells.
CHO cells were transfected with pcDNA3.1+ plasmid DNA containing either full-length 
FOXP3 (lane 2), clone 2 (lane 1) or clone 10 (lane 3). 24 hours post-transfection, cell lysates 
were prepared and analysed by Western blotting using rabbit polyclonal antisera to human 
FOXP3. Visualisation of the immunoreactive proteins was achieved using 
chemiluminescence after incubation of the blot with a goat anti-rabbit HRP-conjugated 
antibody. Data shown is from one of two experiments which produced similar results.
It was also important to confirm that the expression levels o f each FOXP3 variant 
were equivalent before any conclusions could be drawn with regard to functionality. 
Purified human CD4+ T cells were transfected with 9pg o f plasmid DNA containing 
FOXP3 variant DNA or FKH mutant DNA, per 4 x l0 6 cells. Cells were incubated at 
37°C for 24 hours. Cell lysates were then prepared and assayed for total protein 
content. Equal amounts o f total protein were then loaded onto 10% (w/v) tris-glycine 
SDS-PAGE gels and separated by gel electrophoresis. Following transfer onto PVDF 
membrane, the blots were probed with a rabbit polyclonal antisera raised against 
recombinant human FOXP3. The immunoblot in figure 6.5 shows that both splice 
variants are expressed in human CD4+ T cells. However the levels o f expression o f 
both clone 2 and clone 10 appeared to be slightly higher than both the full-length 
FOXP3 protein and the FKH mutant. This also appears to be true for the immunoblot 
shown in figure 6.4. One explanation for this may be that the absence o f exon 2 
renders the protein more stable and resistant to degradation, thus giving the 
appearance o f increased expression levels. Nevertheless, it was felt that because the
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full-length protein and the FKH mutant were expressed at comparable levels, it would 
still be valid to draw conclusions from the functional studies.
1 2  3 4
Figure 6.5 Expression of different variant forms of the FOXP3 protein in human CD4+
T cells.
Human CD4+ T cells were purified from peripheral blood using a MACS CD4+ negative 
selection isolation kit. The CD4+ T cells were transfected with pcDNA3.1+ plasmid DNA 
containing either full-length FOXP3 (lane 2), clone 2 (lane 1), clone 10 (lane 3) or FKH 
mutant (lane 4). 24 hours post-transfection, cell lysates were prepared and analysed by 
Western blotting using rabbit polyclonal antisera to human FOXP3. Visualisation of the 
immunoreactive proteins was achieved using chemiluminescence after incubation of the blot 
with a goat anti-rabbit HRP-conjugated antibody. Data shown is from one of two experiments 
which produced similar results.
In chapter 4 immunoblot analysis o f human CD4+CD25+ regulatory cells revealed 
that FOXP3 appeared to migrate as a doublet (figure 4.2). Following the identification 
o f splice variant forms o f the FOXP3 protein it was likely that the doublet represented 
both full-length FOXP3 and at least one o f the splice variant forms. In an attempt to 
confirm this cell lysates were prepared from both human CD4+CD25+ and 
CD4+CD25- T cells and from CD4+ T cells transfected with either full-length 
FOXP3, clone 2 or clone 10. Cell lysates were then prepared and assayed for total 
protein content. Equal amounts o f total protein were then loaded onto 10% (w/v) tris- 
glycine SDS PAGE gels and separated by gel electrophoresis. Following transfer onto 
PVDF membrane, the blots were probed with a rabbit polyclonal antisera raised 
against recombinant human FOXP3. Although the loading o f the immunoblot in 
figure 6.6 does not appear to be equal, it shows that the upper band o f the doublet 
present in freshly isolated CD4+CD25+ regulatory cells does appear to correspond to
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full-length F0X P3. Conversely, the lower band o f the doublet appears to correspond 
to clone 2. There is also a hint o f a third band which may represent clone 10, however 
due to the loading o f clone 10, this is difficult to confirm. From these data, it appears 
that a variant form o f FOXP3 that lacks exon 2 does appear to be expressed in 
naturally occurring CD4+CD25+ regulatory cells.
1 2 3 4 5
Figure 6.6 Expression of FOXP3 in freshly isolated human CD4+CD25+ and 
CD4+CD25- T cells and in CD4+ T cells transfected with different variant forms of 
FOXP3 DNA.
Human CD4+ T cells were purified from peripheral blood using a MACS CD4+ negative 
selection isolation kit. A proportion of the CD4+ T cells were transfected with pcDNA3.1+ 
plasmid DNA containing either full-length FOXP3 (lane 4), clone 2 (lane 3) or clone 10 (lane 
5). 24 hours post-transfection, cell lysates were prepared and analysed by Western blotting 
using rabbit polyclonal antisera to human FOXP3. The remaining CD4+ T cells were further 
purified into CD25+ (lane 2) and CD25- (lane 1) fractions using MACS CD25 microbeads 
and positive selection. Cell lysates were prepared and analysed by Western blotting using 
rabbit polyclonal antisera to human FOXP3. Visualisation of the immunoreactive proteins 
was achieved using chemiluminescence after incubation of the blot with a goat anti-rabbit 




6.2.4 Determination of the functionality of the splice variants
The immunoblots in figure 6.4 and 6.5 confirmed that the splice variants were being 
expressed as protein. The next question to answer was whether this protein was 
functional. It was decided to use the chimeric receptor co-transfection system to 
investigate the functionality of the splice variants. As for the previous experiments 
using this system, it was important to confirm that both the viabilities of the 
transfected CD4+ T cells and the expression levels of the chimeric receptor were 
equivalent for each transfected cell population.
Purified CD4+ T cells were co-transfected with 3pg of CD28/TCR<5 chimeric receptor 
DNA and 9pg of either full-length FOXPS DNA (clone 4), clone 2 DNA, clone 10 
DNA or FKH mutant DNA. Viabilities were determined 24 hours post-transfection by 
the levels of PI uptake. Detection of the chimeric receptor was carried out using 
soluble CD33 labelled with Alexa Fluor 488. Figure 6.7A and 6.7B illustrate the data 
obtained following analysis by flow cytometry o f transfected cells from one 
individual donor. Figure 6.7A shows the viability of the cells on the basis of PI 
uptake. The levels of chimeric receptor expression are shown in figure 6.7B. The 
combined results for seven different donors are illustrated in the figures 6.7C and 
6.7D. Figure 6.7C shows that the viabilities of the four transfected populations were 
equivalent with viability levels of around 60-70% being achieved. The levels of 
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Figure 6.7 Measurement of CD4+ T cell viabilities and chimeric receptor expression 
levels following co-transfection with different variant forms of FOXP3 DNA or FKH 
mutant DNA.
Human CD4+ T cells were co-transfected with CD28/TCR2, chimeric receptor DNA and 
either DNA encoding a variant form of FOXP3 or FKH mutant. 24 hours post-transfection, 
cell viabilities were determined using PI staining (A). Values on dot-plots indicate percentage 
viable cells. Chimeric receptor expression was measured using CD33-Alexa Fluor 488 (B). 
Values on dot-plots indicate percentage positive cells expressing chimeric receptor. 
Combined data for cell viability are mean ± SEM, n=7 (C). Combined data for CD33 
expression are mean ± SEM, n=7 (D).
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Once it had been established that the transfection efficiency and the viabilities were 
broadly equivalent for the four different transfected cell populations, subsequent 
experiments concentrated on investigating whether the splice variants had any 
functional effect pn signalling through the CD28/TCR^ chimeric receptor. Human 
CD4+ T cells were co-transfected with DNA encoding the CD28/TCR^ chimeric 
receptor and DNA encoding either a variant form of the FOXP3 gene or FKH mutant 
and seeded onto CD33-coated plates. The culture supernatants were harvested 24 
hours post-transfection and assayed for human IL-2. Cells were removed and stained 
for cell surface CD69 and CD25.
Figure 6.8A shows that there was a significant inhibition of IL-2 production by both 
FOXP3 variants and the full-length version of the protein, as compared to the FKH 
mutant. Figure 6.8B shows that both splice variant forms of the human FOXP3 
protein were also able to inhibit the upregulation of CD69 expression following 
activation through the chimeric receptor. The levels of CD25 expression on the 
surface of cells expressing either a variant form of the FOXP3 protein or the FKH 
mutant were not significantly different (Figure 6.8C). Together these data suggest that 
the two splice variants forms of the human FOXP3 protein are functional inhibitors of 
CD4+ T cell activation and confirm that the absence of a C-terminal flag tag does not 











Figure 6.8 Measurement of CD4+ T cell activation following co-transfection of 
CD28/TCR£ chimeric receptor with different variant forms of human FOXP3 DNA or 
FKH mutant DNA.
Human CD4+ T cells were co-transfected with CD28/TCR£ chimeric receptor DNA and 
either DNA encoding a variant form of FOXP3 or FKH mutant DNA and then rested for 4 
hours post-transfection. Cells were then seeded onto CD33-coated plates and incubated for 24 
h at 37°C. Supernatants were removed and assayed for IL-2 (A). Cells were removed and 
stained for CD69 expression levels (B) and CD25 expression levels (C). Results are mean ± 
SEM, n=7 for CD69 and CD25 and n=8 for IL-2. Values above the bars represent percentage 
inhibition ± SEM. Statistical analysis was by Anova with Bonferroni post-test. **, p<0.01 
versus FKH control, *,p<0.05 versus FKH control.
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6.2.5 Investigation into whether splice variant forms of the Foxp3 gene occur in 
the mouse
The immunoblot of human CD4+CD25+ regulatory cells shown in figure 6.6 
suggested that a variant form of human FOXP3 lacking exon 2 appears to be 
expressed naturally. This led to further studies to investigate whether variant forms of 
the protein are also expressed in mouse CD4+CD25+ regulatory cells. Mouse GD4+ T 
cells were purified from BALB/c splenocytes using a MACS CD4+ negative selection 
isolation kit. The CD4+ T cells were then further purified into CD25+ and CD25- 
fractions using the CD25 positive selection isolation kit. Cell lyates were prepared 
and assayed for total protein content. Equal amounts of protein were then loaded onto 
10% (w/v) tris-glycine SDS-PAGE gels and separated by gel electrophoresis. 
Following transfer onto PVDF membrane, the blots were probed with a rabbit 
polyclonal antisera raised against recombinant human FOXP3 (cross-reacts with 
mouse FOXP3). The immunoblot illustrated in figure 6.9 shows that mouse FOXP3 
protein appears to migrate predominantly as a single band suggesting only one form 
of the protein is highly expressed. This is in contrast to the human FOXP3 protein, 
which is clearly highly expressed as a doublet, possibly even multiple bands. 
Published data using rabbit polyclonal antisera raised against recombinant mouse 
FOXP3 confirms that the FOXP3 is expressed as a single band within mouse 
CD4+CD25+ regulatory T cells (Fontenot et al., 2003). However, certainly in the 
studies described in this thesis, there is a very faint band corresponding to the lower 
band of the FOXP3 doublet in the human CD4+CD25- T cell population and both the 
CD25- and CD25+ populations of mouse CD4+ T cells. The physiological relevance 
of this is as yet unclear.
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Figure 6.9 Expression of FOXP3 in human and mouse CD4+CD25+ and CD4+CD25- T 
cells.
Human CD4+ T cells were purified from peripheral blood using a MACS CD4+ negative 
selection isolation kit. The CD4+ T cells were further purified into CD25- (lane 1) and 
CD25+ (lane 2) fractions using MACS CD25 microbeads and positive selection. Mouse 
CD4+ T cells were purified from splenocytes and were further separated into CD25- (lane 3) 
and CD25+ (lane 4) fractions using a CD25 isolation kit. Cell lysates were prepared and 
analysed by Western blotting using rabbit polyclonal antisera to human FOXP3. 
Visualisation of the immunoreactive proteins was achieved using chemiluminescence after 
incubation of the blot with a goat anti-rabbit HRP-conjugated antibody.
A protein alignment of the mouse and human FOXP3 proteins is shown in figure 6.10. 
Overall there is 86.1% sequence identity between the two proteins. A sequence 
alignment of the mouse and human Foxp3/FOXP3 genes is shown in figure 6.11. At 
the nucleotide level, there is 84.4% Sequence identity. The high degree of sequence 
homology suggests a high degree of evolutionary conservation between the two 
species, signifying the importance of this protein in T cell regulation. In an attempt to 
determine whether variant forms of the mouse gene exist, it was decided to clone the 
mouse Foxp3 gene into the expression vector pcDNA3.1+. The published sequence 
(Genbank accession number NM_054039) was used to design primers muFoxp3FWD 
(5’ primer) and muFoxp3REV (3’ primer) to allow amplification of the mouse Foxp3 
gene. Design of the 5’ oligonucleotide includedan EcoRl site to facilitate cloning and 
a partial Kozak translational initiation sequence for optimal gene expression, 
upstream of the initiator methionine. The 3’ oligonucleotide contained a stop codon 
and a Notl restriction site. An in-house source of BALB/c mouse cDNA generated
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from ConA activated T-cells was used to clone the gene. PCR conditions selected 
were the same as those described for cloning of the human FOXP3 gene (section 4.2.2 
Cloning of human FOXP3).
The large-scale PCR reaction was successful and the PCR product was subjected to a 
Qiagen Qiaquick PCR clean-up step to remove contaminants from the PCR reaction. 
Both the PCR product and the cloning vector (pcDNA3.1+) were then digested with 
EcoRI and Notl and following a second Qiagen Qiaquick clean-up step, the digests 
were separated on a 1% TAE agarose gel by gel electrophoresis and the bands excised 
under low wavelength uv light. The PCR fragment was excised as a large gel slice to 
ensure any variant forms of the gene were not excluded. The gel fragments were 
purified using a Qiagen gel extraction kit and ligations were set-up overnight at 16°C.
The ligated DNA, both vector alone and vector containing mouse Foxp3 DNA (insert) 
were transformed separately into chemically competent E.coli. The transformation 
appeared to be successful, therefore forty-four individual colonies were cultured and 
plasmid DNA was purified. To identify which clones contained the full-length Foxp3 
gene, diagnostic digests were carried out using the restriction enzymes, EcoKL and 
Notl. The reactions were then separated by gel electrophoresis on a 1% TAE gel. 
Figure 6.12 shows a representative gel of 12 individual clones following restriction 
enzyme digestion. Each of the forty-four clones yielded an identical sized fragment of 
approximately 1.3kb. This suggested that if  variant forms of the mouse Foxp3 gene 
were present, they were present only at a very low frequency in the source of cDNA 
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Figure 6.10 Alignment of the published protein sequence for human FOXP3 with the 
published protein sequence for mouse FOXP3.
Comparison of the two protein sequences confirms that the human form of the protein 
contains two extra amino acids compared with the mouse protein (431 amino acids versus 
429). The proteins show an overall similarity index of 86%. The FKH domain has a similarity 
index of 94%. Position 173 highlights a region where there is a cluster of 4 amino acids 
changes. This region maps to exon 4. Red type on a yellow background indicates identical 
residues. Black type on a blue background indicates similar residues, i.e D and E are both 
acidic amino acids. Black type on a white background indicates residues with no similarities.
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Figure 6.11 Alignment of the published nucleotide sequence for human FOXP3 with the 
published nucleotide sequence for mouse Foxp3.
Comparison of the two nucleotides sequences confirms that the human form of the gene at 





Figure 6.12 Identification of pcDNA3.1+ plasmids containing the full-length mouse 
Foxp3 gene.
Small-scale DNA preparations were made of 44 clones. Diagnostic digests were carried out 
on each clone using the restriction enzymes EeoRI and Notl. Fragments were separated by gel 
electrophoresis on a 1% TAE agarose gel. This gel shows the insert fragments for clones 1- 
12.
Clones 10 and 30 were selected for sequence analysis to confirm that the insert 
fragment corresponded to the full-length Foxp3 gene. The sequence alignment data is 
shown in figure 6.13 and confirms that clones 10 and 30 contained the full-length 
mouse Foxp3 gene. Analysis of the 44 clones by restriction enzyme digest and gel 
electrophoresis, showed that all the clones contained an insert which appeared to be 
identical in size. On the basis of the sequence data obtained from clones 10 and 30, 
these data suggest that the 44 clones analysed contained the full length Foxp3 gene. 
Whilst not conclusively proving that splice variant forms of the mouse Foxp3 gene do 
not exist, these data together with the data from the immunoblot in figure 6.9, strongly 
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GC AA GTGGC CTGGTTG TGAGA AG GTCTTCGAGGAGCCAGAAGAGTTTCTCAAGCACTGCCAAGCAGATCATCTC
GC AA GTGGC CTGGTTG TGAGA AG GTCTTCGAGGAGCCAGAAGAGTTTCTCAAGCACTGCCAAGCAGATCATCTC
GC AA GTGGC CTGGTTG TGAGA AG GTCTTCGAGGAGCCAGAAGAGTTTCTCAAGCACTGCCAAGCAGATCATCTC
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(741) 741____________750_____________ 760_____________ 770_____________ 780_____________ 790_____________ @C£)__________________ 814
Mous e Publ ished S e q u e n c e  (741) g g a a a a g g a g a a g c t g g g a g c t a t g c a g g c c c a c c t g g c t g g g a a g a t g g c g c t g g c c a a g g c t c c a t c t g t g g  
C lone 10 (741) g g a a a a g g a g a a g c t g g g a g c t a t g c a g g c c c a c c t g g c t g g g a a g a t g g c g c t g g c c a a g g c t c c a t c t g t g g  
C lone 30  (741) g g a a a a g g a g a a g c t g g g a g c t a t g c a g g c c c a c c t g g c t g g g a a g a t g g c g c t g g c c a a g g c t c c a t c t g t g g
 Sect ion 12
(815) 8 1 5 ____ 820_____________ @30_____________ [340_____________ @50_____________ @60_____________ @70_________________________ 8 88
Mous e Published S e q u e n c e  (815) c c t c a a t g g a c a a g a g c t c t t g c t g c a t c g t a g c c a c c a g t a c t c a g g g c a g t g t g c t c c c g g c c t g g t c t g c t  
C lone 10 (815) c c t c a a t g g a c a a g a g c t c t t g c t g c a t c g t a g c c a c c a g t a c t c a g g g c a g t g t g c t c c c g g c c t g g t c t g c t  
C lone 30 (815) c c t c a a t g g a c a a g a g c t c t t g c t g c a t c g t a g c g a c c a g t a c t c a g g g c a g t g t g c t c c c g g c c t g g t c t g c t
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Sect ion 13
(889) 88 9 _______________ 900_____________ 9 10 _____________ 920_____________ 9 30_____________ 9 40 _____________ 950_______________962
Mouse Publ ished S e q u e n c e  (889) c c t c g g g a g g c t c c a g a c g g c g g c c t g t t t g c a g t g c g g a g g c a c c t c t g g g g a a g c c a t g g c a a t a g t t c c t t  
C lone 10 (889) c c t c g g g a g g c t c c a g a c g g c g g c c t g t t t g c a g t g c g g a g g c a c c t c t g g g g a a g c c a t g g c a a t a g t t c c t t  
C lone 30 (889) C C T C G G G A G G C T C C A G A C G G C G G C C T G T T T G C A G T G C G G A G G C A C C T C T G G G G A A G C C A T G G C A A T A G T T C C T T
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Sect ion 14
(963) 96 3 9 70 _____________ @@0_____________ @90_____________ 1000____________ (1010____________ J 0 2 0 ___________________ 1036
Mouse Publ ished S e q u e n c e  (963) c c c a g a g t t c t t c c a c a a c a t g g a c t a c t t c a a g t a c c a c a a t a t g c g a c c c c c t t t c a c c t a t g c c a c c c t t a  
C lone 10 (963) C C C A G A G T T C T T C C A C A A C A T G G A C T A C T T C A A G T A C C A C A A T A T G C G A C C C C C T T T C A C C T A T G C C A C C C T T A  
Clone 30  (963) c c c a g a g t t c t t c c a c a a c a t g g a c t a c t t c a a g t a c c a c a a t a t g c g a c c c c c t t t c a c c t a t g c c a c c c t t a
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Sect ion 15
(1037) 1037_________________ 1050____________ 1060____________ 1070____________ 1080____________ 1090____________ VI00_________1110
Mouse Publ ished S e q u e n c e  (1037) t c c g a t g g g c c a t c c t g g a a g c c c c g g a g a g g c a g a g g a c a c t c a a t g a a a t c t a . c c a t t g g t t t a c t c g c a t g  
C lone 10 (1037) t c c g a t g g g c c a t c c t g g a a g c c c c g g a g a g g c a g a g g a c a c t c a a t g a a a t c t a c c a t t g g t t t a c t c g c a t g  
C lone 30 (1037) t c c g a t g g g c c a t c c t g g a a g c c c c g g a g a g g c a g a g g a c a c t c a a t g a a a t c t a c c a t t g g t t t a c t c g c a t g
 Sect ion 16
(1111) i r n ___________1120____________ H 3 0 ____________ 1 140 ____________ 11150____________ H 6 0 ____________ H 7 0 ________________ H 8
Mo us e Publ ished S e q u e n c e  (1111) t t c g c c t a c t t c a g a a a c c a c c c c g c c a c c t g g a a g a a t g c c a t c c g c c a c a a c c t g a g c c t g c a c a a g t g c t '
Clone 10 (1111)  T T C G C C T A C T T C A G A A A C C A C C C C G C C A C C T G G A A G A A T G C C A T C C G C C A C A A C C T G A G C C T G C A C A A G T G C T '  
Clone 30 (1111) T T C G C C T A C T T C A G A A A C C A C C C C G C C A C C T G G A A G A A T G C C A T C C G C C A C A A C C T G A G C C T G C A C A A G T G C T '
 Sect ion 17
(1185) 1185 ,1190____________ 120 0____________ 1210____________ 1 2 2 0____________ 1230____________ 1240_______________________ 125
Mouse Pub l ished S e q u e n c e  (1185) t g t g c g a g t g g a g a g c g a g a a g g g a g c a g t g t g g a c c g t a g a t g a a t t t g a g t t t c g c a a . g a a g a g g a g c c a a i  
C lone 10 (1185) t g t g c g a g t g g a g a g c g a g a a g g g a g c a g t g t g g a c c g t a g a t g a a t t t g a g t t t c g c a a g a a g a g g a g c c a a <
Clone 30  (1185) T G T G C G A G T G G A G A G C G A G A A G G G A G C A G T G T G G A C C G T A G A T G A A T T T G A G T T T C G C A A G A A G A G G A G C C A A l
 Sect ion 18
(1259) 1259______________ 1270____________ ,1280 1290
Mouse Publ ish ed S e q u e n c e  (1259) g c c c c a a c a a g t g c t c c a a t c c c t g c c c t t g a  
C lone 10 (1259) g c c c c a a c a a g t g c t c c a a t c c c t g c c c t t g a  
C lone 30 (1259) g c c c c a a c a a g t g c t c c a a t c c c t g c c c t t g a
3 ’ -  C T T  G A C  G A G G T T  A G G G A C  G G G A A C T  C  G C  C  G G C  G A G  A G  A G  -  5 ’
Notl
Figure 6.13 Alignment of the published sequence for mouse Foxp3 with 2 clones 
obtained from PCR reactions using mouse T cell cDNA.
Sequence analysis of two different clones (10 and 30) produced following amplification of the 
mouse Foxp3 gene from activated T cell cDNA derived from the Balb/c mouse. The 5’ and 3’ 
cloning primers are shown. The blue residues indicate the enzyme restriction site and the 
green residues represent a partial Kozak translation initiation site. The red nucleotides protect 




The functional characterisation of FOXP3 and the FKH mutant in the previous 
chapter, confirmed that FOXP3 acts as an inhibitor of T cell activation. These data 
also confirmed that the inhibition observed was critically dependent on the presence 
o f a functional C-terminal FKH domain. During the initial cloning of the human 
FOXP3 gene, two novel isoforms of the gene were also identified. Both of the 
isoforms lacked exon 2 and in addition, clone 10 also lacked exon 7. Exon 2 maps to a 
proline-rich region of the protein and exon 7 maps to a portion of the leucine-zipper.
It was decided to investigate whether these domains were important for function by 
determining whether the splice variants were able to inhibit T cell activation induced 
through the CD28-TCR^ chimeric receptor. Initial transfection studies confirmed that 
the variant forms of the protein were capable of being expressed in CD4+ T cells, 
which implied that the missing exons were not affecting the ability of the proteins to 
be translated. It also appeared that expression levels of the FGXP3 isoforms were 
higher than both the full-length and the FKH mutant forms of the protein. One 
explanation for this observation was that the absence of exon 2 somehow improved 
overall protein stability. Interestingly the variant form of the protein lacking exon 2 
also appeared to be expressed in freshly isolated peripheral blood derived 
CD4+CD25+ regulatory T cells. This strongly suggested a functional role for this 
isoform.
The data generated from the functional studies showed that both variant forms of the 
FOXP3 protein significantly inhibited chimeric receptor induced CD4+ T cell
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activation, as measured by the release of IL-2. As mentioned in chapter 5, there is a 
caveat with measuring inhibition of IL-2 production as it could be due to consumption 
of IL-2. One way to address this would be to include a blocking antibody to CD25, 
Due to the short nature of the assay, measuring IFNy production is probably not a 
suitable alternative. There was also an inhibition of cell surface CD69 expression. 
These data demonstrated that the lack of exons 2 and 7 did not affect the ability of the 
FOXP3 protein to inhibit T cell activation. This was surprising since the missing 
exons encoded protein domains that might have been expected to be key to the 
function of FOXP3. Indeed gene analysis of an IPEX patient has revealed an in-frame 
three base-pair deletion (E251) within the leucine zipper (Chatila et ah, 2000). In this 
study, the authors speculated that this deletion prevented dimerisation, thus resulting 
in the failure of effector function. There has also been a reported mutation within 
exon 2. However in this case, the mutation was a single base deletion resulting in a 
frame-shift and a predicted premature termination codon, resulting in a truncated 
protein lacking the functional FKH domain (Gwen etal., 2003).
It is still not clear however if  FOXP3 actually needs to dimerise in order to bind to 
DNA. It had been reported that FKH proteins bind to DNA as monomers (Carlsson 
and Mahlapuu, 2002). However studies with Foxpl, Foxp2 and Foxp4, three FKH 
proteins which act as repressors of lung-specific gene transcription (Shu et ah, 2001), 
have shown that these FKH family members do require dimerisation before DNA 
binding and transcriptional repression can occur. Interestingly this group showed that 




Clearly in the studies described in this thesis, the absence of a portion of the leucine- 
zipper did not prevent the FOXP3 protein from inhibiting T cell activation, suggesting 
that dimerisation is not required for this function. The absence of a region of the 
proline-rich region is also not vital for inhibition to occur. As mentioned in the 
previous chapter, the molecular interactions and targets of FOXP3 are still unknown. 
It is possible that the signalling pathway that leads to inhibition of T cell activation is 
distinct from the signalling pathway that generates regulatory activity. It is feasible 
that the FKH domain is the critical domain for DNA binding and this domain alone is 
sufficient to inhibit T cell activation. This may occur via the active repression of 
target promoters in for example, proinflammatory genes. Hence each of the three 
isoforms of the FOXP3 protein investigated, were equally effective at inhibiting 
chimeric receptor induced CD4+ T cell activation.
Conversely to generate regulatory activity, there might be a requirement for FOXP3 
to interact with other proteins to form for example a multiprotein complex. The 
proline-rich region could be important for bringing different proteins together and the 
zinc-finger might stablilise this interaction. The leucine-zipper would allow an extra 
level of post-translational regulation. It is feasible that the FOXP3 protein could form 
both homo-and heterodimers and these molecules could target the transcription of a 
different set of genes to the monomeric form of the protein. These genes could be 
responsible for the generation of regulatory T cell activity.
It is also possible that FOXP3 itself does not need to bind DNA to induce regulatory 
activity, but by forming a multiprotein complex it allows other as yet unidentified 
factors to bind to DNA (Schubert et ah, 2001). Evidence to support this possibility is
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provided by an IPEX patient who does not have a mutation in the coding region of 
FOXP3 (Wildin et al.9 2001). This patient also exhibited milder symptoms of disease. 
It is possible that this patient has a mutation within the non-coding sequence of 
FOXP3 and this affects transcriptional regulation or RNA splicing. Alternatively this 
patient could have a mutation in an as yet unidentified protein that forms part of the 
putative multiprotein complex. This might also explain the milder symptoms, because 
if  FOXP3 does indeed signal through different pathways, the inhibition of T cell 
activation by the FKH domain would still be functional.''
These studies have confirmed that the FKH domain is critical for inhibiting T cell 
activation. Unfortunately the chimeric receptor system does not allow investigation 
into the regulatory activity of the FOXP3-transfected cells. However it would be very 
interesting to determine whether the splice variants also exhibited regulatory activity. 
As already mentioned, the establishment of a lentiviral-based system allowing 
continuous expression of the FOXP3 protein, would provide the conditions necessary 
to investigate this. Another more elegant method for determining whether the variant 
forms of the FOXP3 protein are capable of also generating regulatory activity, would 
be to try and use some form of targeted siRNA to repress expression of either exon 2 
or exon 7 in naturally occurring CD4+CD25+ regulatory cells. The ability of these 
cells to regulate could then be investigated. One limitation of this method is the 
number of CD4+CD25+ regulatory cells recovered from peripheral blood, however 
there are methods of expanding these cells in vitro (Godfrey et a l , 2004).
Comparison of the immunoblot of the human and mouse CD4+CD25+ regulatory T 
cells showed that whilst the human form of the protein appeared to be expressed as a
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doublet, the mouse form of the protein was predominantly expressed as a single band, 
corresponding to full-length FOXP3. Indeed the lower band of the doublet in the 
human CD4+CD25+ appeared to represent a variant form of the protein lacking exon 
2. Scotto et al. have confirmed that this isoform of FOXP3, which they refer to as 
FOXP3a, is expressed in naturally occurring human CD4+CD25+ regulatory T cells 
(Scotto et al., 2004), although they do not attribute a function to it. Yagi et al. have 
also shown the expression of FOXP3 as a doublet in human CD4+CD25+ regulatory 
cells and confirmed that the lower band represents a splice isoform lacking exon 2 
(Yagi et al., 2004).
Attempts to identify isoforms of the mouse Foxp3 gene by cloning of the gene and 
subsequent analysis of clones by diagnostic restriction enzyme digest, proved 
unsuccessful. Whilst not conclusively proving that isoforms of the mouse FOXP3 
protein do not exist, this suggests that if they are expressed, the expression levels are 
very low and indeed the immunoblot data in figure 6.9 appears to support this. The 
human and mouse FOXP3/Foxp3 genes and FOXP3 proteins do however share a high 
degree of sequence identity (84% at the gene level and 86% at the protein level) and 
the exon mapping is identical with both fullrlength proteins consisiting of 11 exons. 
The appearance of isoforms within the human FOXP3 protein suggests some form of 
evolutionary pressure may have occurred in the human. This has resulted in the 
generation of different forms of the protein which may have specific functions.
Currently there is no published data to show whether the two FOXP3 isoforms have 
regulatory activity. It is possible that both variants do have the ability to generate 
regulatory activity. However this is thought to be highly unlikely for the isoform
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lacking both exons 2 and 7, especially as there is an IPEX patient who exhibits an in­
frame mutation within exon 7. Unfortunately the data from the immunoblots was not 
able to confirm whether the isoform lacking both exons 2 and 7 is naturally expressed 
in CD4+CD25+ regulatory cells. Nevertheless it was felt that this isoform was 
unlikely to be a PCR artefact as the missing region mapped to a complete exon. 
Future studies using monoclonal antibodies to specific exons should be able to 
address whether this isoform is expressed naturally.
If the isoform lacking exon 2 is naturally expressed in human CD4+CD25+ regulatory 
cells but not in mouse, this poses the question, what is the functional significance of 
this isoform? It is possible that this isoform has evolved in humans to limit T cell 
activation without also playing a role in the signalling pathways required to generate 
regulatory activity. Evidence is emerging showing that human CD4+CD25- can 
upregulate FOXP3 following stimulation (Walker et al., 2003a). Whether these cells 
are generated as an expansion of CD25- T cells expressing low levels of FOXP3, 
which are already committed to the regulatory T cell lineage, is unclear. Experiments 
carried out as part of this thesis generation, have also shown the upregulation of 
FOXP3 in human CD4+CD25- T cells following activation with anti-CD3 and anti- 
CD28. However the results obtained were inconsistent, with the upregulation of 
FOXP3 expression not always being obtained, hence the data was not included within 
this thesis. Nevertheless, when FOXP3 expression was upregulated, it was noted that 
the lower band of the doublet appeared to be expressed at a higher level than the band 
corresponding to full-length FOXP3 protein. This suggested that the isoform lacking 
exon 2 might indeed play a role in controlling T cell activation. It is difficult to 
ascertain whether this is also true of the immunoblots in the studies of Walker et al. It
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is also important to note that the activated CD4+CD25- T cells generated in the 
studies of Walker et al. were shown to acquire regulatory activity.
The studies presented in this chapter have confirmed that, splice variant forms of the 
human FOXP3 protein exist. Whether these isoforms each have distinct functions is 
unclear. Transient expression of the isoforms in human CD4+ T cells showed that 
both variants significantly inhibited CD28-TCR£ chimeric receptor-induced T cell 
activation. However the apparent absence of these isoforms in the mouse suggests 
additional functions for these isoforms which may have evolved over time. Clearly as 
the signalling pathways involving FOXP3 are elucidated, the significance of these 








It is now widely accepted that a population of T cells with regulatory properties do 
exist within the mammalian immune system. This acceptance has led to a realisation 
that exploitation of these cells may offer both novel and effective therapies designed 
to target different clinical diseases. Potentially these cells offer many advantages over 
conventional therapies. They offer both active and specific regulation and can provide 
long-term tolerance. Evidence is also emerging to show these cells can be 
manipulated ex vivo to increase cell numbers (Godfrey et al., 2004; Hoffmann et al., 
2004; Taylor et al., 2002). However* therapeutic manipulation of these cells also 
raises several issues. There is the potential for pan immunosuppression if the cells are 
not antigen specific. This might result in increased risk of infection and/or cancer. The 
low frequency of these cells is also an issue. As already mentioned, there are 
protocols for expanding these cells ex vivo. However, the potential disadvantage with 
this treatment currently, is the potential expansion of CD25+ effector T cells.
Clearly, if effective therapies are going to be developed, the biology surrounding 
these cells needs to be well defined. Currently, the mechanism of suppression by 
regulatory T cells remains controversial. This is primarily due to differences between 
in vitro and in vivo studies, involving the role of cell-cell contact versus soluble 
cytokines. In an attempt to understand more about the biology of human CD4+CD25+ 
regulatory T cells, the work presented in this thesis has focussed on characterising 
human CD4+CD25+ regulatory T cells, both in terms of cell surface marker 
expression and functionality. The aims were to identify cell surface markers that 
offered greater specificity than CD25 and also to attempt to identify cell surface
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molecules or cytokines that were responsible for mediating suppression. These initial 
studies were subsequently expanded to investigate the biology of FOXP3 and its role 
in T cell activation and regulation.
Identification of specific markers which distinguish a population of ‘naturally 
occurring’ CD4+ T cells with regulatory activity from conventional CD4+ effector T 
cells, has provided immunologists with a difficult challenge. If these cells are to be 
isolated from patients for ex vivo manipulation, the purity and specificity of the 
population will be absolutely paramount. Analysis of cell surface marker expression 
described in this thesis did not identify any cell surface markers that were truly 
specific to the CD4+CD25+regulatory T cell population.
Whilst clearly the analysis of cell surface marker expression described in this thesis 
was not exhaustive, it does support the concept that a specific cell surface marker for 
CD4+CD25+ regulatory T cells may not exist. This suggests that T cell-mediated 
suppression may not be dependent upon one specific molecule. Indeed, the 
differences in cell surface marker expression between the studies described in this 
thesis and published studies, highlights the complexity and hetereogeneity of this 
population of cells. Various groups have carried out detailed microarray analyses and 
have failed to find a unique marker for these cells that is specific and not expressed on 
activated CD4+CD25- responder T cells (Gavin et al., 2002; McHugh et al., 2002). It 
is conceivable therefore that regulatory T cells express markers common to effector T 
cell and it is the combination of these molecules, or the levels of expression or timing 
of expression of these shared cell surface markers, which dictates functionality.
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Subtle differences in cell surface marker expression may also give rise to 
subpopulations of regulatory T cells, supporting the idea that regulatory T cells 
represent a heterogeneous population. As mentioned earlier in this thesis, 
CD4+CD25+ regulatory T cells expressing different integrins, have the capacity to 
generate either IL-10 or TGF(3 producing regulatory T cells in vitro (Stassen et al,,
2004) Recent studies have also shown that human CD4+CD25hl regulatory T cells 
can be subdivided into HLA-DRhl and HLA-DRlow expressing cells (G Baecher-Allen,
Vn2005). Whilst both cell populations can suppress responder T cells, the DR cells 
appear to act early in the response to suppress proliferation whilst the DRlow act later 
and also produce IL-10. This level of heterogeneity suggests that there may be 
specific subsets of naturally occurring regulatory T cell with distinctive modes of 
suppression that are dispersed within different locations in the body. The local 
microenvironment may affect the expression of certain cell surface molecules on 
these cells and this may in part explain some of the differences in mechanism of 
suppression that have been reported.
The FOXP3 signalling pathway has yet to be elucidated, however forced expression 
of this molecule is sufficient to convert non-regulatory T cells into regulatory T cells 
(Hori et al., 2003; Fontenot et a/., 2003). How FGXP3 achieves this functional switch 
is unknown but the FOXP3 signalling pathway does appear to be dependent on TCR 
signalling (Zahorsky-Reeves and Wilkinson, 2001). One possibility therefore is that 
encounter of the regulatory T cell with antigen and other cell surface 
molecules/cytokines, leads to activation of the FOXP3 signalling pathway resulting in 




It is possible that FOXP3 plays an additional role outside of regulatory T cell biology. 
The studies described in this thesis have shown that FOXP3 appears to play a role in 
controlling T cell activation. Indeed a recent study has shown that FOXP3 can inhibit 
IL-2, IL-4 and IFNy production by human CD4+ T cells following transduction with 
FOXP3-expressing retrovirus (Bettelli et al., 2005). The studies go on to show that 
FOXP3 is a specific repressor for NFAT and NF-kB. Whether FOXP3 plays a role in 
T cell activation during the course of a normal immune response is unclear. The 
chimeric receptor co-transfection system described in this thesis, the Jurkat T cell 
system (Schubert et al., 2001) and the recent paper describing overexpression in 
human CD4+ T cells (Bettelli et al., 2005), have all shown that FOXP3 is capable of 
inhibiting effector T cell activation. Certainly an additional role for FOXP3 outside of 
regulatory T cell biology is an attractive one and might in part explain discrepancies 
in phenotype between CD25-deficient mice and the scurfy mouse.
The identification of splice variant forms of the protein suggests an additional level of 
complexity surrounding the biology of FOXP3. The functional relevance of these 
proteins has yet to be determined, although the studies described in this thesis have 
shown that each splice variant was capable of inhibiting T cell activation as measured 
by inhibition of IL-2 production. It may be that the isoform lacking exon 2, which is 
naturally expressed in the human CD4+CD25+ T cell population, plays a role in 
limiting T cell activation without also playing a role in the signalling pathways 
required to generate regulatory activity. If the sole function of the isoform lacking 
exon 2 is to inhibit T cell activation, one might expect freshly isolated CD4+CD25+ 
thymocytes to only express the full-length version of the gene. Unfortunately there is 
no published data to confirm or refute this theory. Freshly isolated CD4+CD25+
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express both forms of the protein, and this may be because they represent a mixed 
population of regulatory cells and previously activated cells.
It is also conceivable that CD4+CD25+ regulatory cells isolated from the periphery 
consist of a mixed population of CD4+CD25+ regulatory T cells derived from the 
thymus which express full-length FOXP3 and activation-induced CD4+CD25+ 
regulatory T cells which express the isoform lacking exon 2. Both variant forms of the 
protein might be capable of inducing regulatory activity and the differences in exon 
structure might simply be the result of different exon splicing mechanisms within the 
two cell populations.
The presence of a leucine-zipper and proline-rich regions within the FOXP3 protein 
suggests that regulatory activity may only occur when the full-length FOXP3 interacts 
with other proteins forming a multi-protein complex, as discussed in chapter 6. 
However, it is also conceivable that the splice variants could themselves act as 
regulators of the full-length protein. During the course of an immune response when 
an effective CD4+CD25- T cell response is required, the splice variant form of the 
protein might bind directly to the full-length version of the protein, or to an accessory 
protein required to form part of the multiprotein complex, and prevent active 
suppression. Following resolution of the immune response, changes in cytokine levels 
and/or expression of various cell surface molecules might trigger either increased 
expression of the full-length FOXP3 protein, or the release of bound full-length 
protein and/or accessory proteins, resulting in the generation of regulatory activity. 
Alternatively, the splice variant form of the protein may have evolved to have 
additional functions distinct from regulatory activity that have yet to be identified.
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Clearly the ability of each of the splice variants to generate regulatory activity needs 
to be investigated. Identification of the frequency of each splice variant form within 
the mixed CD4+CD25+ T cell population will also aid the investigation into the 
significance of these variant forms. Analysis of the expression of splice variant forms 
of FOXP3 in CD4+CD25+ T cells isolated from patients with autoimmune disease 
may also provide an insight into the functional significance of the different isoforms.
There could be a link between the expression of different isoforms of the FOXP3 
protein and disease incidence and symptoms. Clearly in the study of CD4+CD25+ 
regulatory T cells isolated from patients with RA, the CD4+CD25+ regulatory cells 
were competent at inhibiting proliferation but not cytokine production (Ehrenstein et 
al., 2004). This difference may be due to the expression of different isoforms of 
FOXP3. Determination of the expression profile of FOXP3 in CD4+CD25+ 
regulatory T cells isolated from patients before and after treatment with anti-TNFa 
also needs to be investigated. However, this type of frequency analysis is reliant upon 
the generation of good quality monoclonal antibodies specific to the exons of interest. 
The use of a bicistronic model system, recently described, may offer an alternative 
method of investigating the cellular distribution of the splice variants (Wan and 
Flavell, 2005). This system uses a bicistronic reporter expressing a red fluorescent 
protein that has been knocked into the Foxp3 locus, to track expression of FOXP3 in 
different cell types. Using this system, the group have shown de novo FOXP3 
expression following anti-CD3 and anti-CD28 antibody-mediated stimulation of 
CD4+FOXP3-T cells, in the presence of TGF(3.
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A second group have also recently reported their results following the use of a GFP- 
Foxp3 fusion protein-reporter ‘knock-in’ model (Fontenot et al., 2005). This group 
showed that FOXP3 expression is highly restricted to a(3 T cells and primarily CD4+ 
T cells, although they do identify a small population of FOXP3+ CD8+ T cells. 
Interestingly the group demonstrated that a significant proportion of FOXP3+ CD4+ 
T cells did not express CD25. This was especially true of cells isolated from the 
spleen and lung, highlighting that CD25 expression does not necessarily correlate 
with regulatory function. This again might in part explain discrepancies between the 
phenotype of the CD25-knockout mouse and the scurfy mouse. In contrast to data 
from other groups and data presented in this thesis, the group argue against arole for 
FOXP3 in controlling T cell activation and inflammatory cytokine production. They 
show that OT-IIRAG1-/- CD4+ T cells from Foxp3- and Foxp3+ mice have identical 
T cell proliferative responses following stimulation with ova peptide. They also claim 
de novo expression of FOXP3 cannot be induced during the course of an immune 
response.
The future for the area of regulatory T cell biology is both an exciting and challenging 
one. One of the biggest challenges facing this field is to convert the knowledge 
surrounding the biology of these cells into a clinical application to treat human 
diseases including autoimmune disease, cancer and allergy. Studies are being 
undertaken involving the ex vivo expansion of CD4+CD25+ regulatory T cells with 
the ultimate aim to transfer the cells back into patients (Roncarolo, 2005). However, 
the potential disadvantage with this treatment, as already alluded to, is the expansion 
of potential CD25+ effector T cells. One way the group is trying to counter this is by 
treating the cells with rapamycin that selectively inhibits proliferation of the effector
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T cells but not the regulatory T cells (Battaglia et al., 2005). Nevertheless, this 
method is costly and intensive and even if proved successful, is potentially antigen 
non-specific. The studies by Fontentot et al. have also highlighted the significant 
proportion of cells that are FOXP3+ but CD25-, supporting the fact that CD25 has 
limitations as a marker of regulatory T cells. (Fontenot et a l, 2005).
Alternatives to ex vivo manipulation of regulatory T cells include peptide-based 
therapies. This type of therapy is much easier to initiate although, it does require 
knowledge of the antigen responsible for causing disease. In addition, studies using 
anti-CD25 antibodies to selectively deplete GD4+CD25+ regulatory T cells in cancer 
may also prove beneficial. One particularly interesting study that emerged during the 
course of this thesis was the use of chimeric receptors to treat a mouse model of EAE 
(Mekala and Geiger, 2005). The adoptive transfer of GD4+CD25+ T cells isolated 
from transgenic mice expressing an MBP-specific chimeric receptor, was effective at 
inhibiting MBP-peptide induced EAE. These chimeric receptor expressing cells were 
more effective than non-antigen specific CD4+CD25+ regulatory T cells. However, 
the really exciting area for therapeutic drug design is likely to reside within the 
biology of FOXP3.
Determination of the signalling pathways both upstream and downstream of this key 
molecule should provide a wealth of targets for therapeutic intervention. The studies 
by Fontentot et al. (2005) suggest that FOXP3 is the only truly specific marker of the 
regulatory T cell lineage, and hence targeting of this molecule should directly affect 
this T cell subpopulation. Overexpression studies have confirmed its role in regulatory 
T cell function and additional studies, including those described in this thesis, have
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shown a potential additional function for the protein in non-regulatory T cells, 
through the inhibition of T cell activation. Therefore, direct inhibition of the FOXP3 
signalling pathway might be beneficial in cancer treatment. Alternatively molecules 
that resulted in the upregulation of FOXP3 expression might be beneficial in 
treatment of autoimmune disease, either through the induction of a T cell population 
with a regulatory phenotype or simply through the inhibition of activated effector T 
cells.
The biology of FOXP3 is probably complicated and the identification of splice variant 
forms of the protein adds an additional layer of complexity. The functionality and 
frequency of these splice variant forms is yet to be determined. It is feasible that these 
isoforms have different functions, which might lead to highly specialised therapies 
that could potentially activate one isoform over the other, dependent upon the desired 
therapeutic effect.
7.2 Conclusions
The work presented in this thesis has highlighted the complexity of the CD4+CD25+ 
regulatory T cell population. Whilst CD25 expression is a convenient marker for 
isolation of regulatory T cells from the resting state, its use is limited following T cell 
activation. Attempts to identify a more reliable cell surface marker were unsuccessful, 
although both CD95 and TNFR2 proved to be additional reliable markers for resting 
CD4+ regulatory T cells. Attempts to investigate the cell surface molecules 
responsible for suppression of human CD4+CD25- T cells in vitro was also 
unsuccessful and probably reflects the complexity of the mode of action of these cells.
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These studies have confirmed the association of FOXP3 expression with the 
CD4+CD25+ regulatory T cell population. A role for FOXP3 in controlling T cell 
activation both in CD4+ and CD8+ T cells has also been demonstrated. Novel 
findings showing that isoforms of human FOXP3 have functionality and can inhibit 
activation-induced IL-2 production have also been reported. The functional 
significance of these isoforms requires further investigation and may lead to a better 
understanding of the biology of FOXP3.
7.3 Future Work
Clearly the biology surrounding FOXP3 and the splice variant forms of the protein 
warrant further investigation. Future studies include developing a more robust 
transfection system that allows continous expression of the protein. One possible 
method is the lentiviral transfection system, as this allows studies to be carried out 
using both resting and activated T cells. Development of this system would also 
enable investigation into whether the splice variants are capable of generating 
suppressor activity, in addition to inhibiting T cell activation.
The generation of stable cell lines expressing each of the variant forms of the protein 
will allow further investigation into the mechanism of action of FOXP3. Expression 
could be controlled using an inducible expression system so that the effects of various 
stimuli could be investigated both pre- and post-FOXP3 expression. Another key area 
to investigate further is the signalling pathway upstream of FOXP3. Linking the 
FOXP3 promoter to a reporter gene will enable studies to be undertaken investigating 
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